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Abstract 
Purpose: 
Dementia with Lewy bodies (DLB) is a common form of dementia, yet its clinical 
features remain poorly understood. We investigated in vivo structural and micro-
structural changes in DLB compared to Alzheimer’s disease (AD) and normal ageing 
using magnetic resonance imaging (MRI) techniques and their relationship to clinical 
features. 
 
 
Methods: 
Study subjects (35 DLB, 36 AD, 35 Controls) completed clinical and cognitive 
assessments and structural and diffusion tensor MRI scans. Voxel based 
morphometry (VBM) techniques were used to investigate patterns of regional grey 
matter atrophy. To investigate white matter tract change, diffusion tensor imaging 
(DTI) indices, fractional anisotropy (FA) and mean diffusivity (MD) were measured 
across the entire white matter skeleton using the tract based spatial statistics (TBSS) 
analysis. 
 
 
Results: 
Groups were well matched for demographic and clinical factors, although, as 
expected, the DLB group also had more neuropsychiatric features, greater 
parkinsonism and more functional impairment than the AD group. 
VBM analysis indicated a less diffuse pattern of grey matter atrophy in DLB than 
observed in AD, with areas of loss including the posterior and subcortical regions 
without significant frontal atrophy. DLB had greater preservation of the medial 
temporal lobe structures when compared to AD, which was associated with less 
impaired memory function. 
The pattern of FA change in DLB compared to controls involved the parieto-
occipital white matter tracts; in AD, the FA change was more diffuse.  In DLB, an 
association was found between reduced FA and the phonemic fluency tasks in the 
white-matter tracts of the precentral gyrus, anterior cingulate and precuneus in DLB.  
 
Abstract 
ii 
Conclusions: 
Despite a similar level of dementia severity, the patterns of structural and diffusion 
tensor MRI changes in AD and DLB differ significantly. DLB was associated with 
less grey matter volume loss and less white matter tract change than AD along with 
differing regional patterns of change.  
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1 
Chapter 1 Introduction 
Dementia currently affects approximately 7% of those over the age of 65 and 30% of 
people over the age of 80 and it is estimated that the prevalence of dementia will double 
over the next 30 years (Knapp and Prince, 2007). In the UK alone, it is estimated that 
over a million people will be affected by 2025. Dementia is associated with significant 
morbidity and mortality and has therefore become a national health and social care 
priority. 
Dementia has many forms, of which Alzheimer’s disease (AD) and dementia with Lewy 
bodies (DLB) are the most common. Distinguishing between AD and DLB can be 
difficult during life as clinical symptoms often overlap. However, establishing an 
accurate clinical diagnosis is important in order to improve patient care. Additional 
markers are therefore required, which, when combined with clinical information can 
improve diagnostic accuracy.  
Neuroimaging can investigate both brain structure and function. Magnetic resonance 
imaging (MRI) offers a non-invasive method to study cerebral changes in more detail. It 
can provide highly detailed information about the structure of the brain without using 
ionizing radiation, and has been utilised in studies of AD and DLB. MR technology and 
methods of analysis continue to improve with MRI becoming a more powerful tool for 
detecting neuronal structural and functional change. Diffusion tensor imaging is a more 
recently developed MRI technique which reflects the white matter tracts, the 
microstructure of the brain. It has potential to be more sensitive to early and possibly 
preclinical change. By investigating the structural and micro-structural alterations of 
these conditions and studying the neurobiological correlates we can add to the weight of 
clinical information and potentially improve the diagnostic accuracy. 
This thesis describes a study in which structural and diffusion MR was used to 
investigate brain changes in DLB and AD subjects together with a group of similarly 
aged controls. 
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2 
1.1 Overview of Thesis Contents. 
Chapter 1. Introduction – describes DLB and AD, outlining their aetiology, clinical 
features, pathological changes and management.  
Chapter 2. MRI in Lewy body dementias – provides a review of the MRI literature in 
Lewy body dementias. Structural imaging changes are presented, then diffusion tensor 
imaging, proton magnetic spectroscopy and functional MRI.  
Chapter 3. Study aims – outlines the aims, objectives and hypotheses of the research 
undertaken in this thesis. 
The following 3 chapters present and discuss the results of the study. 
Chapter 4. Clinical and neuropsychological features of DLB – presents the methods of 
study recruitment and provides a detailed account of the clinical and neuropsychological 
features of the study cohort. 
Chapter 5. Structural imaging changes in DLB – focuses on the patterns of MRI grey 
matter atrophy in DLB compared to AD and age-matched controls using voxel based 
morphometry analysis methods. 
Chapter 6. Diffusion tensor imaging in DLB – focuses on MRI white matter tract 
changes in DLB compared to AD and age-matched controls using tract based spatial 
statistics analysis method. Correlations with key clinical and neuropsychological data 
are presented and discussed. 
Chapter 7. Conclusions and future studies – presents the conclusions drawn from the 
structural and diffusion imaging studies in assessing DLB, including the study strengths 
and limitations with a discussion of potential future directions. 
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1.2 Dementia with Lewy bodies 
DLB is the second commonest cause of degenerative dementia in older people, only AD 
being more common. Despite this, its clinical features are poorly understood and under 
recognition is common. An accurate clinical diagnosis is important in order to improve 
individual patient care and is essential for furthering research into the disorder. 
This section summarises the clinical and pathological features of DLB as well as the 
current management strategies. The diagnostic difficulties between DLB and AD and 
the relationship between DLB and Parkinson’s disease dementia (PDD) will also be 
discussed. 
1.2.1 Epidemiology 
 Prevalence estimates of DLB rely on referrals to specialty health service providers or 
autopsy case series and vary from between 15% to 35% of cases of dementia, 
suggesting that it is the second most common form of dementia (McKeith et al., 2004). 
In a UK community based prevalence study of dementia subtypes in those over 65, 
Stevens et al. (2002) reported that almost 10% of the sample fulfilled consensus criteria 
for probable DLB and 30.5% for either possible or probable DLB.  
DLB is more common in men and the average age of onset is 75 years, although there is 
wide variation (Geser et al., 2005). Dementia is the most frequent clinical presentation, 
although psychiatric symptoms; including visual hallucinations, delusions and 
depression and autonomic dysfunction and falls can also be early features (McKeith et 
al., 2004). 
Overall the disease progresses at a rate comparable to that seen in AD. A study by 
Ballard et al. (2001b) of patients referred to Old Age Psychiatry dementia services, 
showed that the rate of cognitive decline was approximately 4 mini-mental state 
examination (MMSE) points and 12-14 Cambridge Cognitive Assessment (CAMCOG) 
points per year in AD, DLB and vascular dementia with no significant differences 
between the groups. However, more recent studies suggest greater functional decline, 
resource use and reduced quality of life in DLB compared to AD (Bostrom et al., 
2007b; Bostrom et al., 2007a). Parkinsonism tends to worsen at a similar rate to that 
seen in PD, approximately 10% per year and the average survival time is also similar to 
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that of AD with some DLB patients showing a more rapid progression and death within 
1-2 years of onset (Geser et al., 2005). 
1.2.2 Clinical features 
Internationally agreed clinical diagnostic criteria for DLB were first established by 
consensus in 1996 following the publication of clinical features characteristic of the 
disorder which was based on several different case series of DLB subjects (McKeith et 
al., 1996). The criteria were then validated by several groups and generally found to 
have high specificity, up to 100% in larger referral centres, although they lacked 
sensitivity meaning that the diagnosis will be missed in many cases (up to 50%) during 
life (Litvan et al., 2003). This was the main reason that they were revised in 2005, with 
the aim to help improve case detection (see summary Tables 1.1 and 1.2)  (McKeith et 
al., 2005; McKeith et al., 1996). 
The initial consensus criteria included the central feature of progressive cognitive 
decline of sufficient magnitude to interfere with social or occupational function, along 
with a triad of core clinical features of the condition: (1) recurrent visual hallucinations, 
(2) cognitive fluctuation and (3) spontaneous motor parkinsonism, with at least 2 of the 
core features required to make a clinical diagnosis of probable DLB (Table 1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1. Consensus Criteria for the Clinical diagnosis of dementia with Lewy bodies 
(McKeith et al., 1996). 
Central Feature (essential) 
 Dementia defined as progressive cognitive decline of sufficient magnitude to 
interfere with normal social or occupational function.  
Core Features  
Probable DLB – 2 core features 
Possible DLB – 1 core feature  
 Fluctuating cognition with pronounced variations in attention and alertness 
 Recurrent visual hallucinations  
 Spontaneous features of parkinsonism 
Supportive features 
 Repeated falls 
 Syncope 
 Transient loss of consciousness 
 Neuroleptic sensitivity 
 Systematised delusions 
 Hallucinations in other modalities 
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In the revised version, the 3 core features remain unchanged, however, greater 
weighting has been given to neuroleptic sensitivity reactions, reduction of the dopamine 
transporter on imaging and the presence of rapid eye movement (REM) sleep behaviour 
disorder by including them as ‘suggestive’ features (Table 1.2), one of which (in the 
presence of at least one core feature) is now sufficient for a diagnosis of probable DLB. 
Central Feature (essential) 
 Dementia defined as progressive cognitive decline of sufficient magnitude to interfere 
with normal social or occupational function.  
Core Features  
Probable DLB – 2 core features 
Possible DLB – 1 core feature 
 Fluctuating cognition with pronounced variations in attention and alertness 
 Recurrent visual hallucinations 
 Spontaneous features of parkinsonism 
Suggestive features  
Probable DLB – 1 or more suggestive feature with 1 or more core feature  
Possible DLB – 1 or more suggestive feature 
 REM sleep behaviour disorder 
 Severe neuroleptic sensitivity 
 Low dopamine transporter uptake in basal ganglia (SPECT or PET) 
Supportive features 
 Repeated falls and syncope 
 Transient unexplained loss of consciousness 
 Severe autonomic dysfunction 
 Hallucinations in other modalities 
 Systematised delusions 
 Depression 
 Relative preservation of medial temporal lobe structures on CT/MRI scan 
 Generalised low uptake on SPECT/PET perfusion scan with reduced occipital activity 
 Abnormal (low uptake) MIBG myocardial scintigraphy 
 Prominent slow wave activity on EEG with temporal lobe transient sharp waves 
Table 1.2. Revised Consensus Criteria for the diagnosis of DLB (McKeith et al., 2005). 
 
The addition of disease biomarkers to the revised criteria was an important step forward. 
Abnormal dopamine transporter imaging is extremely helpful to distinguish between 
AD and DLB. However, it remains somewhat limited by its sensitivity, which peaks at 
approximately 80% (McKeith et al., 2007), as well as possible inaccuracy of the gold 
standard (clinical consensus criteria) against which the biomarker has been judged, the 
exception being the studies of Walker and Walker (2009)  who found 100% sensitivity 
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when judged against autopsy. This may, in part, be because not all DLB cases have loss 
of the dopamine transporter. Preservation of hippocampal and medial temporal lobe 
volume on MRI (Burton et al., 2009; Whitwell et al., 2008; Barber et al., 1999a) and 
occipital hypoperfusion and hypometabolism without occipital atrophy on MRI imaging 
have been consistent findings in imaging studies of DLB (Middelkoop et al., 2001; Ishii 
et al., 1999; Imamura et al., 1997). These were incorporated into the revised criteria for 
DLB as supportive features as the findings currently lack diagnostic specificity. 
Scintigraphy with 
123
I-metaidobenzyl guanidine (MIBG) is a method that can measure 
postganglionic sympathetic cardiac innervation. This has been shown to be reduced in 
DLB compared with AD and suggested to be more reliable than orthostatic testing, 
although further validation studies are indicated (Idiaquez and Roman, 2011; King et 
al., 2011; Treglia and Cason, 2010). 
Further development of disease biomarkers is therefore needed, which, when combined 
with the clinical features of the DLB syndrome may help improve case detection (Sinha 
et al., 2011). 
1.2.2.1 Differential Diagnosis of DLB 
The main differential diagnoses are (1) other dementias (most especially AD), (2) 
delirium, (3) the spectrum of other disorders with parkinsonism, such as progressive 
supranuclear palsy (PSP) and corticobasal degeneration (CBD) or (4) those with 
psychiatric features such as delusional disorders or depression with psychosis. 
1.2.2.2 Lewy body dementias – the relationship between DLB and PDD 
Dementia is a frequent complication of PD. The risk of progression to dementia 
increases with age and affected over 70% of PD patients in an 8 year prospective 
longitudinal study, six times the rate of healthy controls (Aarsland et al., 2003). The 
clinical and neuropathological phenotype of DLB and PDD are similar with no specific 
features reliably separating the conditions (Lippa et al., 2007). Since the discovery of 
alpha synuclein the relationship between PD, DLB and PDD has been able to be further 
established and they probably represent differing points along a spectrum of Lewy body 
disorders (Lippa et al., 2007). 
Given the similarity between DLB and PDD, the so called ‘1-year rule’ between the 
development of motor symptoms and dementia was established by consensus in order to 
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separate the two conditions (McKeith et al., 2005). The diagnosis of PDD is appropriate 
where dementia develops in established PD and DLB where cognitive impairment 
precedes or coincides within a year of the development of motor parkinsonism 
(McKeith et al., 2005). This rather arbitrary approach was deemed necessary 
particularly for clinical research purposes so as not to confound data pooling and allow 
for comparison across studies (McKeith et al., 2005). It is also a useful clinical 
descriptor for two disorders that can have very different initial clinical presentations. In 
pathological studies, a collective approach including both PDD and DLB in a Lewy 
body dementia or -synucleinopathy group may be more appropriate (McKeith et al., 
2005). In terms of clinical practice, it has been recommended that strict application of 
the 1-year rule may not be helpful and that the most predominant and problematic 
symptom (dementia or movement disorder) might best define the patient (McKeith et 
al., 2005). 
1.2.2.3 Neuropsychological features 
Typically DLB manifests as recurrent confusion on a background of progressive 
cognitive decline (McKeith et al., 2004). In the early stages, the cognitive profile is one 
of predominantly subcortical neuropsychological impairment with significant 
attentional and visuo-perceptual difficulties (Metzler-Baddeley, 2007). Generally, 
patients with DLB perform better than those with AD on tests of memory but worse on 
visuo-spatial performance tasks.  
Global measures (MMSE) are usually comparable to AD patients at a similar stage of 
dementia (McKeith et al., 2003). Patients with DLB however, have disproportionately 
more severe deficits in tasks of attention and executive function when compared to AD 
(Collerton et al., 2003). 
Cognitive fluctuations represent one of the core features for the clinical diagnosis of 
DLB and are largely a result of problems with attention (McKeith et al., 2005). 
Cognitive ability in DLB can vary over minutes, hours, or days and such cognitive 
fluctuations occur in up to 90% patients (McKeith et al., 1996). Computer-based tasks 
of attention have detected variations in DLB task performance on a second to second 
basis, greater than observed in AD (Ballard et al., 2001a). However, accurate detection 
of cognitive fluctuation in DLB remains a challenge. This was highlighted in a study of 
the clinical symptoms of DLB which found that it was the most difficult feature to 
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accurately assess, with low inter-rater reliability reported (Mega et al., 1996). To help 
address this, scales were developed to try to objectively assess fluctuation and are 
currently in use (Ferman et al., 2004; Walker et al., 2000b).  
Impaired visual perception is a consistent finding in DLB (Metzler-Baddeley, 2007). To 
quantify this, Mosimann et al. (2004) aimed to quantify visual discrimination, space-
motion and object form perception in patients with DLB, PDD and AD matched for 
overall dementia severity. They found that all aspects of visuo-perceptual function were 
impaired in DLB and PDD subjects who performed worse than patients with AD.  
Patients with DLB and hallucinations were also more impaired on the visual perception 
tasks than those without hallucinations (Mosimann et al., 2004).  
Language can also be affected, manifest early as difficulty verbalizing simple words 
which may relate to fronto-subcortical dysfunction. In the later stages of the disease, 
deficits are more global and can be indistinguishable from AD (Geser et al., 2005). 
1.2.2.4 Neuropsychiatric features 
Visual hallucinations are common in patients with DLB (McKeith et al., 2005). The 
visual hallucinations are quite characteristic; typically recurrent, highly detailed and 
often involve children or animals. The reaction of a person with DLB experiencing 
hallucinations can vary widely from indifference to highly distressing (McKeith et al., 
2004). The misidentification of objects or visual illusions is also common and often 
overlaps with visual hallucinations, suggesting a common mechanism. 
Other neuropsychiatric features that occur in patients with DLB include auditory 
hallucinations, delusions, depression, anxiety and apathy (McKeith et al., 2005). 
1.2.2.5 Motor features 
Motor parkinsonism is a syndrome of bradykinesia, rigidity, rest tremor and gait and 
postural reflex abnormalities. It is a prominent feature of DLB, occurring in up to 75% 
of patients (McKeith et al., 2005). Severity of parkinsonism in DLB is similar to that of 
idiopathic PD, however, the subtypes differ (Burn et al., 2006; Burn et al., 2003). In 
DLB, parkinsonism is typically axial with prominent gait abnormality and postural 
instability, commonly referred to as the postural instability gait difficulty (PIGD) 
subtype (Burn et al., 2003). Tremor is also usually bilateral and less pronounced than in 
PD rather than the asymmetrical tremor dominant (TD) subtype seen more commonly in 
Chapter 1 Introduction 
9 
PD (McKeith et al., 2004). Burn et al. (2003) found that the PIGD subtype account for 
69% of DLB cases, significantly more than in PD (38%).  
1.2.2.6 Sleep disorders 
REM sleep behaviour disorder (RBD) is a parasomnia which can precede the onset of 
dementia or parkinsonism by many years (Boeve, 2010; Turner, 2002). It involves the 
loss of normal skeletal muscle atonia during REM sleep which can be confirmed 
clinically by polysomnography (Boeve, 2010). A suggestive history is usually obtained 
from the patient’s partner. Patients appear to be acting out their dreams, flailing, 
vocalizing and moving about the bed, sometimes violently. RBD is usually associated 
with an underlying synucleinopathy – PD, DLB or Multisystem Atrophy and rarely 
other neurodegenerative diseases (Boeve et al., 2003).  
Other relatively common sleep disorders associated with DLB include excessive 
daytime sleepiness, insomnia, circadian dysrhythmia, obstructive sleep apnoea, restless 
legs, nightmares and confusion on waking (Boeve, 2005; McKeith et al., 2004) . 
1.2.2.7 Autonomic dysfunction 
Autonomic dysfunction is relatively common in patients with DLB (O'Brien et al., 
2006). Frequent clinical features include problems with bladder and bowel function and 
orthostatic hypotension (Horimoto et al., 2003). Syncope and falls are included as 
supportive features for the clinical diagnosis of DLB and may be contributed to by 
underlying autonomic dysfunction (McKeith et al., 2005).  
1.2.3 Neuropathology 
1.2.3.1 Lewy related pathology  
Definitive diagnosis of DLB rests on pathological verification of the presence of Lewy 
body pathology which includes Lewy bodies (LB) and Lewy neurites (LN), both of 
which contain aggregates of the synaptic protein, -synuclein. ‘Classical LB’ are 
typically found in the brainstem and have a hyaline core and pale halo (Figure 1.1). The 
‘Cortical LB’ are composed only of filaments without an obvious core (Figure 1.2). The 
most specific method of detecting Lewy related pathology is using 
immunohistochemistry with anti--synuclein antibodies (Gomez-Tortosa et al., 2000). 
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Figure 1.1. Classic Lewy body (green arrow) in the Substantia Nigra, X400 High Power Field, 
haematoxylin and eosin staining.* 
 
 
 
 
 
Figure 1.2. alpha-synuclein immunohistochemistry X200 High Power Field. Cortical Lewy 
bodies (red arrows) and diffuse Lewy neurites (brown staining background) in the cingulate 
gyrus.* 
 
*Images represented in Figure 1.1 and 1.2 above were obtained from Dr Johannes Attems, Institute for Ageing and 
Health and have not been published elsewhere. 
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1.2.3.2 Other pathological features of DLB 
Other pathological features associated with DLB include regional neuronal loss, 
particularly brainstem and the nucleus basalis of Meynert, plaques and neurofibrillary 
tangles and spongiform change (microvaculoation) which occurs predominantly in the 
visual association areas and temporal cortex (Kovari et al., 2009). 
1.2.3.3 The Braak Hypothesis 
Lewy body pathology is also seen in other degenerative disorders including Parkinson’s 
disease and multiple system atrophy which share some of the clinical features of DLB 
and are referred to as synucleinopathies (Jellinger, 2003).  
The accumulation of -synuclein within neuronal cells is associated with dysfunction 
and cell death although the process is not clear. Projection neurons with long, thin 
unmyelinated axons are more commonly affected, which suggest that the process of 
neuronal damage in Lewy body disease follows certain rules (Braak et al., 2004). Braak 
et al. (2003) proposed a scheme to stage Lewy related pathology in PD. They 
hypothesized that the accumulation of -synuclein begins in the dorsal motor nucleus of 
the vagus in the lower brainstem and progresses in an ascending fashion to the limbic 
and neocortex in a caudo-rostral distribution. It was suggested that the clinical features 
of the disease also mirror this, although with differing individual thresholds to manifest 
symptoms, and devised a pathological staging system to reflect this: (i) preclinical 
(Stages 1-2); (ii) early (Stages 3-4) and (iii) late (Stages 5-6).  
It was therefore suggested that -synuclein pathology might behave in a “prion-like” 
manner, with between cell transfer of the abnormal protein, although without the 
infectivity properties of a prion disease (Angot et al., 2010). However, recent studies 
have found that up to 49% of DLB cases do not follow the distribution of the Braak 
hypothesis (Zaccai et al., 2008; Kovari et al., 2003; Gomez-Tortosa et al., 1999) and 
among AD cases with Lewy body pathology, 70% did not show lesions in the medulla 
oblongata (Jellinger, 2003).  
Parkkinen et al. (2008) also found that more than half of their subjects with Braak stage 
5-6 were unaffected by cognitive impairment or parkinsonism. This indicated that some 
people were able to tolerate a significant burden of synuclein pathology. This perhaps 
supports the view that the main pathological culprit is the small synaptic aggregates of 
Chapter 1 Introduction 
12 
synuclein (Kramer and Schulz-Schaeffer, 2007) rather than Lewy bodies, which may 
potentially be neuroprotective (Tanaka et al., 2004).  
1.2.3.4 Amygdala Lewy bodies 
-synuclein aggregates are not specific to the Lewy body spectrum of disease. LB 
confined to the amygdala are seen in around 50% of cases of AD (Lippa et al., 2005; 
Popescu et al., 2004). Findings from neuropathological studies suggested the possibility 
that the presence of tau pathology may modify the distribution pattern of -synuclein 
with accumulation beginning in the amygdala if associated with tau pathology (Arai et 
al., 2001). Arguing against this however are (1) reports of -synuclein occurring in the 
amygdala with  relative sparing of the substantia nigra in DLB cases with mild AD 
pathology (Tsuboi et al., 2007) and (2) the finding in one study that the progression 
pattern of Lewy related pathology was not associated with AD pathology (Zaccai et al., 
2008).  
1.2.3.5 The role of Alzheimer’s pathology in DLB 
Most cases with cortical LB also show some associated Alzheimer pathology (tau-based 
neurofibrillary tangles and neuritic plaque) which modifies the DLB clinical syndrome. 
In cases where the burden of tau-based Alzheimer pathology is high, the key clinical 
features of DLB are likely to be obscured (McKeith et al., 2005). Therefore, the 
sensitivity of the clinical diagnostic criteria is much lower than in cases with more 
concomitant tau-based pathology highlighting the need for improved methods of case 
detection. The effect of diffuse amyloid plaques as opposed to neuritic plaques to 
cognitive impairment in DLB is less clear (McKeith et al., 2005).  
1.2.3.6 Consensus criteria for the pathological diagnosis of DLB 
The pathological criteria for diagnosis of DLB were again revised in 2005 to help 
address some of the boundary issues between AD and DLB. The use of the National 
Institute of Ageing (NIA) − Reagan criteria for defining the significance of concurrent 
AD pathology in DLB was determined by consensus which require the presence of both 
tau-based neurtitic plaques and neurofibrillary tangles and not diffuse amyloid plaques. 
Lewy body type pathology are assigned based on a semiquantitative scale (McKeith et 
al., 2005). 
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Reflecting the fact that DLB, like AD, is a clinico-pathological syndrome the 
pathological diagnosis was represented as a probability statement about “the likelihood 
that the observed neuropathologic findings predict the clinical syndrome of DLB”. That 
is, “the likelihood that the observed neuropathology explains the DLB syndrome is 
directly related to the severity of the Lewy-related pathology and inversely related to 
the severity of concurrent AD type pathology” (McKeith et al., 2005) (represented in 
Table 1.3). 
 Alzheimer Type Pathology 
       NIA-Reagan Low 
(Braak stage 0-II) 
NIA-Reagan Intermediate 
(Braak stage III-IV) 
NIA-Reagan High 
(Braak stage V-VI) 
Lewy body type pathology   
 Brainstem predominant Low Low Low 
 Limbic (transitional) High Intermediate Low 
 Diffuse neocortical  High High Intermediate 
Table 1.3. Assignment of the likelihood that the pathologic findings are associated with the 
DLB clinical syndrome, (McKeith et al., 2005). 
 
1.2.3.7 Clinicopathological Correlations 
Global cognition 
Cognitive impairment has been found to correlate with the burden of cortical Lewy 
bodies in the frontal and temporal lobes in one study (Harding and Halliday, 2001). 
Visual hallucinations 
Interestingly, there are almost no LBs and only sparse LNs in the primary visual cortex 
but more numerous lesions have been reported in the visual association cortices, 
especially the posterior occipitotemporal gyrus. DLB cases with visual hallucinations 
were found to have increased Lewy body numbers in the parahippocampal gyrus and 
amygdala with early hallucinators having higher densities in the parahippocampal gyrus 
and inferior temporal cortex (Harding et al., 2002). 
Parkinsonism 
The striatum is an area typically affected in DLB and often results in motor 
parkinsonism. The Lewy body density in the substantia nigra has been found not to 
differ in DLB patients who develop parkinsonism early or later in the course of the 
disease (Gomez-Tortosa et al., 1999). Neuronal loss in the substantia nigra has been 
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observed in DLB, although neuronal loss in the putamen is perhaps less than in PD. 
Despite this, similar levels of dopamine deficiencies are seen in both DLB and PD and 
are sufficient to cause motor parkinsonism (Piggot et al., 1999).  
Cognitive fluctuation, sleep and autonomic dysfunction 
Attentional dysfunction and cognitive fluctuation are key features of DLB and are 
thought to be mediated in part, by cholinergic system degeneration (Ballard et al., 
2001a).  The nucleus basalis of Meynert, located in the substantia innominata is a major 
source of cholinergic innervation of the neocortex and is subject to greater neuronal loss 
in DLB than AD as well as extensive Lewy related pathology (Lippa et al., 1999). This 
may have an effect on attention as well as global cognitive function.  
Neuronal loss has been reported in the pedunculopontine nucleus in Lewy body disease. 
This may contribute to the development of REM sleep behaviour disorder and, given 
the cholinergic inputs to the thalamus, an important structure in the maintenance of 
attention, may contribute to attentional problems in DLB (Boeve, 2010).  
Neuropathological correlates of autonomic dysfunction are likely to include neuronal 
loss and Lewy-related pathology in the autonomic nuclei of the brainstem and 
sympathetic and parasympathetic ganglia (Idiaquez and Roman, 2011). 
1.2.4 Neurochemistry 
Acetylcholine 
Cholinergic deficiencies (cholinergic neurons and choline acetyl transferase activity) in 
DLB are greater than those found in AD. Areas affected include neocortical areas as 
well as the basal ganglia, including the striatum and the pedunculopontine pathway that 
project to the thalamus (Francis and Perry, 2007). Postsynaptic muscarinic receptors 
have also been shown to be upregulated and more functionally intact in DLB compared 
with AD. This may, in part, explain why patients with DLB benefit from treatment with 
cholinesterase inhibitors (Francis and Perry, 2007; McKeith et al., 2000b). Nicotine 
binding is also reduced by as much as 70% in the substantia nigra in DLB. Similar 
reductions are seen in PD; however this seems mainly due to neuronal loss. In DLB 
patients, neuronal loss is less (40%) and suggests that the loss of cholinergic function 
precedes neuronal degeneration (Francis and Perry, 2007).  
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Serotonin 
Lewy bodies occur at the dosal raphe nucleus and reductions of serotonin levels have 
been reported in the striatum, neocortex and frontal cortex (Francis and Perry, 2007). 
Relatively higher binding to the 5HT transporter reuptake site in the parietal cortex has 
also been shown in DLB patients with major depression compared with those who are 
not depressed (Francis and Perry, 2007). 
Dopamine 
Moderate neuronal loss in the substantia nigra has been found in DLB, although it was 
less than in PD. Striatal dopamine concentration has also been found to be reduced 
almost as much as in PD and would be enough to account for the motor features of the 
disease (Piggot et al., 1999).  
In PD there is loss of the dopamine transporter throughout the striatum. In DLB 
however, the loss is more significant in the caudal (posterior) striatum. Loss of the 
dopamine transporter in DLB can be measured in vivo by FP-CIT SPECT imaging 
which has been found to be reduced when compared with AD and has become a useful 
biomarker for distinguishing between the two conditions (O'Brien et al., 2004).  
Postsynaptic dopamine receptor changes also differ between PD and DLB.  In PD, the 
D2 receptors are upregulated in response to loss of the dopamine transporter which does 
not occur in DLB and are reduced in the caudal striatum when compared with controls 
(Piggot et al., 1999). Given that neuroleptics have dopamine receptor antagonist 
properties, this may explain the neuroleptic sensitivity reactions seen in DLB (Piggott et 
al., 2007; Aarsland et al., 2005). The thalamus also has D2 and D3 dopamine receptors 
which may influence cognitive fluctuation. 
1.2.5 Management of DLB  
The management of DLB is largely symptomatic and should be multi-disciplinary and 
involve consideration of both pharmacological and non-pharmacological strategies.  
1.2.5.1 Acetylcholinesterase inhibitors 
Given that cognitive impairment in patients with DLB has been correlated with cortical 
cholinergic dysfunction and reductions in choline acetyltransferase, a number of studies 
have assessed the impact of cholinesterase inhibitors. 
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McKeith et al. (2000b) reported therapeutic effects of rivastigmine from a multicentre, 
placebo-controlled double blinded trial in 120 patients with probable DLB. They found 
that the rivastigmine treated group were less apathetic, had less anxiety and they also 
had fewer delusions and hallucinations. Hallucinations and psychotic features resolved 
almost completely in over half the patients on rivastigmine. Decreased choline 
acetyltransferase activity in the temporal lobe has also been shown to correlate with the 
presence of visual hallucinations in DLB (Francis, 2009) and the alleviation of this 
symptom in response to cholinergic replenishment supports the association. Open label 
studies using galantamine, donepezil and tacrine in DLB also reported similar benefits 
but also found positive effects on cognition with a median MMSE improvement of 2.7 
(Aarsland et al., 2004). Although McKeith et al. (2000b) did not find a significant 
change in MMSE, later analysis showed that attention did improve (Wesnes et al., 
2002). The pedunculopontine nucleus is subject to degeneration in DLB and provides 
cholinergic input to the thalamus, an important structure for maintenance of attention. 
Given the improvement in attention with cholinesterase inhibitors, it is possible that this 
is an important component of attentional dysfunction and cognitive fluctuation in DLB. 
The beneficial effects of these medications however, were lost after discontinuation, 
suggesting they were due to a symptomatic benefit rather than modification of the 
disease process (McKeith et al., 2000b).  
Over 75% of patients experience side effects particularly when starting cholinesterase 
inhibitors but they are usually of mild to moderate severity with approximately 10% of 
patients needing to stop the medication because of the side effects (Bhasin et al., 2007). 
Cholinesterase inhibitors now form the mainstay of treatment for cognitive symptoms 
and psychosis in DLB (Aarsland et al., 2004).  
1.2.5.2 Memantine 
Memantine is an N-methyl D-aspartate (NMDA) receptor antagonist and has recently 
been trialled for use in DLB (Emre et al., 2010; Aarsland et al., 2009). Changes in 
markers of neuronal glutamatergic activity have been reported in DLB and memantine 
acts to block the effects of raised glutamate levels (Dalfo et al., 2004). There have been 
two randomised controlled trials of memantine in DLB which found improvement in the 
‘clinical global impression of change’ (CGIC) scale (Emre et al., 2010; Aarsland et al., 
2009). In the larger study by Emre et al. (2010) they also reported improvement in the 
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Neuropsychiatric Inventory (NPI). In the DLB group, the improvements in the NPI 
were in the domains of delusions, hallucinations, sleep and appetite or eating. However, 
in contrast to Aarsland et al. (2009) the participants were not able to take cholinesterase 
inhibitors. Memantine did not worsen symptoms and was also well tolerated. Overall, 
memantine might have some mild beneficial effects in global clinical status and 
behavioural symptoms and may be a treatment option for some patients with DLB. 
1.2.5.3 Treatment of Psychotic symptoms 
Psychotic symptoms, particularly visual hallucinations and delusions, are common in 
patients with DLB with as many as two-thirds of patients experiencing quite prominent 
psychotic symptoms at some stage (McKeith et al., 2004). Treatment however, presents 
a therapeutic challenge. In general, psychotic symptoms and behavioural problems in 
dementia are managed with neuroleptics (antipsychotics), but these drugs need to be 
used with caution in older people with dementia because of increased risk of stroke and 
stroke-like events and an increased mortality (Sacchetti et al., 2010). In DLB the 
dangers are even more extreme as they can (and often do) worsen motor parkinsonism 
and precipitate fatal sensitivity reactions in up to 50% of patients with DLB (Aarsland 
et al., 2005). Neuroleptic sensitivity reactions are only seen in patients with DLB and 
include sudden worsening of parkinsonism, confusion and impaired consciousness 
(Ballard et al., 1998; McKeith et al., 1992).  
Adverse effects also occur with use of the newer antipsychotic agents with worsening of 
parkinsonism reported after olanzapine and risperidone (Poewe, 2005). There is 
currently only anectdotal evidence to suggest severe adverse reactions following use of 
clozapine (Burke et al., 1998) despite its efficacy in psychosis associated with PD with 
no worsening of parkinsonism or global cognition (Weintraub and Hurtig, 2007). 
Therefore, cholinesterase inhibitors are the first choice and antipsychotics are reserved 
as second line therapy in DLB. Antipsychotic treatment in DLB should be initiated by 
specialists using atypical agents at low dose with frequent and careful monitoring. 
1.2.5.4 Parkinsonism 
Treatment of the motor features of parkinsonism in patients with DLB follows the same 
principles as in idiopathic Parkinson’s disease. However, patients with the PIGD 
subtype are generally less responsive to levodopa when compared with the TD subtype 
(Sethi, 2008). Given that the PIGD subtype is more common in DLB, the overall 
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effectiveness of levodopa on motor disability would be expected to be less pronounced 
when compared with PD. Only limited studies have been undertaken investigating 
treatment response of motor features of DLB. Both Bonelli et al. (2004) and Molloy et 
al. (2005) showed a significant response to L-dopa in approximately one-third of 
subjects with DLB, less than in PD but still a reasonable proportion who benefit from 
treatment. 
1.2.5.5 Depression, REM sleep behaviour disorder and Autonomic failure 
Depression is common in DLB however, there are no studies assessing the effectiveness 
and safety of an agent targeting depression specifically in DLB. The choice of 
antidepressant is therefore based on patients without parkinsonism (Fernandez et al., 
2003).  
Sleep disorders are common and difficult to effectively treat. The treatment of RBD 
with clonazepam should be considered when there is the potential for harm of the 
patient or their partner (Boeve, 2010). 
Treatment of autonomic failure has not been specifically assessed in DLB. The options 
are therefore similar to those available for the general population. For orthostatic 
hypotension these include conservative measures, compression stockings, or therapeutic 
options such as fludrocortisones or midodrine (1 agonist) (Gupta and Nair, 2008). 
Consideration should be given to referring to a multidisciplinary falls and syncope 
service for further falls risk factor modification and management (O'Brien et al., 2006). 
Anticholinergic medications are often prescribed for urinary tract symptoms of detrusor 
overactivity, which can occur in autonomic failure (Sahai et al., 2006). However, the 
treating clinician should be aware of the potential for worsening cognition and consider 
more selective agents that do not cross the blood brain barrier such as trospium and 
darifenacin. 
1.2.6 Summary 
The clinical and pathological characteristics of DLB have been operationalised as far as 
is possible on the current evidence base to assist with accurate clinical diagnosis and 
also allow for more robust case detection of DLB for research purposes. However there 
remains significant pathological overlap between the different dementia subtypes, 
particularly the boundary between DLB and AD. Alzheimer pathology modifies the 
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clinical expression of DLB symptoms. Therefore, in cases of DLB with significant co-
existent Alzheimer pathology, clinical assessment methods will not be sensitive enough 
to detect DLB. We need to develop techniques which will aid our understanding of the 
underpinnings of the clinical features of DLB and develop biomarkers to assist with 
improving the case detection of DLB. 
 
1.3 Alzheimer’s disease 
Alzheimer’s disease is the most common cause of dementia (Blennow et al., 2006). As 
already discussed in section 1.2.3.5, there is significant overlap between AD and DLB 
with AD pathology modifying the clinical features of DLB. The focus of this section is 
to provide a summary of the clinical and pathological features of AD. This is not an 
exhaustive review but rather its aim is to provide a framework to assist in the discussion 
surrounding comparisons with DLB. 
 
1.3.1 Clinical features 
AD is the leading cause of dementia and accounts for approximately 50-60% of 
dementia cases (Blennow et al., 2006). It is defined clinically by an insidious onset and 
progression of cognitive impairment. Diagnostic criteria require that two or more 
cognitive domains are affected (McKhann et al., 1984). In contrast to DLB, it is 
typically characterized by early and prominent impairment in episodic memory. Other 
signs include dysphasia, dyspraxia and agnosia along with other cognitive symptoms 
such as impaired orientation and judgement (Dubois et al., 2007; McKhann et al., 1984) 
The criteria for the National Institute of Neurological and Communicative Diseases and 
Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) are commonly used for the clinical diagnosis of AD (McKhann et al., 1984). 
The criteria for ‘probable AD’ rely largely on exclusion of other dementias. 
 
1.3.2 Risk factors and associations  
Ageing is the most significant association factor. Findings from epidemiological studies 
suggest the concept of reduced brain reserve which includes reduced brain volume, low 
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educational or occupational level and reduced mental activity during late life (Blennow 
et al., 2006). Other risk factors include head injury and vascular risk factors (Blennow et 
al., 2006).  
 
1.3.3 Genetics 
AD has both sporadic and familial forms. Familial AD is rare, with an estimated 
prevalence of less than 0.01% (Harvey et al., 2003). It is an autosomal dominant form of 
AD with disease onset before the age of 65 years. Causative gene mutations include 
mutation of the amyloid precursor protein (APP) gene on chromosome 21 and 
presenilin 1 (PSEN1) and presenilin 2 (PSEN2) genes (Blennow et al., 2006). 
There is an association between apolipoprotein E (ApoE) ε4 allele and AD, accounting 
for most of the genetic risk in sporadic AD (Raber et al., 2004). ApoE acts as a 
cholesterol transporter in the brain and is less efficient than the other apolipoprotein 
forms in the neuronal repair process. Carrying the gene increases an individual’s risk by 
lowering the age of onset by almost 10 years for each allele copy. Heterozygotes carry 
an approximately 3-fold increased risk of the disease and homozygotes, a 15-fold 
increased risk (Bekris et al., 2010). A number of other AD genes, each with a small 
effect compared to ApoE have recently been described (Hollingworth et al., 2011; Jones 
et al., 2010). Genes involved include clusterin (ApoJ) and those involved with synaptic 
function and inflammation (Hollingworth et al., 2011; Jones et al., 2010). 
 
1.3.4 Pathological features 
The characteristic features of AD include senile or neuritic plaques and neurofibrillary 
tangles in medial temporal lobe structures and other cortical areas. This is often 
associated with neuronal and synaptic degeneration and loss. 
Amyloid plaques 
The amyloid cascade hypothesis suggests that the β-amyloid (Aβ) plaques begin from 
the abnormal processing of the amyloid precursor protein which leads to an imbalance 
between the production and clearance of β-amyloid from the cortex (Hardy and Selkoe, 
2002). It has been suggested that the Aβ accumulation triggers the abnormal 
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accumulation of tau, although the underlying processes are unknown. This then results 
in neuronal and synaptic dysfunction and cell death which is linked with the clinical 
manifestations of dementia (Terry et al., 1991).  
The finding that familial AD is associated with mutations in the APP gene itself or 
presenilin genes which encode protease subunits (gamma secretase) and people with 
Down’s syndrome carry an extra APP gene (located on chromosome 21) and develop 
the plaques earlier in life provide support for this hypothesis.  
Neurofibrillary Tangles 
Neurofibrillary tangles (NFT) are composed of hyperphosphorylated tau protein. The 
normal function of tau is in the assembly and stabilization of neuronal cell 
microtubules. In AD, hyperphosphorylation begins intracellularly and tends to 
aggregate into insoluble fibrils and tangles (NFT) which impair neuronal function. Tau 
pathology begins in the transentorhinal region then hippocampus and amygdala and 
later, other cortical regions (Ballard et al., 2011). Interestingly, the deposition of NFT 
and the process of neurodegeneration follow a similar distribution. In contrast, the Aβ 
plaques are extracellular and occur in a somewhat differing pattern to that of 
neurodegeneration, although with a degree of overlap. 
Clinical features of AD have been found to be related to NFT, rather than plaque 
formation. However, neurodegeneration and specifically synaptic loss has been found to 
be the most closely associated with the clinical features of AD (Terry et al., 1991). 
 
1.3.5 Imaging changes 
Structural imaging using CT or MRI is important in the diagnosis of AD to exclude 
other causes such as subdural haematoma, tumours or extensive vascular lesions.  
Cerebral atrophy can also be identified and is largely caused by the loss of neurons and 
synapses. The progression of atrophy correlates with cognitive decline (Savva et al., 
2009). However, atrophy is not specific to AD, so there is significant overlap with other 
dementias. 
Early degenerative change in AD occurs in the medial temporal lobe structures 
including the entorhinal cortex and hippocampus. MTL atrophy can be identified using 
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structural MRI and is associated with the presence and severity of AD neuropathology 
(Gosche et al., 2002; Jack et al., 2002), the clinical features of AD, and is useful for 
separating those with AD from healthy controls with a greater than 85% diagnostic 
accuracy (Scheltens et al., 2002). 
FDG-PET is used to measure glucose metabolism, an indicator of synaptic activity 
(Jagust et al., 2007). AD is associated with reduced glucose uptake in the temporo-
parietal, posterior cingulate and precuneal regions (Jagust et al., 2007) with greater 
reductions being associated with severity of cognitive impairment (Jack et al., 2010; 
Minoshima et al., 1997). Reduced blood flow has also been found in these areas using 
99M
TcHMPAO SPECT indicating the susceptibility of temporal and parietal regions to 
functional change in AD (Dougall et al., 2004).  
Amyloid plaques can now been visualized in vivo using PIB (Pittsburgh Compound-B) 
PET enabling further insights into the pathogenesis of AD. In a longitudinal study of 
AD, mild cognitive impairment (MCI) and healthy controls using PIB-PET and 
structural MRI, Jack et al. (2009) found that the PIB rate of change was small and 
similar across groups and did not correlate with cognitive or functional measures. 
Whereas ventricular expansion rate differed by group (AD>MCI>normal) and 
correlated with cognitive and functional measures (Jack et al., 2009). These findings are 
supported by neuropathological data. 
 
1.3.6 Therapeutics 
Cholinergic degeneration of the basal forebrain in AD can result in deficits in input into 
the hippocampus and entorhinal cortex, important structures for memory function. 
Cholinesterase inhibitors have been shown to have symptomatic benefits on cognition in 
AD with a treatment effect of 2.7 points on the Alzheimer’s disease assessment scale – 
cognitive subscale (ADAS-cog) and 1.4 points on the MMSE. In terms of efficacy, all 
available cholinesterase inhibitors seem to be similar and a Cochrane Review concluded 
that they are efficacious in mild to moderate AD (Birks, 2006). 
Memantine, a NMDA-receptor antagonist has shown some benefit on cognitive and 
behavioural symptoms in moderate to severe AD (Raina et al., 2008). Increased 
glutamatergic activity in AD is thought to impair neuronal function so NMDA-receptor 
antagonists are thought to protect the neurons from this without preventing 
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physiological activation. At this time, there is no evidence to support that memantine 
has any disease-modifying or neuroprotective properties (Raina et al., 2008). 
Behavioural symptoms are relatively common in the later stages of AD. These include 
agitation, aggression and psychosis. Cholinesterase inhibitors are important to consider 
as they can help alleviate these symptoms. Atypical antipsychotic medications such as 
risperidone and olanzapine have been shown to have some benefit in reducing 
aggression, agitation and psychosis. Although patients with AD are not as vulnerable to 
neuroleptic sensitivity reactions, it is still important to introduce these medications with 
caution and ensure careful monitoring as they can cause extrapyramidal side effects and 
also increase a person’s risk of cerebral events (Ballard and Corbett, 2010).  
 
1.3.7 Summary 
In summary, AD is characterized by early impairment of episodic memory. The 
pathological hallmarks include amyloid plaque and neurofibrillary tangles and resultant 
neurodegneration with neuronal and synaptic destruction. The imaging features of 
atrophy, particularly in the medial temporal lobe structures reflect neurodegeration and 
correlate with clinical measures of dementia. The functional imaging changes of 
temporal and parietal hypometabolism and hypoperfusion also reflect the clinical and 
pathological features of the disease.  
The next chapter will focus on structural and functional MRI techniques and findings 
from MRI studies in Lewy body dementias.
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Chapter 2 Magnetic Resonance Imaging in Lewy body dementias 
2.1 Introduction 
Lewy body dementias (LBD) include dementia with Lewy bodies (DLB) and 
Parkinson’s disease dementia (PDD) and share common clinical and pathological 
features (Lippa et al., 2007). Given the similarities between DLB and PDD, as 
described in section 1.2.2.2, the separation between the two conditions has been 
determined by consensus based on the duration of parkinsonian features relative to 
the development of dementia; the requirement being less than 12 months for DLB 
(McKeith et al., 2004). Whilst PDD and DLB are not necessarily the same disorder, 
they may represent different points on the same, possibly continuous, spectrum of 
Lewy body disorders (Lippa et al., 2007).  
Clinically differentiating DLB from other dementia subtypes can be equally difficult. 
The consensus criteria for DLB assist with improving the clinical diagnosis although 
it is limited by the low sensitivity (Litvan et al., 2003). It is therefore important to 
establish additional markers which, when combined with clinical assessment can 
improve diagnostic accuracy. Advanced MR techniques can provide a wealth of 
information including structural changes, microstructural changes through diffusion 
tensor imaging, tissue energetics and metabolism through spectroscopy and cerebral 
perfusion. MR neuroimaging in Lewy body dementias may assist with providing 
pathophysiological information as well as increasing the accuracy of ante-mortem 
diagnosis. 
This chapter reviews the MRI literature in DLB and PDD to determine whether there 
are characteristic imaging changes that may assist with the diagnosis, and given the 
clinical and pathological similarities between the conditions, how imaging changes 
may provide further insight into the relationship between DLB and PDD.  
 
2.2 Structural Magnetic Resonance Imaging 
Conventional MRI data has been used extensively in the study of neurodegenerative 
disorders to examine regional changes in tissue volume. Several methods are 
routinely used to analyse MRI data including visual inspection, region of interest 
(ROI) analysis or voxel based morphometry (VBM).  
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Visual rating and ROI analysis methods depend on the appropriate a priori choice of 
structures to be analysed while VBM performs a point by point analysis of each 
voxel within the image across whole data sets allowing unbiased and largely operator 
independent data analysis. All 3 methods have been used to investigate structural 
imaging changes in Lewy body dementias.  
2.2.1 Cortical atrophy  
A common finding in structural MR studies in dementia is whole brain atrophy when 
compared with control subjects, with widespread grey matter reduction in the frontal, 
temporal and parietal areas (Beyer et al., 2007; Ballmaier et al., 2004; Burton et al., 
2002; Hashimoto et al., 1998) (See Table 2.1 on page 27). 
Using VBM, Burton et al. (2004) compared subjects with PD (n=24), PDD (n=31), 
DLB (n=20), AD (n=35) and controls (n=39). They observed a diffuse pattern of 
grey matter atrophy affecting the temporal, parietal, middle and inferior frontal gyri 
and the occipital lobe in PDD when compared with control subjects, with no 
significant difference between the cortical atrophy profile in PDD and DLB. A VBM 
study by Beyer et al. (2007) in PDD (n=15), DLB (n=18), AD (n=21) and healthy 
controls (n=20) also found reduced grey matter in the temporal, parietal and occipital 
lobes. However, in contrast to Burton et al. (2004) the changes were more 
pronounced in DLB than PDD. The authors suggest several explanations for the 
differing result: (1) the clinical criteria for PDD used by Burton et al. (2004) required 
the presence of visual hallucinations or cognitive fluctuations, so the PDD subjects 
selected had a clinically similar phenotype to the DLB subjects, possibly increasing 
the likelihood of similar cerebral changes and (2) a shorter duration of illness in the 
PDD group than in the previous study which may be associated with more severe 
morphological changes. The DLB group included by Beyer et al. (2007) were also 
older; and, although not significant, may have influenced the differing results. 
However, the increased cortical amyloid deposition in DLB compared to PDD, 
reported in pathological and amyloid PET studies would be consistent with the 
finding of greater structural cortical change in DLB (Edison et al., 2008; Gomperts et 
al., 2008). Interestingly, a recent VBM study in PDD has reported greater cortical 
atrophy in patients who developed dementia early in the course of their disease 
(< 8years) compared with those who developed dementia later in the course of their 
illness (> 8 years) (Beyer and Aarsland, 2008). Although they did not include a DLB 
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comparison or control group, this finding is consistent with neuropathological data 
which found more severe plaques and cortical α synuclein pathology in the group 
with shorter duration of PD prior to dementia (Ballard et al., 2006) and reinforces the 
heterogeneity amongst patients with PDD which, in small sample sizes, would 
influence the MR study findings. 
Whitwell et al. (2007b) described what they term a signature MR pattern in DLB. 
Using both VBM and ROI analysis they studied subjects with DLB (n=72), AD 
(n=72) and controls (n=72) with careful matching for age, education and dementia 
severity. They found very little cortical grey matter loss, in contrast to the relatively 
diffuse pattern of grey matter loss observed by others (Beyer et al., 2007; Burton et 
al., 2004; Burton et al., 2002). However, they report scattered regions of cortical loss 
in frontal and parietal lobes, which is in keeping with other studies, but to a lesser 
degree. There was also a region of grey matter loss identified around the third 
ventricle, which may represent the hypothalamus. These findings were in contrast to 
AD, where a widespread pattern of grey matter loss was found, involving the medial 
temporal and temporoparietal regions. As with other MR studies, there was a large 
degree of overlap in results between individual subjects precluding the use of those 
MR methods as diagnostic scans. However, the study contributes useful information 
to patterns of cerebral atrophy in DLB as detected by MR and, in particular, how 
they differ from AD. 
Occipital hypometabolism and hypoperfusion in DLB have been documented in PET 
and SPECT studies respectively (Minoshima et al., 2002; Lobotesis et al., 2001; Ishii 
et al., 1999).  This led to interest into whether there were associated structural MR 
changes. Most volumetric studies using ROI analysis (Middelkoop et al., 2001) and 
VBM (Burton et al., 2004; Burton et al., 2002) did not find a significant occipital 
structural change in DLB. However, a VBM study comparing PD and PDD found 
that there was significant grey matter loss of the left occipital lobe (Burton et al., 
2004). The left occipital gyrus was also found to have more atrophy in DLB 
compared with control subjects using VBM (Beyer et al., 2007). 
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Author NC DLB PDD AD MRI MRI Findings 
Huber  
et al. (1989) 
10 
 
0 10 
(10)
b
 
0 1.5T 
visual image 
analysis 
PDD: brain surface area, ventricular 
measurements, supra- and infra-tentorial lesions 
were not significantly different to PD. 
Middelkoop  
et al. (2001) 
24 23 0 25 1.0T 
semi-automated 
segmentation 
DLB: occipital lobe–no difference in raw or 
normalised volume compared with controls and 
AD. 
Burton  
et al. (2002) 
25 25 0 30 1.0T 
VBM 
DLB: grey matter atrophy–diffuse involving 
temporal, frontal, parietal lobes and insular 
cortices. Occipital lobe–no grey matter loss.  
Ballmaier  
et al. (2004) 
38 16 0 29 1.5T 
cortical pattern 
matching 
DLB: TL and orbitofrontal cortices–relative 
preservation compared with AD.  
Burton  
et al. (2004)  
36 
 
17 26 
(31)
b
 
28 1.5T 
VBM 
PDD: no significant differences to DLB. Grey 
matter atrophy: widespread, temporal lobes, 
occipital lobes, right frontal and left parietal 
lobe.  Occipital grey matter atrophy compared 
with PD.  
Ramirez-Ruiz  
et al. (2005) 
0 0 16/8 
(13/11)
b
 
 1.5T 
VBM 
PDD: progressive grey matter loss 
predominantly in the hippocampal, temporal and 
occipital lobes.  
Summerfield  
et al. (2005) 
13 
 
0 16 
(16)
b
 
0 1.5T 
VBM 
PDD: cortical and subcortical grey matter 
atrophy–hippocampus, thalamus and anterior 
cingulate most affected compared with controls. 
Left superior temporal gyrus and right 
hippocampus atrophy compared with PD. 
Beyer  
et al. (2007) 
20 18 15 21 1.5T 
VBM 
PDD: Grey matter atrophy–diffuse, less than 
DLB.  
Whitwell  
et al. (2007b) 
72 72 0 72 1.5T 
VBM and ROI 
DLB: Grey matter atrophy–dorsal midbrain, 
hypothalamus and substantia innominata. 
Relative sparing of the hippocampus and 
temporoparietal cortex. 
Beyer&Aarsland  
(2008) 
0 0 15 0 1.5T 
VBM 
PDD: group that developed dementia early had 
more areas of atrophy than the late dementia 
group-medial frontal gyrus, right precuneus, left 
inferior parietal lobule, superior frontal gyrus 
and middle temporal gyrus. In the late dementia 
group, there was atrophy in the inferior frontal 
gyrus and in unmodulated images, reduced grey 
matter in the insula.  
a
 number of subjects in another dementia comparison group 
b
PD comparison group  
 
Table 2.1. Structural MRI studies – Cortical Atrophy. 
 
 
2.2.2 Rate of cerebral atrophy 
The rate of cerebral atrophy in DLB has been assessed in several longitudinal MR 
studies (Whitwell et al., 2007a; Burton et al., 2005; O'Brien et al., 2001) and are 
summarised in Table 2.2. The overall brain atrophy rate in DLB has been reported to 
be 1.4% per year, slightly less than in AD (2% per year) but still 3 times the rate in 
similarly aged controls (O'Brien et al., 2001). Whitwell et al. (2007a) reported a 
longitudinal MR study with pathologically confirmed cases of DLB (n=9), AD 
(n=12), mixed AD/DLB (n=13), controls (n=25) and other dementia subtypes. 
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Although there was a large amount of overlap in individual patient brain atrophy 
rates between the groups, a lower atrophy rate (0.4% per year) and ventricular 
expansion rate (4.8% per year) was reported in DLB compared with AD (atrophy 
1.1% per year and ventricular expansion rate of 8.3% per year). The group with 
mixed AD/DLB pathology also had a greater atrophy rate than the DLB group, (1.3% 
per year, ventricular expansion 7.2% per year); a similar rate to that previously 
reported in DLB. Interestingly, the rate of atrophy in the pure DLB was not 
significantly different to the control group. The authors suggest that the subject group 
clinically diagnosed with DLB may contain subjects with mixed pathology and 
conclude that the technique may help to differentiate DLB from AD and be valuable 
for future disease modifying treatment trials (Whitwell et al., 2007a). In a 
longitudinal study (Burton et al., 2005) comparing PD (n=18), PDD (n=13) and 
controls (n=24), whole brain atrophy rates were higher in PDD (1.12% per year) than 
PD (0.31% per year) and controls (0.34% per year), similar to the rate in DLB 
reported by O’Brien et al. (2001) yet higher than reported in DLB by Whitwell et al. 
(2007a). It is possible that the atrophy reflected in the sample of PDD may be partly 
due to Alzheimer pathology rather than Lewy related pathology (Burton et al., 2005).  
Author NC DLB PDD AD MRI 
MRI Findings:  
Cerebral Atrophy Rate (% per year) 
O’Brien et al. 
(2001) 
20 10 0 9 
(9)a 
1.0T 
boundary shift 
integral 
DLB: 1.4 
Controls: 0.5-0.7 
AD: 2.0 
VaD: 1.9 
Burton et al. 
(2005) 
24 
 
0 13 
(18)
b
 
0 1.5T 
boundary shift 
integral 
PDD: 1.12 
PD: 0.31 
Controls: 0.34 
Whitwell et al. 
(2007a) 
25 9 0 12 
(13+12+5+5)a 
1.5T 
semi-automated 
segmentation and 
manual tracing 
DLB: 0.4 
ventricular expansion rate: 4.8% per 
year, not significantly different to 
controls and less than AD. 
a
 number of subjects in another dementia comparison group. 
b
PD comparison group  
 
Table 2.2. Structural MRI studies – Rate of Cerebral Atrophy. 
 
 
2.2.3 Medial temporal lobe 
A robust MR finding in DLB and PDD is that of relative preservation of the medial 
temporal lobe when compared with Alzheimer’s disease (Whitwell et al., 2007b; 
Tam et al., 2005; Burton et al., 2002; Barber et al., 2001; Barber et al., 1999a; 
Harvey et al., 1999) (see Figure 2.1, page 29 and Table 2.3, page 32).  
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Figure 2.1. Coronal view illustrating relative preservation of the Medial Temporal Lobe and 
hippocampus in dementia with Lewy bodies (right) compared with Alzheimer’s disease 
(left). 
 
Barber et al. (1999a) used a standardised visual rating scale to grade medial temporal 
atrophy (MTA) in patients with DLB (n=26), AD (n=28), VaD (n=24) and healthy 
volunteers (n=26) and found that whilst MTA occurred more in all dementia groups 
compared with controls, there was less MTA in DLB compared with AD and VaD. 
The absence of MTA was highly specific for separating DLB from AD (100%) and 
VaD (88%), but with a much lower sensitivity (38%). This finding has been 
consistent in both ROI (Barber et al., 2001; O'Brien et al., 2001; Harvey et al., 1999; 
Hashimoto et al., 1998) and VBM (Beyer et al., 2007; Burton et al., 2004; Burton et 
al., 2002) studies. This was supported by a prospective MRI study with pathological 
verification which found the pathological correlates of MTA include senile plaques 
and neurofibrillary tangles but not Lewy body associated pathology (Burton et al., 
2009). 
The hippocampus itself, which forms part of the medial temporal lobe, is less 
atrophic in DLB than in AD (Whitwell et al., 2007b; Barber et al., 2001; Barber et 
al., 2000a; Hashimoto et al., 1998). Using VBM (Summerfield et al., 2005; Burton et 
al., 2004) and manual volumetric measurement techniques (Junque et al., 2005; Tam 
et al., 2005; Camicioli et al., 2003) subjects with PDD have been found to have less 
hippocampal atrophy than AD but more than controls; a finding that is also 
consistent with the pathological overlap between PDD and DLB. A single study has 
reported contrary findings, with hippocampal volumes in PDD patients smaller than 
in AD (Laakso et al., 1996), although the differences were not statistically 
significant. The authors suggest that this may, in part, be due to coexistent AD 
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pathology in the PDD group and this finding has not been replicated in other larger 
studies. 
Sabattoli et al. (2008) studied hippocampal morphology using manual tracing of 
hippocampal boundaries and computer-assisted post processing in DLB (n=14), AD 
(n=28) and healthy control subjects (n=28). They found that in DLB subjects there 
was global hippocampal volume loss of 10-20% compared with the control group, 
less than in AD with a differing pattern of hippocampal atrophy. DLB was 
characterised by atrophy in the medial and lateral aspects of the hippocampal head 
(anterior CA1) and hippocampal midline (CA2-3 fields, subiculum and 
presubiculum). Whereas AD subjects had greater atrophy in the anterior and 
posterior aspects of the hippocampal tail (CA1 field and subiculum) with the authors 
suggesting differing underlying neuropathological substrates (Sabattoli et al., 2008). 
Using a high resolution MRI sequence at a higher field strength (3T), and manual 
ROI analysis methods, Firbank et al. (2010) also found less atrophy in the subiculum 
and CA1 regions of the hippocampus in DLB (n=16) when compared to AD (n=16) 
although did not find any differences in the CA2 or CA3/4 regions. They also report 
a hypointense line visible on the images between CA1 and CA3/4 that was less 
distinct in AD than in DLB suggesting that it may represent disease related change. 
Using manual tracing (Bouchard et al., 2008) and VBM (Ibarretxe-Bilbao et al., 
2008),  hippocampal atrophy in PDD was found to primarily affect the  head of the 
hippocampus with a similar pattern being observed in the older PD group (Bouchard 
et al., 2008).  
The entorhinal cortex which forms part of the MTL was found to be smaller in DLB, 
PDD and AD compared to control subjects using a manual segmentation technique 
(Kenny et al., 2008). The percentage volume reduction was 14.7% in the PDD group, 
19.9% in the DLB group and 21.9% in the AD group. Although the entorhinal cortex 
volume was the smallest in AD, it was not significantly smaller than other dementia 
groups, suggesting this may reflect a common mechanism (Kenny et al., 2008). 
Hanyu et al. (2005) used the MR technique of magnetisation transfer ratios (MTR) to 
detect regional differences in the white matter between AD, DLB and controls. The 
MTR measurement reflects the degree of interaction between mobile tissue water and 
macromolecular structures such as myelin. They found a significant difference in the 
hippocampal MTR, with the MTR of those with dementia being significantly lower  
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than in healthy controls (controls>DLB>AD). Interpretation of this reduction in 
MTR is consistent with loss of myelin and/or increased tissue water content 
associated with changes in cellular structure and may contribute to a differential 
diagnosis between DLB and AD (Hanyu et al., 2005).  
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Author NC DLB PDD AD MRI MRI Findings 
Hashimoto  
et al. (1998) 
27 27 0 27 1.5T 
semi-automated 
segmentation and 
manual tracing 
DLB: hippocampal formation–relative preservation 
compared with AD. 
 
Barber  
et al. (1999a) 
 
26 26 0 28 
(24)a 
1.0T 
MTA visual rating 
scale 
DLB: MTL–relative preservation. TL atrophy 
correlates with memory impairment and age. 
Harvey  
et al. (1999)  
0 9 0 11 0.5T 
visual rating and 
volumetric analysis 
DLB: MTL–relative preservation 
Barber  
et al. (2000a) 
26 27 0 25 
(24)a 
1.0T 
ROI analysis 
semi-automated 
segmentation 
DLB: larger temporal lobe, hippocampal and 
amygdala volume compared to AD. Ventricular 
volume increased compared with controls, although 
whole brain volume was relatively preserved. 
Barber  
et al. (2001) 
26 26 0 22 1.0T 
ROI analysis 
DLB: MTL–relative preservation 
Burton 
et al. (2002) 
25 25 0 30 1.0T 
VBM 
DLB: MTL–relative preservation compared with AD. 
Ballmaier  
et al. (2004) 
38 16 0 29 1.5T 
cortical pattern 
matching 
DLB: TL–relative preservation (hippocampus, 
parrahippocampus and amygdala) compared with 
AD.  
Burton  
et al. (2004)  
36 
 
17 26 
(31)b 
28 1.5T 
VBM 
PDD: no significant differences to DLB. MTL–
relative preservation compared with AD. 
Hanyu  
et al. (2005) 
18 17 0 31 1.5T 
Magnetisation 
Transfer Ratios 
 ROI 
DLB: hippocampal MTR–lower hippocampal MTR 
than controls, higher MTR than AD 
(Controls>DLB>AD DLB). 
Junque  
et al. (2005) 
16 
 
0 16 
(16)b 
0 1.5T 
Manual tracing 
ROI 
PDD: hippocampal (20%) atrophy compared with 
controls. PD: hippocampal atrophy (10%) compared 
with controls (not statistically significant). 
Summerfield  
et al. (2005) 
13 
 
0 16 
(16)b 
0 1.5T 
VBM 
PDD: cortical and subcortical grey matter atrophy–
hippocampus, thalamus and anterior cingulate most 
affected compared with controls. Left superior 
temporal gyrus and right hippocampus atrophy 
compared with PD. 
Tam  
et al. (2005) 
39 
 
25 31 
(33)b 
31 1.5T 
Visual rating scale 
PDD: MTA–relative preservation compared with AD, 
similar to DLB 
Beyer  
et al. (2007) 
20 18 15 21 1.5T 
VBM 
PDD&DLB:MTL–relative preservation, compared 
with AD. 
Whitwell  
et al. (2007b) 
72 72 0 72 1.5T 
VBM and ROI 
DLB: relative sparing of the hippocampus and 
temporoparietal cortex. 
Bouchard  
et al. (2008) 
44 
 
0 13 
(44)b 
0 1.5T 
Manual tracing 
ROI 
PDD: hippocampal atrophy predominantly in the 
head of the hippocampus. 
Ibarretxe-
Bilbao et al. 
(2008) 
56 
 
0 9 
(16+
19)b 
0 1.5T 
VBM, ROI 
PDD: grey matter loss involving entire hippocampus 
compared with controls. PD+visual hallucinations:  
hippocampal  loss confined to the head of the 
hippocampus. 
Sabbatoli  
et al. (2008) 
28 14 0 28 1.0T 
manual tracing, 
radial atrophy 
mapping 
DLB: hippocampus–10-20% volume loss (compared 
with controls) affecting regions CA1, dorsal midline 
aspect CA2-3 and subiculum and presubiculum. 
Atrophy less than AD. 
Kenny et al. 
(2008) 
37 
 
20 30 
(31)b 
26 1.5T 
manual 
segmentation 
DLB&PDD: total normalised entorhinal cortex 
volumes smaller in dementia (AD, PDD and DLB) 
compared with controls. Smaller entorhinal cortex  
volume in DLB compared with PD.  
Burton et al. 
(2009) 
0 23 0 11 
(12)a 
1.0T (N=20) 
1.5T (N=26) 
visual rating 
DLB: less hippocampal atrophy than AD on MRI in 
pathologically confirmed cases. 
Firbank et al. 
(2010) 
16 16 0 16 3.0T 
High resolution 
sequence 
manual ROI 
DLB: less hippocampal atrophy in CA1and 
subiculum compared to AD. Hypointense line 
between CA1 and CA3/4 less distinct in AD. 
a
 number of subjects in another dementia comparison group, 
b
PD comparison group  
 
Table 2.3. Structural MRI studies – Medial temporal lobe structures. 
Chapter 2 MRI in Lewy body dementias 
33 
2.2.4 Subcortical structures 
DLB and PDD are characterised by a pattern of subcortical structural changes and 
MRI study findings are summarised in Table 2.4. Nigrostriatal degeneration and 
dopaminergic loss, particularly of the dopamine transporter in the striatum occurs in 
LBD but not to a significant extent in AD (Piggot et al., 1999). This can be visualised 
using specific imaging ligands and nuclear medicine techniques. For example, using 
FP-CIT SPECT imaging reductions of 40-50% were documented in striatal structures 
in LBD (O'Brien et al., 2004). These changes were found to have a sensitivity of 
78% and specificity of 90% in distinguishing DLB primarily from AD in a 
multicentre study and have been incorporated in the latest revision of the consensus 
criteria for DLB (McKeith et al., 2007; McKeith et al., 2005). It is important to 
consider how these functional dopaminergic changes may be related to structural and 
other MR changes. Striatal atrophy has been documented in LBD: putamen atrophy 
has been reported in PDD (Summerfield et al., 2005; Burton et al., 2004) and in 
DLB, relative to AD (Cousins et al., 2003). Although no significant structural 
differences were detected in the caudate nucleus in DLB (Almeida et al., 2003; 
Cousins et al., 2003; Barber et al., 2002), atrophy of the right caudate tail was 
reported in PDD in one VBM study (Burton et al., 2004). However, it seems very 
unlikely that the magnitude of atrophy seen (5-10% reduction in volume) is sufficient 
to explain the highly significant (up to 50%) reduction in dopamine transporter 
binding seen with FP-CIT SPECT. 
Atrophy of the substantia innominata and dorsal midbrain in DLB (Hanyu et al., 
2007; Whitwell et al., 2007b; Brenneis et al., 2004) has been documented, findings 
which are supported by the pathological involvement of the areas, including the 
nucleus basalis of Meynert (contained in the substantia innominata) (Lippa et al., 
1999).  
The thalamus has also been reported to be smaller in PDD (Summerfield et al., 2005; 
Burton et al., 2004). Atrophy of the amygdala in DLB was similar to AD in one 
study (Hashimoto et al., 1998) and two other studies have found no difference 
between DLB and controls (Burton et al., 2002; Barber et al., 2000a). A significant 
reduction in amygdala volume in PDD compared with controls has been reported in 
two studies using manual volumetric techniques (Bouchard et al., 2008; Junque et al., 
2005).  
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Author NC DLB PDD AD MRI MRI Findings 
Hashimoto  
et al. (1998) 
27 27 0 27 1.5T 
semi-automated 
segmentation and 
manual tracing. 
DLB&AD: amygdala atrophy comparable. 
Barber  
et al. (2000a) 
26 27 0 25 
(24)a 
1.0T 
ROI analysis 
semi-automated 
segmentation 
DLB: larger amygdala volume compared to AD. 
Ventricular volume increased compared with 
controls, although whole brain volume was 
relatively preserved. 
Hanyu  
et al. (2001) 
12 
 
0 6 
(11)
b
 
(6)a 1.5T 
MTR, ROI 
PDD: lower MTR in the subcortical white matter 
including frontal and genu of the corpus 
callosum compared with controls. 
Barber  
et al. (2002) 
25 26 0 21 
(18)a 
1.0T 
ROI 
DLB: caudate nucleus–no significant volumetric 
difference between dementia groups.  
Almeida  
et al. (2003) 
35 0 20 27 1.5T 
volumetric 
segmentation 
PDD: caudate nucleus volume–no significant 
difference between controls and PD. 
Cousins  
et al. (2003) 
37 14 0 27 1.5T 
volumetric, 
semi-automated 
and manual 
segmentation 
DLB: putamen–smaller compared with controls 
but not AD. When normalised to total 
intracranial volume reduced compared with 
controls and AD. 
Brenneis  
et al. (2004) 
10 10 0 10 1.5T 
VBM 
DLB: basal forebrain atrophy compared with 
AD.  Lateral prefrontal cortex and left premotor 
cortical atrophy compared with controls. 
Burton  
et al. (2004)  
36 
 
17 26 
(31)
b
 
28 1.5T 
VBM 
PDD: no significant differences to DLB. Grey 
matter atrophy: widespread, subcortical regions 
include right caudate tail and putamen and 
bilateral thalamus. 
Junque  
et al. (2005) 
16 
 
0 16 
(16)a 
0 1.5T 
Manual tracing 
ROI 
PDD: amygdala (21%) atrophy compared with 
controls. PD amygdale atrophy (11%) compared 
with controls, not statistically significant. 
Summerfield  
et al. (2005) 
13 
 
0 16 
(16)
b
 
0 1.5T 
VBM 
PDD: cortical and subcortical grey matter 
atrophy–hippocampus, thalamus and anterior 
cingulate most affected compared with controls.  
Wiltshire  
et al. (2005) 
27 
 
0 25 
(24)
b
 
16 1.5T 
ROI 
PDD(&PD): callosal atrophy not significantly 
different to controls or AD. Dementia severity did 
not correlate with corpus callosal atrophy. 
Hanyu  
et al. (2007) 
28 31 0 122 
(34)a 
1.5T 
ROI 
DLB: substantia innominata–smaller than AD.  
Whitwell  
et al. (2007b) 
72 72 0 72 1.5T 
VBM and ROI 
DLB: grey matter atrophy–dorsal midbrain, 
hypothalamus and substantia innominata. 
Relative sparing of the hippocampus and 
temporoparietal cortex. 
a
 number of subjects in another dementia comparison group, 
b
PD comparison group  
 
Table 2.4. Structural MRI studies – Subcortical structures. 
 
 
2.2.5 White matter hyperintensities 
Damage to the white matter is particularly evident in the ageing brain appearing as 
focal punctuate areas of hyperintense signal on T2-weighted MRI. Findings from 
studies investigating white matter hyperintensities (WMH) are summarised in 
Table 2.5. Using a standardised visual rating scale, WMH were shown to be more 
extensive in DLB when compared with control subjects but were similar to AD 
(Barber et al., 2000c; Barber et al., 1999b). However, using automated volumetric 
analysis Burton et al. (2006) found no significant difference between the amount of 
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WMH in the DLB, PDD and control subjects and greater amounts in AD. The 
authors suggest that the non-significance of the results may relate to a smaller sample 
size in their study and use of a different analysis technique. After one year they 
showed that WMH increase significantly in patients with AD, PDD and healthy 
controls, but not in those with DLB; and that the amount of WMH at baseline 
predicts progression, possibly indicating baseline susceptibility in subjects (Burton et 
al., 2006). Interestingly, Beyer et al. (2006) using a visual rating scale, also found 
that there was no significant difference in WMH between PDD (n=16) and control 
(n=20) subjects. However, in contrast to other studies, they also included a PD group 
(n=19), which had significantly lower WMH score than both the PDD and control 
group. The reason for the difference is not entirely clear and may, in part, reflect the 
heterogeneous nature of PD combined with a small sample size. The authors raise the 
possibility of lower neurotransmitter levels in PD compared to controls leading to 
fewer WMH (Beyer et al., 2006). Although, this would presumably apply to both PD 
and DLB and would not necessarily explain the lack of progression of WMH 
observed by Burton et al. (2006) in DLB contrasting with the progression of WMH 
observed in PDD.  
WMH can be further divided into periventricular hyperintensities (PVH) which are 
adjacent to the ventricles and deep white matter hyperintensities (DWMH).  The 
relationship between WMH and brain atrophy was studied by Barber et al. (2000b), 
who found that PVH rather than DWMH in AD and DLB correlated with increasing 
ventricular dilatation suggesting that PVH are associated with atrophy rather than 
cerebral ischaemia (Barber et al., 2000b).   
 
Author NC DLB PDD AD MRI MRI Findings 
Barber  
et al. (2000b) 
0 27 0 25 1.0T, 
semi-automated 
segmentation 
DLB: PVH increase associated with ventricular 
dilatation. DWMH associated with history of 
hypertension. 
Beyer  
et al. (2006) 
20 
 
0 16 
(19)
b
 
0 1.5T 
visual rating 
PDD: more WMH in the deep white matter and 
periventricular areas compared with PD subjects 
however not increased compared with controls. 
Burton  
et al. (2006) 
33 14 13 23 1.5T 
volumetric 
analysis 
DLB: WMH baseline similar to controls, no 
significant increase in progression rate over 12 
months. PDD: WMH increased progression rate 
compared with controls  
b
PD comparison group  
 
Table 2.5. Structural MRI studies – White matter hyperintensities. 
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2.3 MR Diffusion Tensor Imaging (MR-DTI) 
Diffusion weighted MR imaging measures the diffusional displacements of water 
molecules within the tissue on a timescale of milliseconds. Water movements at this 
level are dictated by true diffusion but also by interaction between moving water 
molecule and tissue structures at the cellular level, such as cell membranes and 
intracellular organelles (Le Bihan, 2007).  
Diffusion measurements can also provide detail on tissue microstructure by utilising 
the anisotropic nature of diffusion in neuronal white matter tracts with water 
molecules diffusing further along the tracts than perpendicular to them (Le Bihan, 
2007; Basser et al., 1994). This is represented by a diffusion ellipsoid at each voxel 
(see Figure 2.2), made up of three orthogonal eigenvectors and their component 
eigenvalues (λ1, λ2, λ3). λ1 (axial diffusivity) represents the eigenvalue of the 
direction of maximal diffusion and λ2 and λ3 are the eigenvalues representing the 
perpendicular plane and their average lengths are referred to as radial diffusivity.  
With neuronal degeneration the mean diffusivity, MD = 
 
 
 (λ1+ λ2+ λ3) increases with 
the loss of structural barriers that normally restrict diffusion (also referred to as 
apparent diffusion coefficient, ADC). Also, diffusion becomes less directionally 
oriented with an associated reduction in fractional anisotropy (FA) (Assaf and 
Pasternak, 2008; Beaulieu, 2002) which is a scaled version of the standard deviation 
of λ1, λ2, λ3; scaled so that 0 ≤ FA ≤ 1. 
White matter tract changes that occur in dementia can potentially be detected as 
reflected in alterations diffusion tensor imaging measures. 
 
 
 
 
 
 
 
 
Figure 2.2. Representation of the diffusion tensor ellipsoid: 3×3 tensor matrix, 
eigenvalues λ1, λ 2, λ3. 
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Figure 2.3. Coronal view illustrating Diffusion Tensor Imaging in dementia with 
Lewy bodies.  
 
The colour coded fractional anisotropy (FA) map (right) encodes the degree of 
anisotropy by image intensity, while pixel colour shows the primary direction of 
diffusion (red: left–right, green: anterior–posterior, blue: superior–inferior. (Left) 
Structural scan. 
 
DTI changes in LBD have been reported using conventional region of interest (ROI) 
or voxel based morphometry (VBM) methods (Kantarci et al., 2010; Lee et al., 
2010b; Ota et al., 2009; Firbank et al., 2007a; Firbank et al., 2007b; Matsui et al., 
2007; Bozzali et al., 2005). Some studies found widespread FA changes in 
comparison to healthy controls (Lee et al., 2010b; Bozzali et al., 2005) whilst others 
have found very little change (Kantarci et al., 2010; Firbank et al., 2007b). Bozzali et 
al. (2005) used this technique to investigate DLB (n=15) compared with a control 
group (n=36). Using ROI methods, they report DT-MRI changes in the corpus 
callosum and pericallosal areas (increased diffusivity and decreased FA values). 
White matter was also affected in the frontal, parietal and occipital areas in DLB 
patients with less prominent involvement of the temporal white matter. The caudate 
nucleus had DTI changes with increased diffusivity without an associated FA 
reduction. The authors suggest that the white matter changes found in DLB may 
reflect the pathophysiological process that eventually affect neurons in the 
association cortex (Bozzali et al., 2005). The findings were somewhat limited by the 
small sample size and lack of another type of dementia as a comparison group 
(Bozzali et al., 2005). 
FA reductions have also been reported in the posterior cingulate and precuneal areas 
in DLB and PDD (Lee et al., 2010b; Firbank et al., 2007a; Firbank et al., 2007b; 
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Bozzali et al., 2005). Firbank et al. (2007b) compared subjects with DLB (n=16), AD 
(n=15) and a healthy older control group (n=15) using a DT-MRI technique with 
fluid attenuated inversion recovery (FLAIR) to suppress the confounding signal from 
cerebrospinal fluid (CSF). Using a ROI analysis method they found that the DLB 
group had reduced FA in the precuneal area on ROI analysis. Given that 
hypoperfusion in this area has previously been found in DLB using SPECT (Firbank 
et al., 2003), the authors hypothesised that the disrupted connectivity as 
demonstrated by a reduced FA in the area of the precuneus may result in medial 
parietal hypoperfusion (Firbank et al., 2007b). Diffuse white matter changes found 
by Bozzali et al. (2005) were not replicated in this study. The authors suggested that 
the results by Bozzali et al. (2005) may have been influenced by brain atrophy as the 
use of diffusion sequence without FLAIR CSF suppression results in high ADC 
values from the CSF potentially increasing white matter ADC due to partial volume 
effects. Firbank et al. (2007b) included subjects with moderate white matter 
hyperintensities which may also have contributed to the differing results.  
Further analysis on the same patient group (Firbank et al., 2007b) found bilateral 
clusters adjacent to the posterior cingulate with reduced FA (Firbank et al., 2007a). 
This correlated with global atrophy in AD and DLB. Given that the hippocampus, 
anterior and posterior cingulate and lateral parietal regions show functional 
connectivity, the authors conclude that dementia progression as measured by global 
atrophy is associated with disruption of the white matter connecting the regions 
(Firbank et al., 2007a).  
Matsui et al. (2007) also reported a reduction in the FA in the posterior cingulate 
(ROI)  in a study of  PDD subjects (n=11) compared with PD (n=26) and healthy 
controls (n=10). This finding, along with Firbank et al. (2007a) supports the notion 
that the posterior cingulate may play an important role in the pathological process of 
LBD. 
The most consistent finding in DTI studies has been that of reduced FA in the region 
of the inferior longitudinal fasciculus (ILF) (temporo-occipital), although this area 
has also been found to be affected in AD (Kantarci et al., 2010; Lee et al., 2010b; Ota 
et al., 2009; Bozzali et al., 2005). Using tract based ROI methods Kantarci et al. 
(2010) reported reduced FA in inferior longitudinal fasciculus in DLB, which was 
similar to that reported in AD. In addition, they reported increased diffusivity in the 
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amygdala grey matter which, in contrast to AD, was not proportional to the degree of 
atrophy. Given that dysfunction of the visuo-amygdaloid pathway (via the inferior 
longitudinal fasciculus) has been implicated in visual hallucinations, they suggest 
that the disruption in the inferior longitudinal fasciculus as measured with DTI may 
be related to retrograde degeneration of the axonal projections (Kantarci et al., 2010).  
DTI findings in LBD have been variable. A combination of relatively small sample 
sizes, heterogeneity within cohorts and differing analysis methods make conclusions 
as to the DTI changes in DLB difficult. Consistent changes have been reported in the 
inferior longitudinal fasciculus, precuneus and posterior cingulate regions and 
highlight their potential importance in Lewy body dementias. 
 
2.4 Proton Magnetic Resonance Spectroscopy (1H-MRS) 
Proton MR spectroscopy provides information relating to brain metabolism by 
measuring the signal originating from protons attached to key biomolecules (Soares 
and Law, 2009). The MRS signal is much weaker than MRI due to the lower 
concentration of these biomolecules (mM compared to water protons at 110 Molar). 
To gain sensitivity MRS voxels are typically 1 to 8 cm
3
 in volume (Soares and Law, 
2009; Gaudin, 1995) and are usually only collected from a few pre-selected regions, 
limiting information about true regional differences. The brain proton spectrum 
includes metabolite peaks for 5 important compounds: (1) N-acetyl asparate (NAA) 
is regarded as a marker or neuronal integrity and is reduced in neuronal dysfunction 
or loss. (2) Creatine (Cr) is related to general metabolism, it is assumed to be 
relatively constant and is therefore often taken as an internal reference level. (3) 
Choline (Cho) is seen as an indicator of membrane activity, and (4) myo-inositol 
(mI) is mainly contained in glial cells. (5) Glutamine/glutamate (Glx) metabolism 
occurs in neurons and glial cells and reduction may reflect glial cell or axonal 
impairment (Soares and Law, 2009; Gaudin, 1995). Table 2.6 summarises the 
findings of six 
1
H-MRS studies identified in Lewy body dementias. 
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Author Con Patient number Area  (voxel of interest) DLB PDD 
 -trols DLB PDD AD  NAA/ 
Cr 
Cho/ 
Cr 
Glx/ 
Cr 
mI/ 
Cr 
NAA/ 
Cr 
Cho/ 
Cr 
Glx/ 
Cr 
mI/ 
Cr 
Molina  
et al. (2002) 
11 12 0 0 WM: centrum semiovale 
 
GM: parasagittal parietal 
cortex 
↓ 
 
↔ 
↓ 
 
↔ 
↓↔ 
 
↔ 
NA 
 
NA 
    
Summerfield 
et al. (2002) 
 
13 0 14 0 lentiform/caudate nucleus 
 
bilateral occipital cortices 
    ↔ 
 
↓ 
↔ 
 
↔ 
NA 
 
NA 
↔ 
 
↔ 
Kantarci  
et al. (2004) 
 
206 20 0 121 
(41/8)a 
Right and left posterior 
cingulate gyrus and 
inferior precunei 
 
↔ 
 
↑↔ 
 
↔ 
 
↔ 
    
Griffith  
et al. (2008a) 
12 
 
0 12 
(12)b 
0 Posterior cingulate gyrus     ↓ 
 
↔ 
 
NA ↔ 
 
Griffith  
et al. (2008b) 
61 0 12 22 Posterior cingulate gyrus     ↓  
 
↔ ↓ ↔ 
Xuan  
et al. (2008) 
8 8 0 0 Bilateral hippocampi ↓ 
 
↔ NA NA     
↔ = unchanged, ↓ = reduced, ↑ = increased; WM=white matter, GM=grey matter; NA=not applicable 
a 
number of subjects in another dementia group,
b
PD comparison group 
 
Table 2.6. 
1
H-MRS Studies. 
 
Using a single voxel spanning the right and left posterior cingulate gyri and inferior 
precunei, Kantarci et al. (2004) studied proton MRS in subjects with AD (n=121), 
DLB (n=20), VaD (n=8), frontotemporal lobar degeneration (n=41) and healthy 
controls (n=206). NAA/Cr levels were reduced in all dementias except for DLB 
suggesting posterior cingulate neuronal integrity in DLB as compared with other 
dementia subtypes (Kantarci et al., 2004). This is however in contrast to the DTI 
findings (Firbank et al., 2007a).  Molina et al. (2002) also found that there was no 
change in the NAA/Cr in DLB (n=12) compared to healthy controls (n=11) using the 
parasagittal parietal cortex as a VOI.  They acknowledged the limitation of using a 
single VOI potentially obscuring larger inter-group sized difference. 
Griffith et al. (2008a) compared the spectroscopic profiles in PD (n=12), PDD 
(n=12) and controls (n=12) using a VOI located in the posterior cingulate gyrus. The 
PDD group had significantly reduced NAA/Cr when compared with both the PD and 
control groups with no detected change in Cho/Cr or mI/Cr.  The same group also 
compared the proton MRS in PDD and AD, again using a VOI  located in the 
posterior portion of the posterior cingulate gyrus (Griffith et al., 2008b). A reduction 
in NAA/Cr was found in both PDD and AD suggesting neuronal dysfunction, a 
finding which contrasted with Kantarci et al. (2004) data for DLB subjects. A 
reduced Glu/Cr was also reported in PDD, differing from an increased mI/Cr in AD 
(Griffith et al., 2008b). 
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In a proton MRS study by Xuan et al. (2008) in DLB (n=8) and healthy controls 
(n=8), the right and left hippocampi were chosen as VOI, an area that has been 
previously studied in AD, and a significant decrease in the NAA/Cr ratio was 
observed. 
Summerfield et al. (2002) compared 
1
H-MRS in subjects with PDD (n=14), PD 
(n=12) and controls (n=13). Using a single voxel technique, they selected an area of 
the basal ganglia and the occipital cortex. Subjects with PDD showed lower NAA/Cr 
values than in PD or controls without an associated change in mI/Cr in the occipital 
cortex suggesting neuronal dysfunction without glial involvement. The results are in 
contrast to those of AD: decreased NAA/Cr and increased mI/Cr in the occipital area 
(Soares and Law, 2009). 
In summary, some but not all studies found relatively normal NAA/Cr ratios in DLB 
while in PDD, similar reductions to AD are seen. The differing voxels of interest, 
comparison groups and small sample size currently limit the generalisabilty of 
results. 
 
2.5 Functional MRI (fMRI) 
Functional MRI (fMRI) can be used to image regional brain activity. This technique 
relies on the fact that the magnetic state of haemoglobin (Hb) is oxygen dependent 
and changes from diamagnetic to paramagnetic as oxyhaemoglobin is deoxygenated 
(Jezzard et al., 2001). The increased consumption of oxygen by neurons during 
activation is accompanied by a disproportionate supply of oxygenated blood so that 
there is a net reduction in deoxy-Hb downstream from the area of activation which 
leads to an increase in the MR signal (T2 or T2* weighting), a process described as 
Blood Oxygenation Level Dependent (BOLD) contrast (Jezzard et al., 2001). 
As previously noted, SPECT and PET studies have reported changes in occipital 
blood flow and glucose metabolism respectively in DLB compared with AD 
(Minoshima et al., 2002; Lobotesis et al., 2001; Ishii et al., 1999). However, the 
cause of this is not clear and may not relate to structural changes (Burton et al., 2002; 
Middelkoop et al., 2001). Greater deficits have been observed in the lateral 
occipitotemporal cortex compared with ventral and medial areas (Ishii et al., 1999). 
In an exploratory fMRI study, Sauer et al. (2006) looked at task-related brain activity 
using a visual motion task as the lateral occipitotemporal probe and colour and face 
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discrimination task as the ventral occipitotemporal probe in 32 subjects: AD (n=10), 
DLB (n=9) and controls (n=13). Subjects were given task-related instructions and 
asked to respond using an alternative key, pressing as quickly and as accurately as 
possible. The motion task resulted in reduced activation in the lateral 
occipitotemporal area in DLB subjects compared with AD and controls and a trend 
toward a slower reaction time. Deficits were also evident in the face task 
(discriminating gender) with reduced ventral occipitotemporal activation and 
accuracy in the DLB group compared with AD and controls. The superior temporal 
sulcus (STS) is known to be atrophied in AD and to a lesser extent, in DLB (Gomez-
Isla et al., 1999), and a greater resting blood flow in the right medial temporal lobe 
has also been documented in a SPECT study (Ishii et al., 1999).  Sauer et al. (2006) 
found greater motion-related STS activation in DLB than AD suggesting that the 
slower reaction time in the motion task was less likely to be a result of non-specific 
effects such as fatigue. Since these fMRI studies rely on indirect detection of activity 
(the BOLD effect), any underlying changes in the microvasculature at the capillary 
level may confound interpretation of changes in activity measured in these studies 
(Sauer et al., 2006). 
A recent study investigated the functional connectivity using the resting BOLD 
contrast (T2* weighting) in DLB (n=15), AD (n=35) and controls (n=38) (Galvin et 
al., 2011). Using a precuneal seed, they found differing patterns of functional 
connectivity in DLB compared with AD. In DLB, there was increased connectivity 
in the putamen and inferior parietal cortex (dorsal attention network) and decreased 
connectivity in the medial prefrontal cortex, frontoparietal operculum (frontoparietal 
executive control networks) and primary visual cortex. The findings were somewhat 
limited by the sample size, with results reported uncorrected for multiple 
comparisons. However, they are suggestive of differences in the functional 
connectivity pattern between AD and DLB and warrant further investigation. 
 
2.6 Conclusions 
MR changes in DLB and PDD are similar and are characterised by a profile of 
atrophy predominantly affecting the subcortical structures with relative preservation 
of the medial temporal lobe structures which are very consistent with the 
characteristic clinical and cognitive features of the disease. These structural imaging 
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similarities provide support for the view that DLB and PDD represent points along a 
spectrum of Lewy body disorders. Relative preservation of the MTL compared with 
AD shows promise as a diagnostic marker in differentiating AD from DLB and has 
been incorporated into the revised criteria for the clinical diagnosis of DLB 
(McKeith et al., 2005). The rate of cerebral atrophy has potential as an outcome 
measure in therapeutic trials of putative disease modifying agents. However, further 
longitudinal studies looking at serial rates of atrophy are required before this can be 
fully established. In particular, as with the validation of any surrogate marker, a link 
between atrophy rate and some clinically significant outcome needs to be established 
for DLB, as has been done for AD (O'Brien et al., 2001).  
It is not yet possible to form robust conclusions about the utility of other MR 
measures. A combination of inconsistent results reported between studies and a 
degree of overlap in MR measures between dementia subtypes currently limits the 
diagnostic utility of some imaging techniques. There are many factors which may 
contribute to the varying results including the heterogeneity in study populations 
with differing levels of education, age range and cognitive and functional deficits, all 
of which are inherent to any clinical study in dementia. Other factors may include 
differing MR techniques and analysis methods, recruitment strategies and the fact 
that clinical research, despite the application of well-validated clinical diagnostic 
criteria remains limited by a level of diagnostic uncertainty. It is also possible that a 
number of subjects have more than one type of dementia pathology, for example, 
PDD or DLB subjects may also have varying degrees of Alzheimer pathology, which 
would dilute the differences between the conditions. However, there is little doubt 
that DLB and PDD are different clinicopathological entities to AD. The challenge is 
discovering the link between the clinical presentation and a relatively non-invasive in 
vivo technique to refine the ante-mortem diagnosis thereby allowing patients access 
to appropriate prognostic information and treatment strategies. MR techniques offer a 
non-invasive method to study cerebral changes in more detail. MR studies to date 
have been single modality, mostly looking at structural change. Advanced MR 
techniques such as DTI offer more sensitive measures for detecting early and 
potentially preclinical changes. 
The next chapter will describe the aims and hypotheses of the research undertaken in 
this thesis:  Structural and diffusion MRI in dementia with Lewy bodies. A 
comparison with Alzheimer’s disease and normal ageing.
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Chapter 3 Study aims, objectives and hypotheses 
3.1 Aims 
The main aim of this research was to use high field strength (3T) MRI to investigate 
structural and microstructural (diffusion imaging) changes in DLB, and to compare 
these findings both to healthy older controls and those with AD, a disease control. 
Our intention was to better understand neurobiological changes underpinning DLB, 
and investigate MR indices that may be helpful for both early and differential 
diagnosis of DLB, and subsequently show promise for monitoring disease 
progression. 
 
3.2 Objectives and hypotheses 
To examine and compare the regional volumetric grey matter (GM) changes in DLB 
compared to AD and healthy controls using voxel based morphometry analysis of the 
structural T1 weighted images acquired at 3T, and investigate the relationship of GM 
volume loss with clinical and neuropsychological measures. 
 
 DLB will be associated with less grey matter atrophy than AD but more than 
controls. The pattern of regional GM atrophy will display a posterior (parieto-
occipital) and subcortical predominance compared to controls. This will be in 
contrast to AD, which will be whole brain atrophy with prominent temporo-
parietal GM volume loss. 
 There will be less GM atrophy in the medial temporal lobe structures in DLB 
when compared with AD. 
 
To examine and compare the diffusion tensor imaging changes in the white matter 
tracts of DLB patients compared to AD and healthy controls using the tract based 
spatial statistics method of analysis. To investigate the relationship between DTI 
indices and clinical and neuropsychological measures.  
 
 There will be less white matter tract change in DLB than AD. In DLB the 
pattern of regional change in DTI indices will include the visual association 
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areas and subcortical structures, consistent with the neuropsychological 
profile. There will be less change in the white matter tracts of the medial 
temporal lobe structures in DLB than seen in AD. 
 Impaired episodic memory will correlate with DTI change in medial temporal 
lobe structures in both AD and DLB and executive dysfunction will correlate 
with DTI change in a fronto-subcortical pattern in DLB.
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Chapter 4 Clinical and Neuropsychological Characteristics  
4.1 Introduction 
As described in section 1.2.2.3, the pattern of neuropsychological impairment in 
DLB has been described as reflecting the combination of frontosubcortical 
dysfunction and the cortical cognitive deficits typically seen in AD (Janvin et al., 
2006). This typically manifests in DLB as a dysexecutive syndrome with prominent 
visuo-perceptual problems and fluctuating attention (McKeith et al., 2004). Memory 
is also affected, but usually to a lesser extent than seen in AD, at least in the earlier 
stages of illness (McKeith et al., 2004). The pathological substrates for these specific 
cognitive features are less clear and possibly reflect differing contributions of 
neurochemical and morphological changes when compared with AD. 
This chapter aims to characterise the clinical and neuropsychological features of a 
cohort of DLB participants in comparison to AD and healthy ageing. These subjects 
were recruited to undergo detailed MR imaging so that the specific aims and 
hypotheses which have been specified in Chapter 3 could be tested. Parameters 
which may separate the groups will be of particular interest as a means of developing 
a useful ‘probe’ for subsequent correlations with imaging changes in order to explore 
the potential pathological underpinnings of clinical features.  
 
4.2 Methods 
4.2.1 Subjects 
Subjects with dementia 
Seventy one people with dementia over the age of 60 (both sexes) were recruited 
from a community dwelling population of patients referred to local Old Age 
Psychiatry, Geriatric Medicine or Neurology Services. The research was approved by 
the local ethics committee. All patients and where appropriate, their nearest relative 
provided written informed consent. 
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Control Subjects 
Thirty-five control subjects were recruited from among relatives and friends of 
subjects with dementia or people who volunteered via advertisements in local 
community newsletters. A detailed examination was undertaken to exclude those 
with evidence of dementia (from history or CAMCOG score < 80), depression 
(history and assessment) or a history of any other significant neurologic, physical or 
psychiatric disorder including drug and alcohol abuse. 
4.2.2 Assessment and Diagnosis 
Diagnosis was made following a detailed clinical assessment. This included review 
of clinical records, a psychiatric and medical history review and physical 
examination. For those with dementia, a standard dementia screen was also 
completed which included haematology and biochemistry analysis, B12 and folate 
concentrations, thyroid function tests, syphilis serology and CT brain. Diagnoses of 
AD and DLB were made in accordance with NINCDS/ADRDA (McKhann et al., 
1984) and dementia with Lewy bodies consensus criteria (McKeith et al., 2005; 
McKeith et al., 1996) respectively by consensus agreement between three 
experienced raters (RB, JO’B and RW – as outlined in the declaration) blinded to all 
information from the research MRI scans.  
4.2.3 Clinical and Neuropsychological measures 
4.2.3.1 Clinical Scales 
For subjects with dementia, neuropsychiatric features were assessed using the 
Neuropsychiatric Inventory (NPI), an informant-based scale that is the most widely 
used neuropsychiatric tool in dementia and covers all relevant behavioural domains. 
It includes questions to assess 10 behavioural disturbances occurring in dementia 
patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, 
disinhibition, irritability/lability, apathy and aberrant motor behaviour  (Cummings et 
al., 1994). For each behaviour the presence followed by its frequency and severity 
were determined. 
Cognitive fluctuations were assessed using the Clinician Assessment of Fluctuation 
(CAF),  a carer-based questionnaire which rates the frequency (scale 0-4) and 
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severity (scale 0-4) of fluctuating cognition or consciousness over the 4 weeks prior 
to assessment, with 0 (and 16 by definition) representing no fluctuation and 12 
representing a high degree of fluctuation (Walker et al., 2000b). The CAF is one of 2 
fluctuation scales that have been validated in DLB and the only scale that has been 
validated against a biological standard (Ferman et al., 2004; Walker et al., 2000a; 
Walker et al., 2000b) 
Function was assessed using the Bristol Activities of Daily Living scale. It is a carer 
based questionnaire related to 20 daily living activities, developed specifically for 
use in people with dementia (Bucks et al., 1996). It has been validated and is widely 
used (Bucks and Haworth, 2002).  
The Geriatric Depression Scale was used to assess depressive symptoms in all 
subjects (Sheikh and Yesavage, 1986). The short version selected is a 15 item self-
report (yes/no) specifically developed and validated for use in the elderly and people 
with dementia (Gerety et al., 1994; Norris et al., 1987).  
Motor symptoms were assessed using the Unified Parkinson’s Disease Rating Scale-
III (motor subsection) as it is the most widely used and validated scale for 
assessment of motor features of Parkinson’s disease (Ramaker et al., 2002; Fahn et 
al., 1987). Ballard et al. (1997) has also identified 5-items of the UPDRS-III as 
motor features that were independent of confounding by cognitive impairment, 
comprising (1) Tremor at Rest, (2) Bradykinesia, (3) Action Tremor, (4) Facial 
Expression and (5) Rigidity. 
 
4.2.3.2 Neuropsychological Assessment 
Global Cognitive Measures 
Assessment of global cognitive measures in all subjects (AD, DLB and controls) 
included the Cambridge Cognitive Examination (CAMCOG) which incorporates the 
Mini-Mental State Examination (MMSE) (Folstein et al., 1975). 
The National Adult Reading Test (NART) was completed by all participants (Nelson 
and Willison, 1991) which provided an estimate of pre-morbid intelligence and 
educational level.  
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Attention – CDR System 
Attention was assessed with the Cognitive Drug Research (CDR) computerised 
assessment system—see http://www.cognitivedrugresearch.com/. This computerised 
attentional battery was selected as it has been used in dementia and, in particular, has 
been validated for use in DLB and AD (Ballard et al., 2002; Wesnes et al., 2002; 
Ballard et al., 2001a). The attentional battery included Simple Reaction Time (SRT), 
Choice Reaction Time (CRT) and Digit Vigilance (Vig) (Table 4.1).  The difference 
between CRT and SRT is referred to as Cognitive Reaction Time (CogRT).  
The tests were administered using a portable laptop computer placed at a standard 
distance from participants. The responses were recorded using a response pad with 2 
buttons, one marked “no” and the other marked “yes”. 
Task Task Explanation Variables Measured 
Simple Reaction 
Time 
Each time “yes” was presented on the 
screen, the participant was required to press 
the “yes” button as quickly as possible on 
the response pad provided. 
Response time (msec) 
 
Choice Reaction 
Time 
Each time the word “yes” or “no” appeared 
on the screen, and the participant was 
required to press the corresponding “yes” 
or “no” button as quickly as possible on the 
response pad provided. 
Response time (msec) 
Cognitive Reaction 
Time 
Difference between Choice Reaction Time 
and Simple Reaction Time  
CRT Mean – SRT Mean 
Response time 
difference (msec) 
Digit Vigilance A digit was randomly selected and 
constantly displayed on the right of the 
screen. A series of digits were presented in 
the centre of the screen (80 per minute for 
4 minutes) and the participant was required 
to press the “yes” button when the digit in 
the series matched the one on the right. 
Response time (msec); 
percentage of accurate 
responses 
Table 4.1. CDR Attentional Task Battery. 
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Executive Function 
1. CAMCOG executive function subscore 
The CAMCOG executive function subscore (max 28) comprised category fluency 
(max 6), abstract thinking (max 8), ideational fluency (max 8) and visual reasoning 
(max 6). 
2. Delis Kaplan executive function – verbal fluency tasks 
As indicated in Chapter 1, DLB is characterised by a prominent dysexecutive 
syndrome. We therefore adopted the Delis Kaplan verbal fluency tasks which have 
been used in people with dementia and included: (1) letter fluency (FAS), (2) 
category fluency (animals/boys names) and (3) category switching (fruits/furniture) 
(Delis et al., 2001). Higher level functions required for these tasks include initiation, 
simultaneous processing, systematic retrieval and speed of processing.   
Praxis 
Given the visuo-perceptual difficultiles in DLB compared with AD, the CAMCOG 
Praxis subscore (max 12) was of interest as it includes tasks of visuo-spatial function 
– copying 3 figures (max 3) as well as clock drawing (max 3). 
Memory 
1. CAMCOG memory subscale  
This included assessment of recent and remote memory and new learning. 
2. Episodic memory  
The Hopkins Verbal Learning Test (HVLT) and Brief Visual Memory Task – 
Revised (BVMT), are both widely used and well-validated measures of episodic 
memory (Benedict, 1997; Benedict and Groninger, 1995; Brandt, 1991). In brief, the 
HVLT consisted of a 12 word list which was read aloud 3 times (3 trials). After each 
trial, the participant was asked to recall as many words as they could from the list 
(total recall). The participant was then asked to recall as many items from the list 
following a 20 minute delay (delayed recall). Following this, there was a recognition 
trial where 12 items and 12 distractors (items not on the original word list) were read 
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aloud and the participant was asked if the items were on the original word list and 
asked to respond “yes” or “no”. The BVMT structure was similar. It involved the 
participant viewing an A4 sheet of paper with 6 figures for 60 seconds. The sheet 
was then covered and the participant was asked to draw as many items as they could 
recall (1 point for each correct figure and 1 point for each figure correctly placed). 
This was repeated 3 times (total recall) and then after a 20 minute delay (delayed 
recall). The participant was then shown 6 of the original figures and 6 distractors 
(figures not on the original sheet), one at a time and asked if the figures were on the 
original sheet of figures ‘yes’ or ‘no’ (recognition trial).  
In order to incorporate all aspects of the task, we derived a composite score of 
episodic memory (verbal and visual). Using Statistical Package for Social Sciences 
(SPSS, version 17), we normalised the scores of the cohort (AD, DLB and Controls) 
for each task component (total recall, delayed recall and recognition) creating a z-
score. That is, zi (task component) = 
    –         
        
 ; where i = study participant.  
The episodic memory composite was then calculated by adding the normalised 
scores (z-scores) of the components of the HVLT and BVMT (equal weighting). 
Episodic Memory Composite = z_HVLT total recall + z_HVLT delayed recall + 
z_HVLT recognition (true positive + true negatives) + z_BVMT total recall + 
z_BVMT delayed recall + z_BVMT recognition (true positives + true negatives).  
4.2.4 Statistics 
Descriptive analyses of the group characteristics were completed using the statistical 
software, SPSS 17. Data was reviewed for normality by visual inspection of the 
histograms and using the Shapiro-Wilk test. Differences in demographic and clinical 
data were assessed using either t-tests, Analysis of variance (ANOVA), or rank-sum 
tests (Kruskal Wallis or Mann-Whitney U) as appropriate for continuous variables 
and χ2 test for categorical data. Where post hoc analysis was required to test for 
group differences following ANOVA, a Tukey correction for multiple comparisons 
was applied to control for Type I errors. For each test statistic, a probability value  
p<0.05 was regarded as significant. 
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4.3 Results  
4.3.1 Subject characteristics  
One hundred and six participants were included in the analysis (36 AD, 35 DLB and 
35 Controls). Seventy-one participants with dementia were recruited between 
November 2008 and September 2010 along with 35 age-matched healthy control 
subjects. 
Thirty six subjects met the NINCDS/ADRDA criteria for probable AD (McKhann et 
al., 1984).  
Thirty four subjects met the original consensus diagnostic criteria for probable DLB 
and one for possible DLB (McKeith et al., 1996) and all 35 DLB subjects fulfilled 
the revised consensus criteria for probable DLB (McKeith et al., 2005).  
4.3.2 Subject demographics 
The demographic data for patients and control subjects are summarised in Table 4.2. 
Subject groups were well matched for age (F2,105=0.804, p=0.450) and educational 
level (F2,104=0.979, p=0.379). There were more men included in the DLB group, 
consistent with the male predominance reported in DLB but this difference did not 
reach statistical significance (χ2=3.85, df=2, p=0.146). NART-FS was similar in the 
dementia groups and, as expected, lower than the control group (F2,103=7.69, 
p=0.001; post hoc DLB vs AD, p=0.998). 
The AD and DLB group mean CAMCOG (t69=0.58, p=0.566) and MMSE (t69=0.71, 
p=0.480) scores were comparable suggesting a similar level of dementia severity. As 
expected these measures were significantly lower than the control group.  
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Characteristic DLB 
(n=35) 
AD 
(n=36) 
NC 
(n=35) 
p value 
Age (years) 78.46.9 78.35.8 76.75.2 0.450* 
M:F (% male) 27:8 (77%) 21:15 (58%) 20:15 (57%) 0.146§ 
Education (years) 10.82.6 11.13.5 11.72.6 0.379* 
NART-predicted IQ  102.812.4 102.613.6 112.49.2 0.001*, 0.998** 
Estimated dementia 
duration, months 
 
40.620.6 52.627.4 NA 0.042† 
MMSE (max 30) 20.35.3 19.54.4 29.11.0 0.480† 
CAMCOG (max 107) 67.715.3 65.812.1 97.33.8 0.566† 
Values expressed as mean  1SD (unless otherwise stated). 
* ANOVA – Controls, AD and DLB; **post hoc AD vs. DLB  
§Pearson’s Chi-square test – Controls, AD and DLB;  
† Student’s t-test – AD vs. DLB 
Table 4.2. Subject demographics. 
 
4.3.3 Clinical features 
4.3.3.1 Dementia with Lewy bodies subject characteristics 
 
The core clinical diagnostic features of the DLB group are summarised in Table 4.3. 
Visual Hallucinations 
Twenty-nine subjects had a history of visual hallucinations which were fully formed, 
occurring on more than one occasion and not attributable to medical factors, 
medications or advanced dementia. Using the NPI, we found that 26/33 (79%) had 
visual hallucinations in the 4 weeks prior to study assessment. An informant or carer 
was not available for 2 DLB subjects who had a history of hallucinations. Two DLB 
informants reported no visual hallucinations in the previous 4 weeks although the 
DLB subjects had a clear history of recurrent hallucinations prior to this. One DLB 
informant reported occasional visual hallucinations which did not meet the criteria 
for recurrent and fully formed visual hallucinations.   
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*Twenty-two patients had FP-CIT SPECT imaging prior to study inclusion, all were abnormal.  13 
patients did not have FP-CIT SPECT imaging, which is not needed to make a diagnosis of probable 
DLB.  
 
Table 4.3. Clinical features of the DLB cases. 
 
Cognitive Fluctuation 
Cognitive fluctuations were present in the majority of DLB cases 32/35 (91%) as 
assessed by 2 independent raters (RW and JO’B) according to the consensus 
diagnostic criteria (Table 4.3). There were significantly more DLB carers who 
reported fluctuation 28/33 (85%) than AD carers 11/35 (31%) (χ2=23.10, df=7, 
p=0.002), the results are represented in Figure 4.1 and Table 4.4. Of the 3 DLB 
subjects that were assessed as non-fluctuators by diagnostic rating, 2 did not have 
informants and the other was also reported by the informant not to fluctuate using the 
fluctuation scale. Therefore, there were 4 DLB subjects who were rated as fluctuators 
but reported by their informant not to have cognitive fluctuations in the 4 weeks prior 
to assessment as assessed by the fluctuation scale. 
 
 
 
 
 
Clinical Features Present 
Yes : No (%Yes) 
Core Features  
Recurrent Visual Hallucination 
 
29 : 6 (83%) 
Cognitive Fluctuation  32 : 3 (91%) 
Spontaneous Motor Parkinsonism  29 : 6 (83%) 
Supportive Features 
REM sleep behaviour disorder 
 
21 : 14 (60%) 
Abnormal dopaminergic SPECT imaging* 22 (100%) 
Neuroleptic sensitivity reactions 0 (0%) 
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Figure 4.1. Clinician’s Assessment of Fluctuating Cognition. 
 
Characteristic DLB 
n=33 
AD 
n=35 
p-value 
Fluctuation Scale (max 16)  6.1±3.8 2.2±3.6 0.001* 
Values expressed as mean ± 1SD 
*Rank sum test (Mann Whitney U) AD vs. DLB 
 
Table 4.4. The Clinician Assessment of Fluctuation. 
 
Motor parkinsonism 
Spontaneous motor parkinsonism, as defined by the UK Parkinson’s Disease Society 
Brain Bank Criteria (Hughes et al., 1992) was present in 29 DLB cases, and 11 
(31%) of the DLB participants were taking anti-parkinsonian medication. The 
estimated duration of parkinsonism was 31 months and the maximum duration was 
72 months. The severity of parkinsonism was rated with the Unified Parkinson’s 
Disease Rating Scale – III (UPDRS-III). The average UPDRS-III for the DLB group  
( x =26.0±10.7) was higher than the control group ( x =2.0±1.9), and the AD group 
( x =5.6±4.3) (DLB > AD; ∆ = 20.4, 95% CI: (16.6, 24.2); t69=10.6, p<0.001). The 
‘5-item UPDRS’ was also significantly higher in the DLB than the AD group  
(∆ = 9.7, 95% CI: (8.0, 11.4); t69=11.3, P<0.001) represented in Table 4.5.  
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Characteristic DLB 
n=35 
AD 
n=36 
Controls 
n=35 
p-value 
UPDRS III 26.010.7 5.64.3 2.01.9 <0.001† 
5-item UPDRS  10.95.0 1.31.2 0.40.7 <0.001† 
Values expressed as mean  1SD (unless otherwise stated). 
† Student’s t-test – AD vs DLB 
 
Table 4.5. Group UPDRS scores and motor parkinsonism. 
 
REM sleep behaviour disorder 
Twenty-one DLB subjects (60%) met the International Classification of Sleep 
Disorders-II diagnostic criteria B for Rapid Eye Movement sleep behaviour disorder 
(AASM, 2005) as assessed by two independent raters (RW and JO’B).  
Dopaminergic imaging 
Twenty-two DLB subjects underwent dopaminergic SPECT imaging as part of their 
clinical diagnostic work-up prior to study inclusion. All 22 (100%) had abnormal 
images showing reduced striatum dopaminergic binding consistent with their 
diagnosis. The remaining 13 DLB subjects did not have dopaminergic imaging, as it 
was not judged to be clinically indicated.  
Neuroleptic sensitivity reactions 
None of the DLB subjects had a documented history of neuroleptic sensitivity 
reactions; 3/35 were prescribed neuroleptics whilst involved in the study (2 
quetiapine and 1 aripiprazole). 
4.3.3.2 Clinical scales 
Results for the clinical assessment scales are shown in Table 4.6. 
Neuropsychiatric Symptoms  
As expected, the DLB group had more depressive features as measured by the 
Geriatric Depression Scale than the AD group ( x DLB=6.2±3.7, x AD=2.8±1.8; 
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AD<DLB ∆ = 3.4, 95% CI: (1.8, 5.0); DLB, AD & NC: F2,105=26.8, p<0.001). There 
was not a significant difference in the average GDS score between the AD and 
Control groups. Interestingly, despite higher rates of depressive symptoms, fewer 
DLB informants (14/33, 42%) reported depression than AD informants (21/35, 60%) 
and the average NPI depression score between AD and DLB was similar ( x DLB = 
1.58±2.85, x AD = 1.69±1.89 t66=0.19, p=0.851). Therefore, in DLB, informants were 
less likely to report depressive symptoms than the subject themselves and in AD, the 
informants were more likely to report depressive symptoms than the subject 
themselves. 
The mean NPI score was higher in the DLB group, although, the difference was not 
statistically significant ( x DLB=21.5±17.1, x AD=16.8±11.9; t66=1.30, p=0.197). From 
the 10 symptoms measured: visual hallucinations were more common in DLB than 
AD; and disinhibition was reported more frequently in AD (31%) than in DLB (3%) 
(χ2=9.43, df=1, p=0.002). Although delusions were reported slightly more frequently 
in DLB (39%) than AD (27%) as was apathy (DLB 64%, AD 50%), these difference 
were not significant. 
Function  
The DLB group had slightly more overall functional impairment than the AD group 
as assessed by the Bristol ADL scale ( x DLB=18.2±9.6, x AD=14.1±7.2, ∆=2.04, 
95% CI: (0.05, 8.2); t66=2.02, p=0.042). 
 
Clinical Scales DLB 
n=35 
AD 
n=36 
Controls 
n=35 
p-value 
GDS (max 15) 6.23.7 2.81.8 1.72.2 <0.001* 
NPI total a21.517.1 b16.811.9 NA 0.197† 
NPI: depression, Yes (% yes) 
a
14 (42%) 
b
21 (60%) NA 0.491§ 
NPI: VH, Yes (% yes) 
a
26 (79%) 
b
3 (9%) NA <0.001§ 
NPI: delusions, Yes (% yes) 
a
13 (39%) 
b
10 (29%) NA 0.346§ 
NPI: apathy, Yes (% yes) 
a
21 (64%) 
b
17 (50%) NA 0.260§ 
NPI: disinhibition, Yes (% yes) 
a
1 (3%) 
c
11 (31%) NA 0.002§ 
Bristol ADL a18.29.6 c14.17.2 NA 0.042† 
Values expressed as mean  1SD (unless otherwise stated). 
* ANOVA – Controls, AD and DLB;  
§ Pearson’s Chi-square test – Controls, AD and DLB;  
† Student’s t-test – AD vs DLB 
a (n=33), b (n=34), c(n=35) 
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Table 4.6. Results of clinical scales by group. 
4.3.3.3 Other clinical variables 
Vascular Risk Factors 
The vascular risk factor profile of all participants was similar (Table 4.7). A greater 
proportion of the DLB group were taking anti-platelet agents (51%) compared with 
controls (23%). This difference reached statistical significance between the DLB and 
Control group (χ2=6.12, df=1, p=0.013), but not between the DLB and AD groups 
(χ2=1.13, df=1, p=0.288). 
 DLB 
(n=35) 
AD 
(n=36) 
NC 
(n=35) 
p-value 
Vascular Risk Factors 
Hypertension 
 
11 (31.4%) 
 
14 (39%) 
 
18 (51.4%) 
 
ns 
Hypercholesterolaemia 11 (31.4%) 14 (39%) 16 (45.7%) ns 
Type 2 diabetes mellitus 4 (11.4%) 2 (5.7%) 3 (8.3%) ns 
Cardiovascular disease 8 (22.9%) 3 (8.3%) 3 (8.6%) ns 
Smoking history 
Current: Past: Never 
 
2:15:17 
 
2:15:19 
 
2:21:12 
 
ns 
Medications 
Antihypertensives 
 
19 (54.3%) 
 
16 (44%) 
 
19 (54.3%) 
 
ns 
Cholesterol lowering agents 11 (31.4%) 13 (36.1%) 14 (40%) ns 
Antiplatelet agents 18 (51.4%) 14 (38.9%) 8 (22.9%) 0.047, *ns, 
Warfarin 1 (2.9%) 1 (2.8%) 3 (8.6%) ns 
Oral hypoglycaemic agents 1 (2.9%) 1 (2.8%) 1 (2.9%) ns 
Statistical tests - χ2 across all groups;  
*χ2 between AD and DLB; 
ns, not significant (p>0.05).  
Table 4.7. Vascular risk factors in all groups. 
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Other medications taken by dementia subjects  
The majority of both AD (92%) and DLB (86%) groups were taking cholinesterase 
inhibitors. Fifteen (43%) DLB participants were taking anti-depressant medication 
compared with 9 (25%) of those with AD, although the difference was not 
statistically significant (χ2=1.82, df=1, p=0.177). Very few subjects were taking 
antipsychotic medication: 3 DLB (9%) and 1 AD (3%) (Table 4.8). 
 
Medication DLB 
(n=35) 
AD 
(n=36) 
p-value 
Cholinesterase Inhibitors 30 (86%) 33 (92%) ns 
Memantine 1 (3%) 2 (6%) ns 
Benzodiazepines 2 (6%) 0 ns 
Antidepressants 15 (43%) 9 (25%) ns 
Antipsychotics 3 (9%) 1 (3%) ns 
Table 4.8. Medications taken by dementia subjects. 
 
4.3.4 Neuropsychological Assessment 
4.3.4.1 Attention 
The task mean results were not normally distributed and, for each variable the 
correlation between mean and standard deviation was such that             , 
p<0.001. We therefore transformed the data to carry out group comparisons. For 
SRT, CRT and Vig group mean data, we used a reciprocal transformation [SRT 
Mean_T = 1/SRT Mean] and for CogRT mean, and group standard deviation data we 
used a logarithmic transformation [SRT SD_T = log(SRT SD)]. χ2 was used to 
compare the differences in Vig accuracy. For all other group comparisons, ANOVA 
was used. For post hoc testing between AD and DLB a Tukey correction for multiple 
comparisons was applied. All results are represented in Table 4.9 and Figure 4.2. 
As can be seen, the dementia groups had larger response times and greater variability 
in response times than controls in all CDR tasks. Within the dementia groups, the 
DLB group were also significantly slower than the AD group in all tasks. The 
CogRT time is the difference between CRT and SRT and, effectively accounts the 
motor response time, which is often slower in DLB. CogRT mean was also slower in 
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DLB than AD (F2,99=21.47, p<0.001, post-hoc CogRTDLB>CogRTAD, p=0.029, 
corrected). The DLB group also had greater variability in response times than AD 
(SD) which reached statistical significance in all tasks suggestive of fluctuating 
levels of attention.  
The accuracy rate in the vigilance task was also significantly lower in the DLB group 
than in the AD (χ2 =13.43, df=4, p=0.009) and control groups (χ2=26.70, df=4, 
p<0.001), consistent with more severe attentional deficits in DLB. 
CDR Task DLB 
(n=34) 
AD 
(n=34) 
Controls 
(n=35) 
p-value 
SRT Mean 692 (309) 484 (452) 320 (71) <0.001*, 0.012** 
SRT SD 309 (569) 139 (228) 64 (24) <0.001*, 0.032** 
CRT Mean 1104 (738) 779 (345) 517 (92) <0.001*, 0.020** 
CRT SD 477 (665) 259 (220) 99 (29) <0.001*, 0.021** 
CogRT Mean 
b
477 (321) 
c
335 (198) 197 (80) <0.001*, 0.029** 
CogRT SD 
b
561 (870) 
c
271 (226) 120 (30) <0.001*, 0.011** 
Vigilance Mean 
a
608 (110) 520 (102) 424 (51) <0.001*, 0.002** 
Vigilance SD 
a
133 (47) 104 (38) 62 (20) <0.001*, 0.017** 
 
Vig accuracy  
 
n=29 
 
n=34 
 
n=35 
 
<0.001
§
, 0.009
§§
 
0-50%,  7 (24%) 2 (6%) 0  
51-75% 7 (24%) 1 (3%) 0  
76-99%,  7 (24%) 14 (41%) 3 (9%)  
100% 8 (28%) 17 (50%) 32 (91%)  
Values represented as mean (standard deviation), in milliseconds except for Vig accuracy, where 
values are represented as number of participants (percentage).  
a
n=29, 
b
n=32, 
c
n=33; 
ANOVA on transformed variables – *DLB, AD and Controls, with post hoc **DLB vs AD group 
comparison;  
χ2– §DLB, AD, Controls and §§DLB vs AD. 
 
Table 4.9. CDR Computerised attentional task: response by group. 
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Bar chart representing CDR task mean response time in milliseconds (ms) by group. 
 
Figure 4.2. CDR Computerised attentional task: response by group. 
 
4.3.4.2 Praxis and Executive Function 
The results of neuropsychological tests of praxis and executive function are 
represented in Table 4.10. 
The CAMCOG praxis subscale includes 4 items involving visuo-spatial and visuo-
constructive tasks: copying a pentagon, spiral, 3D house and clock face drawing. The 
other items relate to ideomotor (e.g. wave good-bye, brush teeth) and ideational 
praxis (placing paper in an envelope). Given the weighting toward visuo-
spatial/visuo-constructive domains, it was not surprising that that DLB mean group 
performance was worse than the AD group ( x DLB =7.0±2.5, x AD= 9.5±1.4; ∆=2.5, 
95% CI: (1.5, 3.4); t69=5.07, p<0.001). 
The CAMCOG executive function subscale includes abstract thinking, verbal and 
ideational fluency and visual reasoning. These domains are affected in both AD and 
DLB and were comparable in our dementia cohort ( x DLB=12.1±5.3, x AD=13.4±4.0; 
t63=0.71, p=0.266). 
Verbal fluency tasks included the letter fluency, category fluency and category 
switching. The DLB group performance for the letter fluency task was significantly 
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worse than the AD group ( x DLB=20.8±13.3; x AD=27.5±14.3; t67=2.00, p=0.049) and 
slightly worse in the category fluency task although this did not reach statistical 
significance ( x DLB=17.6±9.1; x AD=20.1±8.5; t67=1.22, p=0.227). The category 
switching task performance between dementia groups was similar. 
 
Task  DLB 
(n=35) 
AD 
(n=36) 
Control 
(n=35) 
p-value 
(AD vs DLB)† 
Praxis 
CAMCOG Praxis (max 12) 
 
7.02.5 
 
9.51.4 
 
11.31.1 
 
<0.001 
Executive Function 
CAMCOG –EF  (max 26) 
 
12.15.3 
 
13.44.0 
 
22.42.7 
 
0.266 
Letter Fluency  a20.813.3 b27.514.3 41.011.1 0.049 
Category Fluency  a17.69.1 b20.18.5 37.98.6 0.227 
Category Switching 6.23.4 6.32.8 13.62.4 ns 
Values expressed as mean  1SD (unless otherwise stated).  
† Student’s t-test – AD vs DLB 
a 
(n=34), 
b 
(n=35) 
 
Table 4.10. Praxis and executive function task results by group. 
4.3.4.3 Memory  
The results of neuropsychological tests of memory are represented in Table 4.11. 
The CAMCOG Memory subscale includes assessment of recent and remote memory 
as well as new learning. The dementia groups performed significantly worse than the 
control group. When the dementia groups were compared, the DLB group performed 
significantly better than the AD group in this task, suggestive of less impaired 
memory function. Memory was further assessed with the verbal and visual measures 
of episodic memory using the HVLT and BVMT (Table 4.11). The total recall was 
similar in both AD and DLB groups and significantly lower than the controls. 
Sixteen DLB participants (45.7%) were able to recall at least one item after a 20 
minute delay, compared with only 4 AD (11.4%) participants, and they also had 
greater retention as evidenced by higher scores on the recognition trial (∆=3.8, 
95% CI: (2.47, 5.06); t67=5.79, p<0.001). The DLB group also performed better than 
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the AD group in the BVMT with improved mean total recall (∆=1.37, 
95% CI: (0.35, 2.40); t41.9=2.23, p=0.031), retention (DLB 58.8%, AD 34.3%) and 
recognition (∆=1.87, 95% CI: (0.95, 2.79); t66=4.06, p<0.001) with a higher 
recognition trial discrimination index (DI) (∆=1.87, 95% CI: (0.46, 2.79); t66=1.87, 
p<0.001). Scores for each of these components: total recall, delayed recall and 
recognition for both HVLT and BVMT were then normalised and added to form an 
episodic memory composite score for all groups (higher score indicating a better 
performance). The episodic memory composite was significantly lower in the AD 
group when compared with the DLB group (∆=2.84, 95% CI: (1.61, 4.07); t69=4.61, 
p<0.001) and, as expected, both dementia groups had significantly lower scores than 
the controls group ( x AD= -4.45 < x DLB= -1.61 < x NC = 6.25, F2,100 = 163.5, p<0.001). 
 
Task DLB 
(n=35) 
AD 
(n=36) 
Control 
(n=35) 
p-value 
(DLB vs AD)* 
CAMCOG Memory (max 27) 15.04.7 9.74.0 23.61.6 <0.001
†
 
HVLT total recall (max 36) 10.84.8 10.15.0 25.94.6 ns
†
 
HVLT delayed recall (>0)  16 (46%) 4 (11%) 34 (97%) 0.010
§
 
HVLT recognition (max 24) 18.12.9 14.42.5 221.9 <0.001
†
 
BVMT Total (max 36) a6.96.7 b4.12.5 18.86.5 0.027 
†
 
BVMT delayed recall (>0) 
a
20 (59%) 
b
12 (34%) 35 (100%) 0.041
§
 
BVMT recognition (max 12) 
c
9.2±2.1 
b
7.3±1.7 11.0±1.0 <0.001
†
 
BVMT recognition DI  c3.22.1 b1.31.7 4.91.1 <0.001
†
 
Episodic Memory Composite  c-1.63.2 b-4.51.5 6.22.6 <0.001
†
 
Values expressed as mean  1SD;  
Values for HVLT and BVMT delayed recall (>0) represent, number (percentage) of participants with a result 
greater than zero. 
*AD and DLB group comparisons were all significantly different to controls. 
§ χ2– Controls, AD and DLB;  
† Student’s t-test – AD and DLB 
a (n=34), b (n=35) c (n=33) 
 
Table 4.11. Results of the memory tasks by group. 
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4.4 Discussion 
We recruited a large and well characterised group of representative DLB and AD 
subjects as well as a healthy older comparison group. Groups were matched for key 
demographic variables such as age, sex and level of education. Between the DLB and 
AD groups, dementia severity was comparable although the reported duration of 
illness was shorter in DLB than AD (average of 41 months compared with 53 
months; p=0.042).  
4.4.1 Clinical features 
The visual processing system in DLB remains an area of intense research interest 
given the prominent disruptions which manifest as recurrent visual hallucinations 
and visuo-perceptual dysfunction  (McKeith et al., 2004). It seems likely that there is 
a link between the presence of visual hallucinations and visuo-perceptual change in 
DLB. This was supported by a study by Mosimann et al. (2004) that found patients 
with DLB and visual hallucinations had more impaired visual perception than the 
DLB patients without hallucinations. We did not find a difference in the CAMCOG 
praxis subscale between the DLB group with hallucinations and those without. 
However, there were only 7 DLB subjects without hallucinations making the 
comparison difficult. Recurrent visual hallucinations were present in the majority of 
our DLB group (83%), similar to the reported rate in other study cohorts (McKeith et 
al., 2004). Visuo-spatial and visuo-constructive deficits were also observed in the 
DLB group with the CAMCOG praxis subscale score being significantly worse than 
in AD.  
Parkinsonism is one of the core diagnostic features of DLB and was present in most 
of the DLB group (83%). The UPDRS III score was also significantly higher (mean 
26) than in the AD and control group. Although the UPDRS score for the AD group 
was slightly higher than the controls, this did not reach statistical significance. The 
development of motor parkinsonism in DLB is a result of dopaminergic deficiency 
with reduction of the striatal dopamine transporter (Piggot et al., 1999). Interestingly, 
60% (23/35) of the DLB cohort had dopamine transporter imaging (100% positive) 
as part of their clinical care prior to their recruitment into the study. This strongly 
supports that the majority of the DLB cases had striatal dopaminergic deficiency, a 
feature that is characteristic of DLB and rare in AD (O'Brien et al., 2004).  
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While some variation in cognitive performance and function is not uncommon in all 
dementias, pronounced variations in attention and cognitive performance is 
characteristic of DLB (Walker et al., 2000b). Fluctuation is characterised by periodic 
shifts in attention or arousal, though this remains difficult to assess and accurately 
quantify (McKeith et al., 2004). In this study, cognitive fluctuations were present in 
91% of DLB cases as assessed by the clinical diagnostic raters which is consistent 
with the reported 80-90% rate in all DLB cases (McKeith et al., 1996). A similar rate 
was also found using the Clinician Assessment of Fluctuation, a carer based 
questionnaire (Walker et al., 2000b). Interestingly, results of the CDR attentional 
battery were also in accordance with this. The DLB group had significantly slower 
cognitive reaction times, choice reaction times, higher vigilance scores with lower 
accuracy rates and greater variability (SD) in response times in all tasks compared to 
the AD group. This was consistent with more impaired attention and fluctuation in 
DLB subjects (Ballard et al., 2002). It is possible that other factors such as 
parkinsonism or depression may have contributed to these findings. However, the 
cognitive reaction time, which effectively controls for the motor response component 
by subtraction of the SRT from CRT, was also significantly slower in DLB than AD. 
Although this could represent a slowing of cognitive processing speed, the 
significant differences in variability (SD) and deficits in accuracy indicate 
widespread attentional problems in DLB compared with AD (Ballard et al., 2002).  
Attention involves a complex network of anterior and posterior cortical regions. The 
thalamus is also a key area involved in maintaining consciousness and organising 
and processing information between subcortical and cortical structures (Schiff, 
2008). The association between fluctuation and increased thalamic perfusion in DLB 
highlights its potential importance in the underlying pathological process (O'Brien et 
al., 2005). The cholinergic system, particularly the basal forebrain system is also one 
of the key modulating features providing major cholinergic input to the thalamus and 
cortical regions, with significant deficits found in DLB (Lippa et al., 1999; Perry et 
al., 1993). Cholinesterase inhibitors have been shown to improve attentional function 
in DLB (McKeith et al., 2000b) and it is also important to note that 86% of the DLB 
group were prescribed cholinesterase inhibitors but still had quite profound 
attentional deficits. 
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Neuropsychiatric features are more common in DLB than AD (Ballard et al., 1999), 
and not surprisingly, the most common in our DLB cohort was visual hallucinations. 
Delusions and apathy were frequently reported in both the AD and DLB groups with 
symptoms being more common in DLB, although this did not reach statistical 
significance. The DLB group also had significantly more depressive symptoms as 
assessed by the geriatric depression scale and more DLB participants were also 
taking antidepressant medication. This was an expected finding, as depression 
frequently occurs in DLB, and has been incorporated into the consensus criteria as a 
supportive feature of the disease (McKeith et al., 2005).  
The burden of vascular disease is an important consideration in the study of dementia 
as it can contribute to cognitive decline as well as gait disturbance (O'Brien et al., 
2003). Our study groups were reasonably well matched in terms of vascular risk 
factors. The DLB group were more likely to be taking anti-platelet therapy, which 
may be partly attributable to the slightly higher incidence of reported cardiovascular 
disease. All dementia subjects had a CT brain scan prior to study entry and had no 
evidence of major cerebrovascular disease.  
4.4.2 Neuropsychological changes 
Executive function broadly refers to the control of aspects of attention and future 
planning  (Metzler-Baddeley, 2007). DLB patients often have more severe executive 
dysfunction (dysexecutive syndrome) when compared with AD of similar dementia 
severity (McKeith et al., 2004) which was reflected in our study cohort. The DLB 
group performed significantly worse in the letter (phonemic) fluency task than the 
AD group, though the average category (semantic) fluency scores were comparable. 
The finding of reduced letter fluency and similar category fluency in DLB when 
compared with AD has been a consistent finding (Metzler-Baddeley, 2007). 
Suggested reasoning for this is that the reduced category fluency in AD relates to 
impaired semantic memory, which does not affect their performance in the letter 
fluency task. In DLB however, it is hypothesised that verbal fluency task deficits are 
related to frontal-subcortical network dysfunction which affect all verbal fluency 
tasks equally (O'Brien et al., 2006). Disruption in the function of this network may 
be due to reduction or loss of the dopamine projections from the striatum to the 
frontal cortex. Lewy body pathology may also have an influence and studies have 
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reported Lewy body formation in the anterior cingulate and subcortical areas 
including the striatum (Duda, 2004).  
The memory of the DLB subjects was significantly impaired relative to the controls, 
but relatively preserved when compared with AD. While the HVLT total recall was 
similar, the recall rate following a delay was significantly higher in DLB compared 
to AD as was recognition, a finding consistent with other studies (O'Brien et al., 
2006). The DLB group also performed better than AD subjects on the visual memory 
task (DLB 59% vs AD 34%, p=0.027). However, the difference in delayed recall 
between the DLB and AD groups was not quite as striking as the difference in the 
HVLT delayed recall task (DLB 46% vs AD 11%, p=0.010). This may have, in part, 
been due to impaired visual processing in the DLB group. The episodic memory 
composite score (comprised of the sum of z scores for 6 individual tests) was 
significantly higher in DLB than AD suggesting that the AD group had more 
impaired episodic memory. Impaired episodic memory in AD is an early and 
prominent feature of the disease and correlates with hippocampal atrophy (Jack et al., 
2010). Medial temporal lobe structures including the hippocampus atrophy in DLB 
when compared with controls but is to a lesser extent than seen in AD with relative 
preservation of medial temporal lobe structures being an established feature of DLB 
(McKeith et al., 2005). AD pathology is also usually present in DLB in varying 
degrees (Firbank et al., 2010; McKeith et al., 2005). It is therefore possible that 
impaired episodic memory in DLB reflects the burden of AD pathology and medial 
temporal lobe atrophy in DLB.  
This study represents a large and well characterised group of DLB and AD 
participants. Importantly the methods that we utilised for diagnosis were robust and 
have been shown to be highly specific in prospective validation studies (McKeith et 
al., 2000a). A potential limitation of the study is that not all participants were able to 
complete all of the neuropsychological testing. This was usually in participants with 
moderate to severe dementia. This was a particular problem with the CDR vigilance 
task where 6 DLB participants were not able to complete the task. This may therefore 
bias the results. However, a poorer performance in this DLB subgroup would imply 
that the difference in the CDR Vigilance task between AD and DLB would be even 
greater than reported. Some studies report findings in mild disease or, with a MMSE 
> 16 ‘cut-off’ which helps address this problem to some extent. However, it also 
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excludes investigating the spectrum of disease. Instead, we have reported all of the 
available data for the cohort, which is especially important when correlating with the 
imaging data.  
4.5 Summary 
DLB and AD result in similar levels of global cognitive deficits when compared with 
normal ageing with significant overlap in some cognitive domains such as learning. 
However, there were distinct and significant differences in the cognitive profile 
between the conditions. DLB was characterised by cognitive slowing with 
fluctuating levels of attention, impaired executive function and visuo-spatial and 
visuo-constructive deficits. Memory was impaired in both AD and DLB. However, 
in DLB, the deficits in delayed recall and recognition were less than observed in AD. 
This pattern of neuropsychological impairment in DLB is consistent with a 
predominantly subcortical pattern of pathological change with varying degrees of 
Alzheimer pathology, which manifests in the more AD-like cortical syndrome of 
impairment, with deficits in episodic memory. 
The clinical and neuropsychological features of this cohort are characteristic of the 
DLB and AD clinical syndromes. This is an important consideration when 
investigating group differences in imaging parameters and may help to provide a 
better understanding of the in vivo pathological differences between the conditions. 
In the next chapter, we investigate the structural grey matter changes in DLB 
compared to AD and controls. Given the neuropsychological profiles of our DLB and 
AD groups, we expect to find less atrophy in the medial temporal lobes structures in 
DLB than in AD. Other areas of interest include the subcortical structures and, given 
the visuo-perception difficulties, the parieto-occipital regions. 
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Chapter 5 Structural magnetic resonance imaging changes in 
dementia with Lewy bodies 
5.1 Introduction 
As discussed in Chapter 2, structural MRI has been used extensively to investigate 
patterns of grey matter (GM) atrophy in AD but to a much lesser extent in DLB. AD is 
characterised by a pattern of generalised cortical atrophy with particular GM loss of the 
medial temporal lobe structures and temporoparietal association cortices (Whitwell et 
al., 2008; Jack et al., 1992). Visual rating and volumetric studies have shown that 
subjects with DLB have relative preservation of the medial temporal lobe (MTL) when 
compared with AD (Whitwell et al., 2007b; Barber et al., 1999a) (see section 2.2.3). 
Other reported results have been less consistent. Some studies have found atrophy 
affecting subcortical regions such as the putamen, substantia innominata and dorsal 
midbrain (see section 2.2.4) along with overlap of affected areas in AD such as atrophy 
of the amygdala (Hanyu et al., 2007; Whitwell et al., 2007b; Cousins et al., 2003). 
Voxel based morphometry (VBM) performs a voxel-level analysis of tissue 
concentration between subject groups. It is an objective and largely operator 
independent method of MRI data analysis (Ashburner and Friston, 2000). Findings from 
other VBM studies comparing the structural grey matter changes in DLB and AD have 
varied (Takahashi et al., 2010a; Beyer et al., 2007; Whitwell et al., 2007b; Burton et al., 
2004; Burton et al., 2002). Some have reported a diffuse pattern of cortical GM loss 
whilst another has reported relatively little. The pattern of subcortical structural change 
is also unclear. VBM analysis methodology continues to be improved and refined and 
the ‘Diffeomorphic anatomical registration through exponentiated Lie algebra’ 
(DARTEL) image registration algorithm has recently been introduced. DARTEL 
provides a more sophisticated mathematical framework than the standard unified 
segmentation approach (Ashburner, 2007). This has been incorporated into the 
Statistical Parametric Mapping (SPM) toolbox (http://www.fil.ion.ucl.ac.uk/spm) and is 
now in widespread use. DARTEL offers more accurate inter-subject registration of 
brain images, thereby improving the localization and sensitivity of VBM studies 
(Ashburner, 2007). 
With the use of higher resolution imaging (3T) and the improved VBM-DARTEL 
analysis tool in a large group of well characterised DLB subjects we aimed to further 
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define MRI patterns of GM atrophy in DLB that may assist in differentiating it from 
AD. We also aimed to investigate correlations between GM loss and 
neuropsychological measures to help understand the in vivo pathological basis for 
clinical features in patients with dementia. 
 
5.2 Study specific methods 
Subject recruitment and assessment methods were described in section 4.2. 
5.2.1 MRI data acquisition 
Subjects underwent T1-weighted MR scanning on a 3T MRI system (Intera Achieva 
scanner, Philips Medical Systems, Eindhoven, Netherlands) with an 8-channel receiver 
head coil within 2 months of the neuropsychological assessment.  The sequence was a 
standard T1-weighted volumetric sequence covering the whole brain (3D MPRAGE, 
sagittal acquisition, 1 mm isotropic resolution and matrix size of 240 (anterior-
posterior) × 216 (superior-inferior) × 180 (right-left); repetition time (TR) = 8.3 ms; 
echo time (TE) = 4.6 ms; SENSE factor = 2; flip angle = 8°). The acquired volume was 
angulated such that the axial slice orientation was standardised to align with the AC-PC 
line. 
5.2.2 VBM-DARTEL 
The pre-processing steps are represented in Figure 5.1. VBM analysis was performed 
using SPM8 (http://www.fil.ion.ucl.ac.uk/spm) and MATLAB 7.9 (Math-Works, 
Natick, MA, USA). Subject images were visually inspected for any artefacts or gross 
anatomical abnormalities. MR images were then segmented into grey matter (GM), 
white matter (WM) and cerebrospinal fluid (CSF) using the standard unified 
segmentation model in SPM8 (Ashburner and Friston, 2005). GM templates were 
generated from all subjects using DARTEL (Ashburner, 2007). The subjects GM data 
were spatially normalised and warped in DARTEL and transformed to Montreal 
Neurological Institute (MNI) space (http://www.mni.mcgill.ca/). Images were then 
Jacobian scaled (similar to modulation) to ensure that relative volumes of GM were 
preserved following the spatial normalisation procedure and then smoothed with an 
8mm full-width at half-maximum (FWHM) isotropic Gaussian kernel. After spatial pre-
processing, the smoothed, modulated, normalised GM datasets were used for statistical 
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analysis. Total intracranial volume (TIV) of each subject was calculated by summing 
the total tissue probability of grey matter, white matter and CSF from probability maps 
generated during the initial segmentation step. 
 
 
Figure 5.1. VBM-DARTEL pre-processing steps. 
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5.2.3 Statistical Analysis 
Regional volume differences between groups were assessed using the SPM8 General 
Linear Model based on random Gaussian field theory (Friston et al., 1995). An absolute 
threshold mask of 0.05 was used for GM analyses. Age and TIV were included in the 
design matrix as nuisance covariates in all VBM analyses.  
Analyses were also performed to investigate the effects of GM loss and cognitive 
measures (CAMCOG, CAMCOG memory subscale, CAMCOG praxis subscale and 
MMSE) in subjects with AD and DLB, separately and combined as a single dementia 
group.  
Significant effects were assessed using an uncorrected threshold of p ≤ 0.001 and the 
family-wise error (FWE) threshold of pFWE ≤ 0.05, corrected for multiple comparisons. 
Only voxel level significance was considered. The cluster centres were converted from 
MNI space to Talairach coordinates using the programme GingerALE version 2.0.4 
(http://brainmap.org/ale/). The anatomical location was then determined using Talairach 
daemon (http://www.talairach.org/). 
 
5.3 Results 
5.3.1 Subject characteristics 
One hundred and six subjects completed the MRI scan and clinical assessment (35 
DLB, 36 AD, 35 Controls). The MR data for two AD subjects were excluded, one due 
to motion artefact and the other due to inaccuracy in the segmentation step noted on 
visual inspection. 
 
5.3.2 Subject demographics 
The demographic data for all subjects is discussed in section 4.3.2 and an abbreviated 
version of the results is represented in Table 5.1. 
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Characteristic DLB 
(n=35) 
AD 
(n=36) 
NC 
(n=35) 
p value 
Age y 78.4±6.9 78.3±5.8 76.7±5.2 ns
*
 
MMSE 20.3±5.3 19.5±4.4 29.1±1.0 ns
†
 
CAMCOG Memory (max 27) 15.0±4.7 9.7±4.0 23.6±1.6 <0.001
†
 
CAMCOG Praxis (max 12) 7.0±2.5 9.5±1.4 11.3±1.1 <0.001
†
 
UPDRS III 26.0±10.7 5.4±4.3 2.0±1.9 <0.001
†
 
Values expressed as mean ± 1SD 
*ANOVA – DLB, AD, Controls; †Student’s t-test – AD vs DLB 
 
Table 5.1. Demographics, clinical and cognitive measures 
 
5.3.3 Total grey matter, white matter and intracranial volumes across groups 
The average GM, WM and TIV across groups are represented in Table 5.2. As 
expected, the mean TIV was similar across groups (F2,103=1.55, p=0.217). The AD 
group had significantly lower volumes of GM than DLB and controls and lower WM 
volume than controls. There were no significant differences in the WM volume between 
DLB and AD or DLB and controls. 
 
Volume  
(cm
3
) 
DLB 
n=35 
AD 
n=34 
NC 
n=35 
p value* 
GM 558.8±52.4 529.7±56.5 580.3±48.4 F2,103=8.07, p=0.001
†
 
WM 437.3±88.9 412.0±47.6 455.0±57.6 F2,103=3.55, p=0.032
§
 
TIV 1533.7±165.2 1469.4±156.0 1495.0±135.2 F2,103=1.55, p=0.217 
All values are represented as mean ±1SD 
Post Hoc tests: †Con > AD, DLB (p≤0.09); DLB > AD (p=0.02). 
                §Con > AD (p=0.009); Con vs. DLB, AD vs. DLB (ns). 
 
Table 5.2. Grey matter, white matter and total intracranial volumes across groups. 
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5.3.4 Differences in grey matter volume between DLB and Controls 
As illustrated in Figure 5.2, clusters of reduced grey matter volume were observed in 
temporal, parietal and occipital areas (p<0.001, uncorrected) in DLB patients relative to 
controls. Regions of significant difference (p<0.05, corrected) were seen bilaterally in 
the parahippocampal gyrus, amygdala, superior temporal gyrus, uncus and the right 
caudate tail, represented in Figure 5.2 (B) and summarised in Table 5.3 (a).  
 
 
Figure 5.2. Three-dimensional surface renders showing the patterns of cortical  
GM loss in DLB (red) compared to controls; (A) p<0.001, uncorrected and  
(B) p<0.05, FWE-corrected. 
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5.3.5 Differences in grey matter volume between AD and Controls 
Clusters of grey matter atrophy in AD were diffuse and extensive involving bilateral 
frontal, temporal, parietal and occipital lobes when compared with controls as shown in 
Figure 5.3 (A) (p<0.001, uncorrected) and Figure 5.3 (B) (p<0.05, FWE-corrected). 
 
 
Figure 5.3. Three-dimensional surface renders showing the patterns of cortical GM loss 
in AD (red) compared to controls; (A) p<0.001 and (B) p<0.05, FWE-corrected. 
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5.3.6 Differences in grey matter volume between DLB and AD 
There was less atrophy in the medial temporal lobe structures in DLB when compared 
with AD, which was more pronounced on the left. Areas of significant GM volume loss 
in AD when compared to DLB included the left hippocampus and bilateral 
parahippocampal gyri (p<0.05, corrected) (Table 5.3(b) and Figure 5.4). Examples of 
T1 images in AD and DLB are represented in Figure 5.5. 
AD versus DLB 
 
 
Figure 5.4. Three-dimensional surface renders showing the areas of greater cortical  
GM loss in AD (red) compared to DLB (p<0.05, FWE-corrected). 
 
 
 
 
Radiological view 
 
Figure 5.5. Examples of coronal T1 images demonstrating medial temporal lobe  
atrophy in AD on the left and preservation of the medial temporal lobe structures  
on the right in DLB in (a) mild dementia and (b) moderate dementia.  
The left MTL structures are circled in red. 
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5.3.7 Clinical correlations in DLB and AD 
A positive correlation was observed between the CAMCOG memory subscale and 
regions of grey matter atrophy in temporal lobe structures (left>right) in the combined 
AD, DLB group and is represented in Figure 5.6. Table 5.3 (c) shows areas of 
significance. A correlation was observed in the DLB group alone but was strengthened 
by the inclusion of the AD group. However, the correlation was negligible in the AD 
group alone. There was no significant correlation found between regions of grey matter 
atrophy and the CAMCOG praxis subscale or global cognitive measure (CAMCOG and 
MMSE) in either AD or DLB subject groups. 
 
 
Figure 5.6. Three-dimensional surface renders showing the areas of greater cortical  
GM loss in AD (red) compared to DLB (p<0.05, FWE-corrected). 
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(a) DLB v control; (b) AD vs DLB and (c) correlation with the CAMCOG memory subscale in dementia 
(DLB, AD). For each peak, the table shows voxel-level significance (pFWE-Corr), spatial extent (k), t and z 
scores, MNI coordinates and anatomical region 
 
Table 5.3. Location and peak significance of GM volume reduction  
using VBM-DARTEL. 
 
 
Voxel-level 
(pFWE-Corr) 
Extent 
(k) 
t, z MNI Coordinates 
(x,y,z) (mm) 
Anatomical Region 
(Brodmann Area) 
(a) Controls >DLB   
<0.001 3932 7.4, 6.3 -29, -9, -15 Left amygdala 
0.001 1518 6.4, 5.6 30, -4, -29 Right amygdala 
<0.001 3932 7.3, 6.2 -21, 0, -18 Left parahippocampal gyrus (34) 
0.001 1518 6.3, 5.6 24, 2, -24 Right parahippocampal gyrus (34) 
<0.001 3932 6.7, 5.8 -29, -7, -38 Left uncus (36) 
0.027 1518 5.3, 4.8 35, -4, -36 Right uncus (36) 
0.001 3932 6.3, 5.6 -36, 2, -32 Left superior temporal gyrus (38) 
<0.001 3932 7.7, 6.5 -36, -22, -12 Left hippocampus 
0.003 407 6.0, 5.3 35, -27, -6 Right caudate tail 
(b) DLB > AD    
0.001 982 6.4, 5.6 -30, -30, -12 Left parahippocampal gyrus 
0.004 982 5.9, 5.2 -24, -25, -29 Left parahippocampal gyrus (35) 
0.001 316 6.2, 5.5 24, -31, -9 Right parahippocampal gyrus (27) 
0.001 316 6.2, 5.4 26, -28, -12 Right parahippocampal gyrus (28) 
0.001 982 6.3, 5.5 -26, -36, -6 Left hippocampus 
(c) Correlation with CAMCOG memory subscale  
0.002 103 6.1, 5.4 -20, -34, -8 Left parahippocampal gyrus (27) 
0.015 221 5.4, 4.9 -44, -16, -32 Left fusiform gyrus (20) 
0.043 96 5.1, 4.7 -36, 12, 4 Left insula (13) 
0.004 221 5.8, 5.2 -48, -16, -26 Left subgyral grey matter (20) 
0.004 159 5.8, 5.2 41, 3, -18 Right superior temporal gyrus  (38) 
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5.4 Discussion 
In a VBM study using the DARTEL registration algorithm comparing patterns of GM 
loss in DLB and AD, patients with DLB showed a pattern of GM loss involving the 
temporal, parietal, occipital and subcortical structures when compared with controls. 
Areas of significant differences included bilateral parahippocampal gyri, amygdala and 
uncus; left hippocampus and superior temporal gyrus and right caudate tail. These 
structures were also involved to a much greater extent in the AD group as part of 
widespread GM loss. These findings are largely in keeping with a VBM study by 
Whitwell et al. (2007b). Although, other VBM studies have demonstrated a more 
diffuse cortical GM loss in DLB (Beyer et al., 2007; Burton et al., 2002). In a VBM 
study by Burton et al. (2002), diffuse cerebral changes were reported in DLB, including 
frontal areas. We did not find significant changes in the frontal regions in DLB. This 
may, in part, be explained by the differing levels of dementia severity between studies. 
In Burton’s study, the DLB group was more impaired (mean MMSE=13.3) compared 
with our cohort (MMSE=20.3) (Burton et al., 2002). It is possible that as disease 
progresses in our DLB cohort, areas of frontal atrophy may become apparent and 
longitudinal investigation is warranted to determine whether this is the case. Beyer et al. 
(2007) also found widespread changes in DLB, however, in contrast to our study, the 
results were of unmodulated data and reported tissue concentration rather than volume, 
making comparisons difficult. 
We found relative preservation of the medial temporal lobe structures in DLB compared 
with AD. This is in agreement with other MRI studies (Whitwell et al., 2007b; Burton et 
al., 2002; Barber et al., 1999a) and pathological studies (Burton et al., 2009; Lippa et 
al., 1998) and is consistent with the relative sparing of episodic memory in DLB and the 
medial temporal structures (hippocampus and amygdala) underlying this. Our findings 
again highlight the importance of this observation as a potential discriminator between 
AD and DLB and they further validate its incorporation in the revised DLB criteria 
(McKeith et al., 2005). 
Other studies have reported a pattern of subcortical structural change in DLB (Whitwell 
et al., 2007). Our study found GM loss of the right caudate tail in DLB when compared 
to controls. Nigrostriatal dysfunction and dopaminergic loss, particularly of the 
dopamine transporter in the striatum occurs in DLB, but not to a significant extent in 
AD (Piggot et al., 1999). This can be visualised via nuclear medicine techniques using 
Chapter 5 Structural imaging changes in DLB 
 
80 
specific imaging ligands. Using FP-CIT SPECT, reductions of 40-50% have been 
documented in DLB (O'Brien et al., 2004). It is important to consider how these 
functional dopaminergic changes may be related to structural changes.  In our cohort of 
DLB patients, 22 had FP-CIT SPECT imaging as part of their clinical diagnostic work-
up prior to study inclusion. Of the subjects that had FP-CIT SPECT imaging, all were 
abnormal indicating reduced dopamine transporter uptake (see Table 4.3). Other studies 
have not found significant differences in caudate volume using ROI and semi-
automated segmentation analysis methods (Cousins et al., 2003; Barber et al., 2002). 
Interestingly, in a VBM study, Burton et al. (2004) reported atrophy of the right caudate 
tail in Parkinson’s disease dementia but not in the DLB comparison group. In a MRI 
study, using manual segmentation, Cousins et al. (2003) reported reduced putamen 
volume in DLB (approx 10-15%) compared to healthy controls.  When the values were 
normalised to TIV they found that the volume loss was also more pronounced in DLB 
compared with AD. Along with striatal dopamine transporter deficiencies, striatal 
dopamine D2 receptors are also reduced (Piggot et al., 1999). So although there is some 
intrinsic striatal pathology which may account for a degree of structural atrophy, it is 
unlikely that at this level of atrophy it would account for the substantial loss in 
dopaminergic activity (Duda, 2004; O'Brien et al., 2004). 
We identified an association between the CAMCOG memory subscale and atrophy in 
the medial temporal lobe structures in the combined AD and DLB group that was 
significant when corrected for multiple comparisons. Areas included the left 
parahippocampal gyrus, left subgyral grey matter, left fusiform gyrus and right superior 
temporal gyrus. The association was observed in the DLB group although strengthened 
by combining the AD group. The CAMCOG memory subscale is a combination of 
recent and remote memory and new learning with scores ranging from 0-27. The DLB 
group performed better than the AD group on this test, which is in keeping with the 
differing cognitive profiles between the conditions and would suggest that memory 
dysfunction in DLB is associated with GM atrophy in these regions. This correlation 
was not detected in AD alone, but there may be a number of reasons for this. Given the 
early and significant dysfunction of episodic memory in AD, many of the 
neuropsychological tests have a floor effect, making it difficult to detect correlations 
even where they may exist (large type II error probability). 
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In contrast to the memory assessments, the DLB group performed worse on the 
CAMCOG praxis subscale when compared with AD, which again is consistent with the 
expected neuropsychological profile of DLB of more impaired visuo-spatial processing 
and praxis (McKeith et al., 2005). One possible reason for this involves dysfunction of 
the parieto-occipital areas. The parieto-occipital changes in DLB have been 
demonstrated in functional imaging studies with hypometabolism and hypoperfusion in 
PET and SPECT studies respectively (Lobotesis et al., 2001; Ishii et al., 1998). We 
observed a pattern of GM loss preferentially affecting these areas as compared with 
frontal region (Figure 5.2). This was in contrast to AD which showed a more extensive 
and global pattern of cortical atrophy (Figure 5.3). However, we did not find significant 
areas of GM atrophy in the occipital areas (p<0.05, FWE-corrected) in DLB, or 
significant differences between DLB and AD. In a VBM study of patients comparing 
DLB and Parkinson’s disease dementia, Beyer et al. (2007) reported reduced tissue 
concentration of the left occipital gyrus in the DLB group. However, volumetric studies 
using ROI (Middelkoop et al., 2001) and VBM (Whitwell et al., 2007b; Burton et al., 
2002) did not find significant occipital structural changes. Our study suggests that some 
neuronal loss in the parieto-occipital areas does occur, although it did not reach 
statistical significance when corrected for multiple comparisons, nor does it appear 
more pronounced than in AD. It seems more likely that the characteristic 
neuropsychological changes in DLB may reflect neuronal or synaptic dysfunction rather 
than neuronal loss. Our results also support previous studies suggesting that underlying 
structural changes are not sufficient to explain the functional metabolic abnormalities in 
the posterior parietal and occipital cortex which are seen in DLB but not AD. 
The strengths of this study include a large and well-characterised group of patients with 
probable DLB. In addition, the dementia groups were well matched for age, level of 
education and dementia severity. We were therefore able to report results corrected for 
multiple comparisons using the family-wise error, which is in contrast to some other 
studies. This means there is a high likelihood that our findings represent true differences 
between the groups, although, the potential disadvantage with using this method is the 
possibility that we may have missed, or underestimated the degree of true MRI 
differences between the groups (type II error). 
In conclusion, we have demonstrated a pattern of GM loss affecting the temporal, 
parietal, occipital and subcortical structures in DLB when compared with controls. 
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These changes were generally less extensive than seen in AD. In particular, we have 
shown that there was significantly less medial temporal lobe atrophy in the DLB group 
when compared to AD. This finding, along with pathological validation studies, 
suggests that degree of medial temporal atrophy may be a more useful imaging 
biomarker than previously thought. Relative preservation of the MTL structures has 
been included as a supportive feature in the revised consensus criteria for DLB and our 
findings support its inclusion. 
The next chapter will focus on the white matter tract changes in DLB compared to AD 
and healthy ageing using diffusion tensor imaging. Given the patterns of grey matter 
atrophy in DLB, we expect to see more diffuse white matter tract abnormalities.  
Accordingly, we focus on the potential clinical correlations to provide further insight 
into the pathological changes in DLB. 
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Chapter 6 Diffusion tensor imaging in dementia with Lewy bodies 
6.1 Introduction 
 
We have found that DLB is characterised by a pattern of relative structural  
preservation of the medial temporal lobe on MRI when compared to AD, a finding 
consistent with others (Whitwell et al., 2007b; Barber et al., 1999a). Other reported 
changes have been less consistent. This is in contrast to AD where the temporo-
parietal pattern of grey matter atrophy is well established and also corresponds to the 
clinical and functional imaging features of the disease (Jack et al., 2010; Whitwell et 
al., 2008; Jack et al., 1992).  
As discussed in Chapter 2, diffusion tensor imaging (DTI) is an MR technique that is 
commonly used to provide information about the integrity of white matter. DTI 
utilises the anisotropic nature of diffusion in neuronal white matter tracts with water 
molecules diffusing more freely along the tracts than perpendicular to them (Le 
Bihan, 2007; Basser et al., 1994). This is represented by a diffusion ellipsoid at each 
voxel, made up of three orthogonal eigenvectors and measures of their lengths, the 
component eigenvalues.  With neuronal degeneration the mean diffusivity, MD 
increases with the loss of structural barriers that normally restrict diffusion and 
diffusion becomes less directionally oriented. This is also associated with a reduction 
in fractional anisotropy (FA), a measure of the standard deviation in diffusion along 
the 3 principal directions (Assaf and Pasternak, 2008; Beaulieu, 2002).  
Previous studies investigating the DTI changes in DLB have used conventional ROI 
or VBM methods (Kantarci et al., 2010; Lee et al., 2010b; Ota et al., 2009; Firbank et 
al., 2007a; Firbank et al., 2007b; Bozzali et al., 2005). Only Lee et al. (2010b) and 
Kantarci et al. (2010) DTI studies were acquired at 3 Tesla. Some studies found 
widespread FA changes in comparison to healthy controls (Lee et al., 2010b; Bozzali 
et al., 2005) whilst others have found very little change (Kantarci et al., 2010; 
Firbank et al., 2007b). The most consistent finding has been of reduced FA in the 
region of the inferior longitudinal fasciculus (ILF) which provides a connection 
between the temporal and occipital lobes. However, this area was also found to be 
affected in AD (Kantarci et al., 2010; Lee et al., 2010b; Ota et al., 2009; Bozzali et 
al., 2005). FA reductions have also been reported in the posterior cingulate and 
precuneal areas (Lee et al., 2010b; Firbank et al., 2007a; Firbank et al., 2007b; 
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Bozzali et al., 2005). More recently, Kantarci et al. (2010) reported significantly 
lower FA and increased MD in the amygdala which, in contrast to AD, was not 
proportional to the degree of atrophy. DTI therefore shows promise as a useful 
imaging technique to provide important pathological insights into the disease process 
and, in particular, how it differs from AD. However, a combination of relatively 
small sample sizes, heterogeneity within cohorts and differing analysis methods 
make conclusions as to the DTI changes in DLB difficult.  
DTI analysis using ROI and VBM methods have limitations. The placement of ROI 
is operator dependent with the inherent problem of reproducibility. Partial volume 
effects can also be problematic with varying amounts of CSF or grey matter included 
in the ROI, particularly in subjects with brain atrophy. The relatively operator-
independent VBM style of analysis addresses some of these problems although it too 
has its own inter-subject registration and spatial smoothing issues (Smith et al., 
2006). Tract based spatial statistics (TBSS) is a relatively novel methodological 
algorithm designed to combine the benefits of a relatively operator-independent 
VBM style of analysis with the tract based information gained from tractography and 
has already been successfully applied to studies of other dementias (Smith et al., 
2006).  
In this study we applied the TBSS analysis methods to investigate the pattern of 
white matter tract change in DLB, in comparison to AD and aged-matched controls. 
We anticipated that there would be significant FA reduction and MD increase in the 
temporal and parietal regions with generally less change than observed in AD, 
particularly in the medial temporal lobes. By correlating the DTI changes with 
clinical features, we aimed to provide further insights into the potential pathological 
features underpinning the characteristic clinical and cognitive features observed.  
6.2 Study specific methods  
Subject recruitment and assessment methods are detailed in section 4.2.1–4.2.3. 
6.2.1 MRI data acquisition 
Subjects underwent MR scanning on a 3T MRI system (Intera Achieva scanner, 
Philips Medical Systems, Eindhoven, Netherlands) with an 8-channel receiver head 
coil within 2 months of the study assessment. 
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Diffusion tensor imaging  
DTI images were acquired using a Pulsed Gradient Spin Echo (PGSE) sequence and 
multi-slice single shot EPI readout, with TE = 71 ms and TR = 2524 ms. The image 
volumes were angulated such that the axial slice orientation was standardised to align 
with the AC-PC line with 2 mm in-plane resolution, 6 mm slice thickness and matrix 
size of 128 (anterior – posterior) × 128 (right – left) × 24 (superior – inferior). The 
scan was accelerated with SENSE factor of 2 in the Anterior-Posterior direction, and 
reconstructed with the CLEAR algorithm. Diffusion weighting was achieved by 
applying diffusion sensitising gradient pulses with measurements made in 16 
directions with a b value of 1000 s.mm
-2
. 
6.2.2 DTI preprocessing and analysis 
The Functional MRI of the Brain (FMRIB) software library (FSL) program was used 
to process and analyse the raw DTI data (Smith et al., 2004) accessed at 
www.fmrib.ox.ac.uk/fsl. 
To correct for the distorting effect of eddy currents, we adapted the approach of Shen 
et al. (2004) and used an affine registration, in FSL’s FLIRT (FMRIB's Linear Image 
Registration Tool) to register pairs of diffusion weighted images together. The eddy 
corrected diffusion weighted images were then registered with a rigid body 
registration to the b=0 s.mm
-2
 image. The MD and FA images were calculated using 
FSL tensor analysis of the aligned diffusion weighted images at each brain voxel. 
Voxelwise statistical analysis of the FA data was then carried out using Tract based 
spatial statistics (TBSS) (Smith et al., 2006). The steps involved are represented in 
Figure 6.1. All subjects' FA data were aligned to a 1mm isotropic FA target image in 
standard space (FMRIB58_FA) using the nonlinear registration tool FNIRT 
(Andersson et al., 2007a; Andersson et al., 2007b) which uses a b-spline 
representation of the registration warp field (Rueckert et al., 1999). We visually 
checked the data to verify the accuracy of the nonlinear transformation. A mean FA 
skeleton representing the centres of all tracts common  to the group was created by 
(1) averaging the warped FA images and then (2) thresholding at FA>0.2 to exclude 
skeleton voxels which may contain grey matter (Figure 6.1). Each subject's aligned 
FA data was then projected onto the mean FA skeleton, which accounted for residual 
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misalignments between subjects after the initial nonlinear registration. The resulting 
data was fed into voxelwise cross-subject statistics. Data for MD were also projected 
onto the mean skeleton by using non-linear registration and projection vectors from 
the FA images.  
 
 
Figure 6.1. Representation of the pre-processing steps involved in tract based spatial 
statistics method of analysis. 
 
 
6.2.3 White matter hyperintensities 
Identification of white matter lesions generally requires T2 weighted and T2-FLAIR 
imaging.  As part of the study, a more detailed scan protocol was collected in every 
subject providing additional data, which is not presented in this thesis.  Study 
duration prevented collection of FLAIR scans, however the protocol did include 
acquisition of quantitative scans to measure tissue T1 and T2 with isotropic 2mm 
resolution.  These scans were used (Drs Benjamin Aribisala & Michael Firbank) to 
generate FLAIR weighted images, which could be used in conjunction with the high 
resolution T1 weighted scans (Chapter 5 – section 5.2.1) to identify and visually rate 
the burden of white matter hyperintensities in the cohort. 
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Using the Fazekas scale, modified by Coffey (Coffey et al., 1989; Fazekas et al., 
1987) white matter hyperintensities (WMH) were rated by consensus between 2 
experienced raters (Drs Sean Colloby and Robert Barber), blinded to the subject 
diagnosis. In addition, frontal and non-frontal WMH burden was also visually rated. 
We did not exclude subjects with WMH as this is common in normal ageing and 
dementia (Barber et al., 1999b). 
 
6.2.4 Statistics  
Demographic, clinical and cognitive measures 
Descriptive analyses of the group characteristics were completed using the statistical 
software software, SPSS 17 as detailed in section 4.2.4.  
DTI 
Differences in DTI indices in the DLB and AD groups were compared to controls 
using a permutation-based, non-parametric, two-sample, unpaired t-test in the FSL 
randomise programme (included in FSL). Age was included in the design matrix as a 
nuisance covariate in all analyses. Regression analysis was used to investigate the 
effects of clinical and neuropsychological measures on DTI parameters with both age 
and MMSE included as covariates. This was to control for the effects of global 
cognition on the association. We generated 5000 permutations of the data to test 
against at threshold levels (i) p<0.05 uncorrected for multiple comparisons (ii) 
p<0.05 family-wise (FWE) corrected which controls the rate of Type 1 errors for all 
voxels collectively and (iii) p<0.005 FWE corrected. Cluster like structures were 
enhanced using the threshold-free cluster enhancement algorithm (TFCE) (Smith and 
Nichols, 2009). The regions showing significant differences between groups were 
located and labelled anatomically by mapping the statistical map to the JHU DTI 
WM atlas in MNI space and Talairach atlas within the FSL atlas toolbox.  The results 
of analyses are overlaid onto the MNI template image and mean FA skeleton (green) 
(see Figure 6.1). 
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6.3 Results 
6.3.1 Subject characteristics  
One hundred and six subjects completed the MRI scan and clinical assessment (35 
DLB, 36 AD, 35 Controls) as outlined in section 4.2. The MR data for three subjects 
were excluded due to motion artefact (1 AD, 1 DLB, 1 Control). 
 
6.3.2 Subject demographics  
The demographic data for patients and control subjects are presented in section 4.3.2. 
An abbreviated version is represented in Table 6.1 below. 
Characteristic DLB 
(n=35) 
AD 
(n=36) 
NC 
(n=35) 
p value 
Age y 78.46.9 78.35.8 76.75.2 ns
§ 
MMSE (max 30) 20.35.3 19.54.4 29.11.0 ns
† 
Episodic Memory 
Composite Score 
-1.63.2 -4.51.5 6.22.6 <0.001
†
 
Letter Fluency (FAS) 20.813.0 27.514.3 41.011.1 0.038
†
 
UPDRS III 26.010.7 5.44.3 2.01.9 <0.001
* 
Values expressed as mean  1SD. 
* 
ANOVA – Controls, AD and DLB; §Pearson’s Chi-square test – Controls, AD and DLB  
† Student’s t-test – AD vs. DLB 
 
Table 6.1. Demographics, clinical and cognitive measures. 
 
6.3.3 White matter hyperintensities 
The WMH scores were similar across all groups (Table 6.2). As expected, there was 
a trend toward less WMH in the control group when compared with AD and DLB. 
When comparing the frontal vs. non-frontal WMH change, there were no significant 
group differences and a trend toward less WMH burden in non-frontal (posterior) 
regions in the DLB group. 
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 DLB  
(n=35) 
AD  
(n=36) 
Control  
(n=35) 
p value§ 
Periventricular Hyperintensities   0.066 
Absent 13 (37%) 8 (22%) 21 (60%)  
Caps 8 (23%) 8 (22%) 6 (17%)  
Smooth Halo 4 (11%) 7 (20%) 3 (9%)  
Irregular and extending into deep 
white matter 
10 (29%) 13 (36%) 5 (14%)  
Deep White Matter Hyperintensities   0.074 
Absent 12 (34%) 9 (25%) 15 (43%)  
Punctate foci 15 (43%) 7 (19%) 8 (23%)  
Beginning confluence of foci 3 (9%) 11 (31%) 7 (20%)  
Large confluent areas 5 (14%) 9 (25%) 5 (14%)  
Subcortical Grey Matter    0.637 
Absent 16 (46%) 15 (42%) 18 (52%)  
Punctate 12 (34%) 15 (42%) 11 (31%)  
Multipunctate 4 (11%) 6 (16%) 4 (11%)  
Diffuse 3 (9%) 0 2 (6%)  
Frontal Lobe Hyperintensities    0.332 
Absent 14 (40%) 12 (33%) 21 (60%)  
Punctate foci 14 (40%) 13 (36%) 8 (23%)  
Beginning of confluence of foci 5 (14%) 7 (19%) 3 (8.5%)  
Large confluent area 2 (6%) 4 (11%) 3 (8.5%)  
Non Frontal Lobe Hyperintensities   0.286 
Absent 16 (46%) 11 (31%) 16 (46%)  
Punctate foci 11 (31%) 7 (19%) 8 (22%)  
Beginning of confluence of foci 3 (9%) 9 (25%) 7 (20%)  
Large confluent area 5 (14%) 9 (25%) 4 (12%)  
Results represented as Number (percentage); 
§Pearson’s Chi-square test – Controls, AD and DLB 
 
Table 6.2. White matter hyperintensity burden across groups. 
 
6.3.4 Fractional Anisotropy  
6.3.4.1 Comparison of FA between DLB and Controls 
In comparison to controls, the DLB subjects TBSS results for reduced FA are 
represented in Figure 6.2 (p<0.05, corrected). Change was identified in the white 
matter affecting predominantly the parieto-occipital areas. This included the 
precuneal region and bilateral cingulate gyri. 
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Other areas affected included the frontal lobe white matter tracts in the region of the 
right anterior corona radiata, left precentral gyrus and a cluster involving the left 
superior longitudinal fasciculus. 
The area of reduced FA in the temporal lobe was in the region of the posterior 
thalamic radiation, which included the optic radiation and extended into the right 
occipital lobe. A cluster in the cuneus was also identified bilaterally, an area that was 
not affected on the right in the AD group when compared with controls. The tracts 
potentially involved included the inferior longitudinal fasciculus, inferior fronto-
occipital fasciculus and anterior thalamic radiation. 
Areas of reduced FA in the corpus callosum included clusters in the right genu and 
splenium and left body and splenium. 
Radiological view 
 
 
Figure 6.2. TBSS statistical maps for reduced FA in dementia with Lewy bodies.  
The areas of significant differences are represented in blue, overlaid onto the MNI 
template image and mean FA skeleton (green). 
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6.3.4.2 Comparison of FA between AD and Controls 
In the AD group, areas of reduced FA compared to controls were more widespread 
than observed in DLB compared to controls and are represented in Figure 6.3 at 
p<0.05, corrected. These included clusters in the temporal lobes, parieto-occiptal 
areas as well as bilateral frontal lobes. In the frontal lobes, areas of reduced FA were 
extensive and included bilateral medial and superior frontal gyri and subgyral white 
matter.  
In the parietal lobes, the areas of reduced FA were in the bilateral precuneal area 
with an extensive right sided cluster. The tracts involved in these areas included 
association fibres: superior longitudinal fasciculus and cingulum and projection 
fibres: anterior thalamic radiation. 
Clusters of reduced FA were found in bilateral temporal lobes, with the left being 
more affected than the right. A large cluster was found in the left parahippocampal 
gyrus, extending to the posterior thalamic radiation. Other parts of the temporal lobe 
that were affected included bilateral middle temporal gyrus and subgyral white 
matter, right uncus and right superior temporal gyrus. 
Areas of reduced FA in the occipital lobes were bilateral and included the middle 
occipital gyri, cuneus and subgyral white matter with changes being more extensive 
on the left. FA reduction in the corpus callosum was extensive and included the 
genu, body and splenium bilaterally. 
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Radiological view 
 
 
Figure 6.3. TBSS statistical maps for reduced FA in Alzheimer’s disease. Areas of 
significant differences are presented in blue, overlaid onto the MNI template image 
and mean FA skeleton (green). 
 
Generally, the pattern of reduced FA was more widespread in AD than DLB when 
compared with controls. In DLB, there was relatively little involvement of the 
temporal lobes apart from the posterior thalamic radiation (optic radiation) and in 
contrast, there was significant involvement of the parieto-occipital white matter 
tracts. 
 
6.3.4.3  Comparison of FA between DLB and AD 
Figure 6.4 (a) demonstrates areas of reduced FA in DLB compared to AD (p<0.05, 
uncorrected) and these results are summarised in Table 6.3 (a) (page 94). There were 
small clusters of significantly reduced FA in the pons and left thalamus in DLB. 
Other areas included the right precentral gyrus and right cerebellum. 
Areas of reduced FA in AD compared to DLB (p<0.05, uncorrected) are shown in 
Figure 6.4 (b) and summarised in Table 6.3 (b) (page 94). These included clusters in 
the left and right frontal lobes and left parietal lobe. In the temporal lobes, small 
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clusters were seen in the parahippocampal gyri. Other areas include a cluster in the 
fornix and body of right corpus callosum.  
 
(a) Areas of FA reduction: DLB v AD 
 
(b) Areas of FA reduction: AD v DLB 
 
Radiological view 
 
Figure 6.4. Represents the results of the comparison between FA reduction in (a) 
DLB v AD and (b) AD v DLB. The areas of significant differences are represented in 
blue, overlaid onto the MNI template image and mean FA skeleton (green).  
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Table 6.3. Location and significance of Fractional Anisotropy (FA) reduction across 
groups. The table shows voxel level significance, MNI coordinates and anatomical 
region. 
  
Anatomical Region MNI Coordinates 
(x, y, z) 
p value 
(a) AD vs DLB     
Frontal lobe L 
Subgyral white matter 
-27 4 39 0.019 
Frontal lobe L 
Middle frontal gyrus  
-33 7 40 0.007 
Frontal lobe R 
Medial frontal gyrus 
-10 -9 58 0.002 
Parietal lobe L 
Supramarginal gyrus  
-38 -37 36 0.023 
Temporal lobe L 
Parrahippocampal gyrus 
-25 -23 -25 0.040 
Temporal lobe R 
Parahippocampal gyrus 
30 1 -32 0.047 
Temporal lobe R  
Superior temporal gyrus 
42 6 -25 0.042 
Occipital lobe L 
Inferior occipital gyrus 
-35 -81 2 0.031 
Fornix  
Column and body 
0 -1 7 0.046 
Body of corpus callosum R  16 -9 33 0.024 
 
(b) DLB vs AD 
    
Occipital lobe R 
Subgyral white matter 
30 -55 -1 0.036 
Brainstem R 
Pons 
2 -24 -27 0.041 
Brainstem L 
Pons 
-1 -23 -27 0.043 
Thalamus L -14 -18 6 0.004 
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Examples of the quantitative differences in FA between AD and DLB at the voxel 
level are represented in Figure 6.5. These include:  
(a) left medial temporal – cingulum (MNI coordinates, mean ± SD, t-score, df, 
p-value; -25, -23, -25, AD = 0.30 ± 0.06, DLB = 0.33 ± 0.06, t = 2.1, df = 67, p = 0.02),  
(b) fornix (0, -1, 7, AD = 0.23 ± 0.05, DLB = 0.26 ± 0.07, t = 2.2, df = 67, p = 0.02),  
(c) left thalamus – anterior thalamic radiation (-14, -18, 6, AD = 0.29 ± 0.04, 
DLB = 0.26 ± 0.03, t = 2.7, df = 67, p = 0.005),  and  
(d) right occipital – inferior longitudinal fasciculus (30, -55, -1, AD = 0.23 ± 0.05, 
DLB = 0.21 ± 0.03, t = 1.8, df = 57, p = 0.03). 
 
 
Figure 6.5. Graphical representation of the mean Fractional Anisotropy (FA) within a 
white matter tract voxel in AD and DLB. Areas include: (a) left temporal, (b) fornix, 
(c) left thalamus and (d) right occipital. 
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6.3.5 Mean Diffusivity 
6.3.5.1 Comparison of MD between DLB and Controls and AD and Controls 
The results for increased MD in the dementia groups compared to controls were far 
more extensive than observed for reduced FA in both groups. The results of the 
analyses are shown in Figure 6.6 at p<0.005, corrected.  
In comparison to controls, areas of significant MD increase in DLB were global and 
included areas of the brainstem, thalamus, cingulate, temporal, parieto-occipital and 
frontal lobes and are shown in Figure 6.6 (a). These areas were also affected in the 
AD group when compared with controls, represented in Figure 6.6 (b).  
In the DLB group, there was significant MD increase in the thalamus and precuneal 
areas. Although these were also affected in AD, they were part of a more widespread 
pattern of loss. In AD there was also more involvement of the medial temporal lobe 
structures.  
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Radiological view 
(a) DLB > Controls  
 
 
(b) AD > Controls 
 
 
 
Figure 6.6. TBSS statistical maps for increased MD in (a) dementia with Lewy 
bodies and (b) Alzheimer’s disease. Areas of significant differences (p<0.005, 
corrected) are represented in blue overlaid onto the MNI template image and  
mean FA skeleton (green). 
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6.3.5.2 Comparison of MD between DLB and AD 
Areas of increased MD in the AD group compared with the DLB group was seen in 
bilateral temporal lobes (p<0.05, uncorrected). There was a small cluster of increased 
MD in the right pons in the DLB group when compared to AD.  
 
6.3.6 Clinical Correlations 
6.3.6.1 Episodic Memory 
We determined the correlations of MD with the episodic memory composite score in 
DLB and AD groups, controlling for the effects of global cognition and age by 
including them in the design matrix as covariates. These correlations are represented 
in Figure 6.7, and were significant at p < 0.05, uncorrected. 
A correlation between impaired episodic memory and increased MD was regionally 
similar in AD and DLB, and included clusters in bilateral parahippocampal gyri 
(hippocampal cingulum) and left cingulate gyrus (frontal). In DLB, there was also a 
small cluster in the right thalamus. 
We did not find a correlation between FA and episodic memory in AD or DLB. 
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Radiological view 
(a) DLB  
 
(b) AD 
 
 
 
Figure 6.7. Represents the relationship between Mean Diffusivity (MD) and  
Episodic Memory in (a) DLB and (b) AD.  The areas that correlate  
significantly are represented in blue, overlaid onto the MNI template image 
and mean FA skeleton (green). 
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6.3.6.2 Letter Fluency 
Relationship between FA and Letter fluency 
 
The relationship between FA and letter fluency in DLB was significant (p<0.05, 
corrected) and is represented in Figure 6.8. The correlation involved predominantly 
bilateral frontal, parietal and subcortical structures. In particular, the precentral 
gyrus, anterior cingulate, the precuneus and striatal structures were associated. An 
example of this correlation is represented in Figure 6.9. FA values from a voxel in 
the middle frontal white matter tract (MNI 23, 33, 25) is plotted against the letter 
fluency task (r´=0.42, df=29, p=0.009). This correlation was not observed in AD.  
Radiological View 
 
Figure 6.8. Represents the relationship between Fractional Anisotropy and Letter 
fluency in DLB. The areas that correlate significantly are represented in blue, 
overlaid onto the MNI template image and mean FA skeleton (green). 
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Figure 6.9. Fractional Anisotrophy at MNI 23, 33, 25 (location is represented in the 
axial image by the red arrow) plotted against Letter Fluency in DLB.  
 
Relationship between MD and Letter Fluency 
A relationship between MD and letter fluency was observed in DLB and, to a lesser 
extent in AD. In DLB, the areas were subcortical, including areas of the brainstem 
and striatum (p<0.05, corrected). White matter tracts of the precuneus (parietal), 
precentral gyrus (frontal) and corpus callosum (parietal) were also associated (Figure 
6.10). In AD, the relationship between MD and letter fluency was also observed in 
the white matter tracts of the parietal lobes extending to involve some of the frontal 
white matter tracts. 
  
Chapter 6 Diffusion tensor imaging in DLB 
 
102 
 
Radiological View 
 
 
 
Figure 6.10. Represents the relationship between MD and Letter fluency in DLB. 
The areas that correlate significantly are represented in blue, overlaid onto the MNI 
template image and mean FA skeleton (green). 
 
6.3.6.3 Motor Parkinsonism in DLB 
 
Relationship between FA and UPDRS-III 
The relationship between FA and UPDRS III in DLB was investigated. We found a 
correlation between higher UPDRS scores and reduced FA in subcortical structures 
including the thalami, pons and medulla as well as the precentral gyrus. Other small 
clusters were found in the occipital, parietal and temporal lobes, which included the 
precuneus and postcentral gyrus, represented in Table 6.4.  
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Table 6.4. Locations and significance of the correlation between FA and the  
UPDRS-III in DLB. The table shows voxel level significance (p < 0.05, uncorrected) 
MNI coordinates and anatomical region. 
 
  
Anatomical Region MNI Coordinates 
(x, y, z) 
p value 
(a) DLB     
Occipital R 33 -77 13 0.007 
Occipital R (cuneus) 11 -86 26 0.009 
Occipital L (cuneus) -15 -80 19 0.009 
Frontal L -19 -40 55 0.009 
Frontal L 
(precentral gyrus (BA 4)) 
-19 -20 65 0.008 
Frontal R 25 42 8 0.009 
Parietal L (precuneus) -15 -69 45 0.009 
Postcentral gyrus L  -24 -34 61 0.008 
Temporal L -51 -37 -16 0.009 
Temporal L  
(parahippocampal gyrus)  
-40 -24 -20 0.008 
Thalamus R 5 -8 6 0.006 
Thalamus L -6 -25 16 0.014 
Fornix 0 3 4 0.004 
Pons R 7 -33 -27 0.010 
Pons L -4 -31 -27 0.008 
Medulla R 2 -37 -43 0.007 
Medulla L -1 -37 -41 0.009 
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6.4 Discussion 
 
We used Tract Based Spatial Statistics to investigate the patterns of white matter 
tract DTI changes in DLB. The main findings of this study were (i) DLB was 
associated with a significant FA reduction in white matter tracts of the temporo-
occipital and parietal lobes, anterior and posterior cingulate and body and genu of the 
corpus callosum. The changes in MD were more widespread with increased MD also 
found in the subcortical structures including the pons and thalamus. (ii) The pattern 
of FA reduction in AD was more extensive and included white matter tracts of the 
frontal, temporal, parietal and occipital lobes. (iii) When DTI changes between DLB 
and AD were compared directly, DLB was associated with lower FA values in the 
pons and thalamus and increased MD in the right pons. In AD, areas of reduced FA 
and increased MD were found bilaterally in the medial temporal lobes compared 
with DLB. (iv) There was a significant correlation between DTI change and letter 
fluency in DLB and UPDRS-III correlated with FA reduction in the subcortical and 
cortical white matter tracts, including motor areas. The burden of white matter 
hyperintensities was found to be similar between dementia groups suggesting that the 
differing patterns of white matter tract change as measured with DTI was unlikely to 
be completely due to WMH.   
We found a pattern of posterior predominance in the DTI changes in DLB with 
involvement of the parieto-occipital areas and temporal regions with relative sparing 
of the frontal lobes which are broadly in keeping with other DTI studies (Lee et al., 
2010a; Ota et al., 2009; Bozzali et al., 2005). 
These areas are important for visual information processing; the dorsal and ventral 
visual streams are hypothesised to connect the primary visual cortex in the occipital 
lobe to the parietal and temporal lobes respectively (Goodale and Milner, 1992). 
Given that characteristic features of DLB are recurrent visual hallucinations as well 
as early visuo-spatial and visuo-perceptual deficits, it is of great interest that these 
areas were preferentially affected (McKeith et al., 2005). The ventral visual stream 
involves the connection from the primary visual cortex in the occipital lobe via the 
inferior longitudinal fasciculus to the inferior temporal gyrus and parahippocampal 
gyrus, areas that have also been found to be associated with Lewy related pathology 
and visual hallucinations in pathological studies (Harding et al., 2002).  
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Previous DTI studies using ROI methods have found reductions of FA in the 
precuneus, occipital areas and inferior longitudinal fasciculus (ILF) in DLB (Lee et 
al., 2010b; Firbank et al., 2007b; Bozzali et al., 2005). SPECT studies have also 
reported precuneal and occipital hypoperfusion (Colloby et al., 2002) and PET 
studies have reported occipital hypometabolism (Imamura et al., 1997); without 
associated structural grey matter loss of sufficient magnitude to explain this 
(Middelkoop et al., 2001). Therefore, it is possible that the functional imaging 
changes reflect damage to the microstructural white matter connections, supporting 
the notion that DLB is a disease predominantly caused by neuronal synaptic 
dysfunction rather than loss. 
We found reduced FA in the posterior cingulate in both AD and DLB which is in 
agreement with other DTI studies (Lee et al., 2010b; Firbank et al., 2007a). In one 
DTI study, reduced FA in the region of the posterior cingulate was associated with 
global cortical atrophy (Firbank et al., 2007a) and in AD has also been found to 
correlate with hippocampal volume (Xie et al., 2005). SPECT studies have shown 
posterior cingulate hypoperfusion in DLB and AD (Firbank et al., 2003; Colloby et 
al., 2002)  and interestingly, amyloid deposition in the posterior cingulate and 
parietal regions (precuneus and lateral) were related to visuo-spatial impairment in 
DLB (Gomperts et al., 2008). Our findings of microstructural change in the posterior 
cingulate in DLB, an area that may be vulnerable as a result of high metabolic 
demands and amyloid deposition (Gomperts et al., 2008; Buckner et al., 2005), 
highlight its importance in the pathological process of DLB.  
The thalamus organises and processes information between the subcortical and 
cortical structures. These include relaying information to the visual association 
cortices from the retina via the lateral geniculate nucleus and striatal structures to 
motor cortex. It is also a key area in maintaining consciousness (Schiff, 2008). When 
comparing areas of reduced FA between AD and DLB, we found reduced FA in the 
left thalamus in DLB. There were also clusters of increased thalamic MD in DLB 
when compared to controls.  
Structural imaging studies have not found significant change in the thalamus in DLB 
(Burton et al., 2002) whereas functional imaging studies using SPECT have reported 
increased thalamic perfusion and a pattern of covariance with occipital 
Chapter 6 Diffusion tensor imaging in DLB 
 
106 
hypoperfusion in DLB (Shimizu et al., 2008). Increased thalamic perfusion has also 
been shown to be associated with an increase in fluctuation (O'Brien et al., 2005). It 
is possible that microstructural change causes an alteration in the neurotransmitter 
and/or receptor status with resultant perfusion changes in DLB. Multi-modal studies 
of perfusion and diffusion imaging in DLB will be required to help address this. 
We found more extensive microstructural change in the temporal lobes in AD, 
particularly in the medial temporal lobe structures. This is consistent with findings 
from other studies, the known pathological change in the area and the early and 
characteristic impairment of episodic memory (Jack et al., 2010; Scola et al., 2010). 
This differs from DLB where episodic memory is usually not as profoundly affected 
and relative preservation of the medial temporal lobe in structural imaging has been 
well established (McKeith et al., 2005). Interestingly, we also found that the episodic 
memory composite score and medial temporal white matter tract change appear to be 
associated in both AD and DLB. Although this was significant at p<0.05, 
uncorrected, it suggests a common underlying mechanism affecting the episodic 
memory performance in both groups.  The DLB group performed better than the AD 
group on tests of episodic memory, showed less DTI change in the medial temporal 
lobe structures and that the medial temporal lobe change correlated with episodic 
memory in both groups. This suggests that microstructure change in this region may 
be related to Alzheimer pathology. 
AD and DLB pathology commonly coexist, and possibly interact, although 
mechanisms for this are not yet understood (Crews et al., 2009). From clinico-
pathological data, the more AD tangle pathology (i.e. Braak stage V or VI) that 
exists, the less likely the patient is to manifest the core clinical features of DLB even 
when a lot of Lewy related pathology is present (McKeith et al., 2005). So, whilst it 
is likely our cohort had some degree of AD pathology, they all met the clinical 
criteria for probable DLB, so were therefore unlikely to have a high degree of AD 
pathological burden.  
DLB patients usually have more difficulty with tasks involving executive function 
rather than memory when compared with AD. This is thought, in part, to be due to 
the impairment in striatal function and dopaminergic deficiency given the importance 
of the fronto-striatal network in executive function. This network connects the pre-
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frontal cortex and striatum via the thalamus with its function mediated by dopamine 
(Tekin and Cummings, 2002). However, the functional connections involved in tasks 
of executive function are much more complex with some studies indicating that input 
from parietal, occipital and temporal lobes is required, depending on the task demand 
(Woo et al., 2010; Collette et al., 2006).   
We found a significant relationship between reduced FA and increased MD and the 
letter fluency task in DLB, which involved frontal and parietal lobes, the anterior 
cingulate and subcortical structures including the brainstem and striatum. There was 
also a correlation between reduced FA in the white matter tracts of the right 
prefrontal cortex and the letter fluency task.  
Given that both age and MMSE were included in the analysis design as covariates, 
these findings suggest that impaired verbal fluency may be associated with change 
predominantly in the frontal, parietal and subcortical brain microstructure in DLB 
and not driven by global cognitive impairment. In AD, although the task 
performance was impaired, it was not as strongly correlated with change in the white 
matter tracts and no correlation was found with reduced FA. It is possible that 
executive dysfunction in AD, as assessed by the letter fluency task, is not strongly 
associated with microstructural change and may be better represented by other 
imaging modalities such as volumetric or perfusion techniques. However, the 
differences suggest that there may be differing pathological mechanisms 
underpinning executive dysfunction in AD and DLB. 
The UPDRS-III scale, a measure of the severity of motor features of parkinsonism 
correlated with reduced FA in white matter tracts of the motor cortex as well as 
subcortical structures. Motor parkinsonism in DLB is largely a result of 
abnormalities in the basal ganglia with degeneration of dopaminergic neurons and 
striatal dopamine deficiency, although the motor cortex also contributes via thalamic 
projections. The parietal and occipital areas have also been found to be activated 
during motor tasks in patients with parkinsonism suggesting a compensatory 
mechanism (Galvan and Wichmann, 2008).  
PET studies in Parkinson’s disease have demonstrated a positive correlation between 
UPDRS and metabolic change in the primary motor cortex and supplementary motor 
areas (Nagano-Saito et al., 2004) and longitudinal studies have also reported a 
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progressive increase in the metabolic activity of subcortical structures and motor 
cortex (Huang et al., 2007). Interestingly, a SPECT study which compared DLB 
patients with and without parkinsonism found that those with parkinsonism had 
reduced blood flow in the primary and supplementary motor areas compared to those 
without (Takahashi et al., 2010b). A relatively small DTI study using VBM analysis 
techniques in PD reported significant FA reduction in the supplementary motor areas 
and anterior cingulate (Karagulle Kendi et al., 2008). These findings highlight the 
importance of these areas in the pathogenesis of parkinsonism and, along with our 
findings perhaps suggests a more complex mechanism for the motor symptoms in 
DLB with disruption in the white matter in these compensatory or ‘secondary’ 
regions leading to more prominent motor features.   
An important consideration in this study is the impact of WMH which can alter DTI 
parameters. It would be instructive to investigate this relationship further with 
volumetric techniques given we did not exclude cases with WMH. Using a visual 
rating scale however, we found that the dementia groups were similar, which 
provides further support that the differences we observed were unlikely to purely be 
a function of WMH burden.  
In conclusion, DLB was characterised by a predominantly posterior pattern of altered 
diffusivity with generally less change than observed in AD. The involvement of the 
visual association area, thalamus and significant correlations with executive tasks 
suggest the importance of microstructural change in the pathogenesis of the disease. 
DTI may be a useful technique to investigate early, and possibly pre-clinical, 
changes in DLB. 
The next chapter will provide a summary and discussion of the main findings of the 
neuropsychological, structural imaging and diffusion imaging changes in dementia 
with Lewy bodies and highlight important areas for future work.
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Chapter 7 Conclusions and future studies 
With the increasing prevalence of dementia, a better understanding of the 
neurobiological changes underpinning DLB is a vital step forward in order to 
improve early diagnosis, differential diagnosis and inform development of novel 
treatment options. This was the primary motivation for the study. 
 
7.1 Summary of main findings 
The first part of the thesis is concerned with the clinical and neuropsychological 
features of our cohort of AD and DLB subjects. As expected, DLB was characterised 
by a subcortical pattern of neuropsychological impairment with attentional and 
executive dysfunction and less impaired memory compared to AD, consistent with 
the notion that subcortical change predominates in DLB. The visual system was also 
impaired with the majority of DLB cases reporting visual hallucinations and having 
difficulty with visuo-perceptual based tasks.  
The main finding of the structural GM analysis was of relative preservation of medial 
temporal lobe structures in DLB compared to AD. This was highly significant in the 
bilateral parahippocampal gyri and left hippocampus (p <0.05, corrected) and 
consistent with the neuropsychological profile observed of relatively preserved new 
learning (compared to AD). There was much less regional volumetric GM loss in 
DLB than AD. Affected areas included the temporal, parietal, occipital and 
subcortical structures in DLB although only reached statistical significance when 
corrected for multiple comparisons in the temporal regions (including amygdala) and 
caudate tail. Therefore, at a similar level of dementia severity, there was more 
atrophy in AD than DLB, which suggests that there are differing pathological 
mechanisms underpinning the clinical and neuropsychological features of the 
conditions.  
Microstructural changes in DLB were therefore investigated using diffusion tensor 
imaging. As expected, changes in the white matter tracts were less extensive in DLB 
than in AD. In DLB, the regional pattern of change (FA) compared with controls had 
a posterior predominance affecting the visual association areas and subcortical 
structures which, by contrast to the structural changes, were all highly significant,   
(p <0.05, corrected).  
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The letter fluency task was used as an executive function probe and we found a 
significant pattern of correlation (p<0.05, corrected) in DLB affecting frontal, 
parietal and subcortical structures, a pattern not observed in AD, highlighting the 
potential differing pathological mechanisms between the diseases.  
 
7.2 Conclusions 
Cortical atrophy  
Cerebral GM atrophy is largely caused by the loss of neurons and synapses. In 
contrast to DLB, neurodegeneration and particularly synaptic loss has been found to 
be associated with the clinical features of AD (Terry et al., 1991). Our finding of less 
global GM loss in DLB compared to AD was consistent with another large VBM 
study (Whitwell et al., 2007b). Given that the dementia groups were well matched 
for age, dementia severity and level of education, it indicates that DLB and AD have 
differing pathological substrates underpinning the clinical features with AD resulting 
in more neuronal and synaptic loss than DLB. Furthermore, medial temporal lobe 
atrophy on structural imaging has been associated with the presence and severity of 
AD neuropathology (Gosche et al., 2002; Jack et al., 2002) and is a useful biomarker 
in separating AD from healthy controls (Scheltens et al., 2002). We found 
significantly less atrophy in the medial temporal lobes structures in DLB when 
compared to AD, which was also consistent with the neuropsychological profile 
observed of relatively preserved new learning in the DLB group.   
AD pathology commonly coexists in cases of DLB. Large amounts of AD neuritic 
pathology can mask the characteristic features of DLB (McKeith et al., 2005). Given 
that our DLB cohort were selected based on their clinical phenotype – having at least 
2 out of 3 of the core clinical features, they were less likely to have large amounts of 
concomitant AD neuritic pathology.  It is therefore possible that the relatively little 
structural GM loss observed in DLB may reflect the lesser burden of AD pathology 
in this group.  
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Subcortical structures 
The thalamus organises and processes information between the subcortical and 
cortical structures with one of its functions being maintenance of consciousness. 
Similar to other studies, we did not find significant structural change in the thalamus 
in DLB (Whitwell et al., 2007b; Burton et al., 2002). However, we found small areas 
of reduced FA in the thalamus in DLB compared to AD, and we also found increased 
thalamic MD in DLB compared to controls. Functional imaging studies using 
SPECT have reported increased thalamic perfusion and a pattern of covariance with 
occipital hypoperfusion (Shimizu et al., 2008) and increased thalamic perfusion has 
also been shown to be associated with cognitive fluctuation in DLB (O'Brien et al., 
2005). Given these findings, along with the prominent attentional deficits and the 
cognitive fluctuation observed in DLB, further studies are warranted to investigate 
thalamic changes in more detail using DTI ROI or tractography methods in 
combination with perfusion imaging.  
Visual association areas 
Given the early and prominent visuo-perceptual dysfunction in DLB, the finding of 
significant FA change preferentially affecting the parieto-occipital white matter tracts 
(part of the visual association areas), with relative sparing of the frontal white matter 
tracts was of interest. The ventral visual stream involves a connection from the 
primary visual cortex in the occipital lobe via the inferior longitudinal fasciculus to 
the inferior temporal gyrus and parahippocampal gyrus, areas which have been found 
to be associated with Lewy related pathology and visual hallucinations in 
pathological studies (Harding et al., 2002). Other DTI studies have found changes in 
the precuneus, inferior longitudinal fasciculus and occipital areas (Kantarci et al., 
2010; Firbank et al., 2007b; Bozzali et al., 2005) and functional imaging studies 
using SPECT (Colloby et al., 2002) and PET (Imamura et al., 1997) have also 
reported precuneal and occipital hypoperfusion and occipital hypometabolism 
respectively without significant structural GM loss (Middelkoop et al., 2001). It is 
therefore possible that the functional imaging changes observed reflect damage to the 
white matter tracts and potentially contribute to the visuo-perceptual dysfunction 
observed in DLB. Further ROI studies of the dorsal and ventral visual streams 
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investigating the diffusion, perfusion and metabolic changes in combination along 
with clinical and neuropsychological correlates may help to address this. 
Executive function 
DLB was associated with more prominent executive dysfunction than AD. This was 
thought to be at least partly mediated by the striatal dopaminergic deficiency in DLB 
given the importance of the fronto-striatal system in executive function. Our finding 
of a significant correlation between letter fluency and FA and MD white matter tract 
change in DLB highlight the potential differing pathologic mechanisms between AD 
and DLB. It suggests that DTI may be a more sensitive imaging modality than 
structural T1 imaging to detect pathological change in DLB. Indeed, further studies 
are required to address this. In particular, longitudinal studies to review areas more 
vulnerable to white matter tract change, and pathological verification studies to help 
address what causes the observed diffusion tensor imaging changes observed. 
 
7.3 Study strengths and limitations 
Strengths of the study include a large and well-characterised group of DLB subjects. 
It is one of the larger DLB cohorts to complete an MRI study, which therefore 
increases the chance for detecting differences between groups. The clinical and 
neuropsychological scales selected have also been highly cited and validated for use 
in dementia.  
The VBM DARTEL method of structural imaging analysis is a sensitive algorithm 
for detecting regional GM loss (Ashburner, 2007). It is automated, relatively operator 
independent and examines the whole brain without the need for a priori region of 
interest. To ensure that the probability of incorrectly rejecting the null hypothesis for 
the large number (family) of statistical tests associated with voxelwise analyses do 
not exceed α = 0.05, correction methods that control for the family-wise error rate 
(FWE) were used. However, these correction methods are conservative with the 
inherent higher rates of false negatives, and the potential to miss a true difference in 
GM volume loss between groups. So whilst the differences we reported were highly 
significant, other areas of difference could have been missed.  
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TBSS combines the strengths of a relatively operator independent, whole brain, 
VBM style of analysis with the tract-based information usually gained from 
tractography (Smith et al., 2006). This represents the first study using this method of 
analysis in DLB. The DTI performed was 16-directions. We could have improved 
the signal-to-noise ratio by incorporating more directions into the protocol as has 
been shown in other studies (Landman et al., 2007). A reduction in the slice 
thickness may have improved the spatial resolution and finally, the addition of a T2 
weighted FLAIR image would have allowed for a more accurate volumetric 
assessment of white matter hyperintensities and therefore incorporation into the 
model of regional DTI change.   
The reliance on the clinical diagnosis rather than pathological confirmation is a 
potential limitation as it is with all antemortem neuroimaging studies. However, the 
methods used for case detection have been well validated and found to have high 
specificity in prospective studies with autopsy validation (McKeith et al., 2000a). 
Study subjects have also been approached to register for brain tissue donation, which 
will enable future neuropathlogical correlational studies. 
 
7.4 Future directions 
DLB is a complex disease process that affects a number of different neuronal 
systems. Although the mechanisms are not entirely understood, it seems that the 
likely pathological substrate is aggregates of synaptic protein α synuclein resulting in 
neuronal dysfunction and eventual loss. Subcortical structures seem more vulnerable 
with a variety of functional and structural imaging changes observed, in a differing 
pattern to that seen in AD. In order to develop disease biomarkers we need to 
establish a link between the clinical features observed and the in vivo imaging 
changes. 
Structural imaging  
In DLB, cortical areas are potentially affected by a combination of impaired neuronal 
projections from subcortical structures and directly by varying degrees of AD 
pathology. One method to explore this further would be to investigate the differing 
patterns of structural covariance between DLB and AD.  
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Longitudinal imaging studies can also assist in providing insight into more 
susceptible regions of change in DLB, and how the pattern may differ from AD. The 
rate of atrophy also has potential as an outcome measure in therapeutic trials and 
establishing a link between atrophy rate and a clinically significant outcome. In the 
first instance, a longitudinal study using VBM-DARTEL method of analysis 
comparing the regional atrophy rate in AD and DLB would be of interest.   
Multi-modal imaging  
Another approach would be to incorporate information from differing imaging 
modalities. Areas of interest would include the posterior (parieto-occipital) and 
thalamic areas. These are key areas involved in visuo-perceptual and attentional 
function and our DTI findings in DLB indicate that further analysis is warranted. In 
particular, using a ROI method, data from diffusion and perfusion imaging 
techniques could be combined in a multivariate model along with clinical variables, 
to better understand the in vivo functional changes in DLB. This could be 
investigated using SPECT or PET in combination with DT-MRI. However, the main 
advantages for multi-modal MRI studies combining structural imaging, DTI and 
perfusion (using arterial spin labelling) are that all data can be acquired during a 
single session and registration issues are less problematic. 
Sub-group analysis  
It is likely that there were varying degrees of associated AD pathology in the DLB 
group which may be reflected in the degree of episodic memory dysfunction and GM 
volume loss, particularly hippocampal atrophy. To provide more insight into the 
pathophysiological mechanisms of DLB it would be instructive to divide the DLB 
group on the basis of hippocampal volume, a surrogate measure of AD pathology 
and further review any patterns of DTI change in the DLB group with particular 
focus on the relationship with executive function tasks and motor symptoms. This 
has the potential to explore the imaging changes characteristic of DLB pathology 
without the effect of AD ‘diluting’ the differences between the groups. 
Clinical aspects  
Important aspects of clinical imaging studies that need to be considered are a well-
defined patient group with robust methods for characterisation of the core clinical 
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features. Adequate and well validated methods for testing of attention and 
fluctuation, visual perception and motor features is of particular importance so that 
they can be used reliably as probes for correlation with imaging changes. In addition, 
dopamine transporter imaging, amyloid PET and genetic markers (e.g. ApoE4) 
would provide better characterisation of the groups. 
Neuropathological correlational studies 
Finally, neuropathological correlation studies are needed to assist in understanding 
the pathological substrates of imaging changes in DLB. This has been clearly 
demonstrated by others and has been central to our understanding of the basis of 
medial temporal atrophy and amygdala changes in DLB (Burton et al., 2011; Burton 
et al., 2009). 
 
References 
 
116 
References   
 
Aarsland, D., Anderson, K., Larsen, J. P., Lolk, A. and Kragh-Sorenson, P. (2003) 
'Prevalence and characteristics of dementia in Parkinsons disease: an 8 year 
prospective study. ', Archives of Neurology, 60, pp. 387-392. 
 
Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., 
Leroi, I., Pozo-Rodriguez, F., Minthon, L. and Londos, E. (2009) 'Memantine 
in patients with Parkinson's disease dementia or dementia with Lewy bodies: a 
double-blind, placebo-controlled, multicentre trial', Lancet Neurology, 8, (7), 
pp. 613-618. 
 
Aarsland, D., Mosimann, U. P. and McKeith, I. G. (2004) 'Role of Cholinesterase 
Inhibitors in Parkinson's Disease and Dementia with Lewy Bodies', Journal of 
Geriatric Psychiatry Neurology, 17, pp. 164-171. 
 
Aarsland, D., Perry, R., Larsen, J. P., McKeith, I. G., O'Brien, J. T., Perry, E. K., 
Burn, D. and Ballard, C. G. (2005) 'Neuroleptic sensitivity in Parkinson's 
disease and parkinsonian dementias', Journal of Clinical Psychiatry, 66, (5), 
pp. 633-637. 
 
Almeida, O. P., Burton, E. J., McKeith, I., Gholkar, A., Burn, D. and O'Brien, J. T. 
(2003) 'MRI study of caudate nucleus volume in Parkinson's disease with and 
without dementia with Lewy bodies and Alzheimer's disease', Dementia and 
Geriatric Cognitive Disorders, 16, (2), pp. 57-63. 
 
American Academy of Sleep Medicine (2005) The International Classification of 
Sleep Disorders 2: Diagnostic and Coding Manual. Chicago  
 
Andersson, J. L. R., Jenkinson, M. and Smith, S. (2007a) Non-linear optimisation. 
FMRIB technical report TR07JA1 from www.fmrib.ox.ac.uk/analysis/techrep  
 
Andersson, J. L. R., Jenkinson, M. and Smith, S. (2007b) Non-linear registration, 
aka Spatial normalisation. FMRIB technical report TR07JA2 from 
www.fmrib.ox.ac.uk/analysis/techrep  
 
Angot, E., Steiner, J. A., Hansen, C., Li, J. Y. and Brundin, P. (2010) 'Are 
synucleinopathies prion-like disorders?', Lancet Neurology, 9, (11), pp. 1128-
1138. 
 
References 
 
117 
Arai, Y., Yamazaki, M., Mori, O., Muramatsu, H., Asano, G. and Katayama, Y. 
(2001) 'Alpha-synuclein-positive structures in cases with sporadic Alzheimer's 
disease: morphology and its relationship to tau aggregation', Brain Research 
888, (2), pp. 287-296. 
 
Ashburner, J. (2007) 'A fast diffeomorphic image registration algorithm', 
NeuroImage, 38, (1), pp. 95-113. 
 
Ashburner, J. and Friston, K. J. (2000) 'Voxel-based morphometry - The methods', 
NeuroImage, 11, (6), pp. 805-821. 
 
Ashburner, J. and Friston, K. J. (2005) 'Unified segmentation', NeuroImage, 26, (3), 
pp. 839-851. 
 
Assaf, Y. and Pasternak, O. (2008) 'Diffusion tensor imaging (DTI)-based white 
matter mapping in brain research: A review', Journal of Molecular 
Neuroscience, 34, (1), pp. 51-61. 
 
Ballard, C. and Corbett, A. (2010) 'Management of neuropsychiatric symptoms in 
people with dementia', CNS Drugs, 24, (9), pp. 729-739. 
 
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D. and Jones, E. (2011) 
'Alzheimer's disease', Lancet, 377, (9770), pp. 1019-1031. 
 
Ballard, C., Grace, J., McKeith, I. and Holmes, C. (1998) 'Neuroleptic sensitivity in 
dementia with Lewy bodies and Alzheimer's disease', Lancet, 351, (9108), 
pp. 1032-1033. 
 
Ballard, C., Holmes, C., McKeith, I., Neill, D., O'Brien, J., Cairns, N., Lantos, P., 
Perry, E., Ince, P. and Perry, R. (1999) 'Psychiatric morbidity in dementia with 
Lewy bodies: A prospective clinical and neuropathological comparative study 
with Alzheimer's disease', American Journal of Psychiatry, 156, (7), pp. 1039-
1045. 
 
Ballard, C., McKeith, I., Burn, D., Harrison, R., Obrien, J., Lowery, K., Campbell, 
M., Perry, R. and Ince, P. (1997) 'The UPDRS scale as a means of identifying 
extrapyramidal signs in patients suffering from dementia with Lewy bodies', 
Acta Neurologica Scandinavica, 96, (6), pp. 366-371. 
 
Ballard, C., O'Brien, J., Gray, A., Cormack, F., Ayre, G., Rowan, E., Thompson, P., 
Bucks, R., McKeith, I., Walker, M. and Tovee, M. (2001a) 'Attention and 
References 
 
118 
fluctuating attention in patients with dementia with Lewy bodies and 
Alzheimer disease', Archives of Neurology, 58, (6), pp. 977-982. 
 
Ballard, C., O'Brien, J., Morris, C. M., Barber, R., Swann, A., Neill, D. and McKeith, 
I. (2001b) 'The progression of cognitive impairment in dementia with Lewy 
bodies, vascular dementia and Alzheimer's disease', International Journal of 
Geriatric Psychiatry, 16, pp. 499-503. 
 
Ballard, C., Ziabreva, I., Perry, R., Larsen, J. P., O'Brien, J., McKeith, I., Perry, E. 
and Aarsland, D. (2006) 'Differences in neuropathologic characteristics across 
the Lewy body dementia spectrum', Neurology, 67, pp. 1931-1934. 
 
Ballard, C. G., Aarsland, D., McKeith, I., O'Brien, J., Gray, A., Cormack, F., Burn, 
D., Cassidy, T., Starfeldt, R., Larsen, J. P., Brown, R. and Tovee, M. (2002) 
'Fluctuations in attention - PD dementia vs DLB with parkinsonism', 
Neurology, 59, (11), pp. 1714-1720. 
 
Ballmaier, M., O'Brien, J. T., Burton, E. J., Thompson, P. M., Rex, D. E., Narr, K. 
L., McKeith, I. G., DeLuca, H. and Toga, A. W. (2004) 'Comparing gray 
matter loss profiles between dementia with Lewy bodies and Alzheimer's 
disease using cortical pattern matching: diagnosis and gender effects', 
Neuroimage, 23, (1), pp. 325-335. 
 
Barber, R., Ballard, C., McKeith, I. G., Gholkar, A. and O'Brien, J. T. (2000a) 'MRI 
volumetric study of dementia with Lewy bodies: a comparison with AD and 
vascular dementia', Neurology, 54, (6), pp. 1304-1309. 
 
Barber, R., Gholkar, A., Scheltens, P., Ballard, C., McKeith, I. G. and O'Brien, J. T. 
(1999a) 'Medial temporal lobe atrophy on MRI in dementia with Lewy bodies', 
Neurology, 52, (6), pp. 1153-1158. 
 
Barber, R., Gholkar, A., Scheltens, P., Ballard, C., McKeith, I. G. and O'Brien, J. T. 
(2000b) 'MRI volumetric correlates of white matter lesions in dementia with 
Lewy bodies and Alzheimer's disease', Int J Geriatr Psychiatry, 15, (10), 
pp. 911-916. 
 
Barber, R., McKeith, I., Ballard, C. and O'Brien, J. (2002) 'Volumetric MRI study of 
the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer's 
disease, and vascular dementia', Journal Neurology Neurosurgery and 
Psychiatry, 72, (3), pp. 406-407. 
 
References 
 
119 
Barber, R., McKeith, I. G., Ballard, C., Gholkar, A. and O'Brien, J. T. (2001) 'A 
comparison of medial and lateral temporal lobe atrophy in dementia with Lewy 
bodies and Alzheimer's disease: magnetic resonance imaging volumetric study', 
Dementia and Geriatric Cognitive Disorders, 12, (3), pp. 198-205. 
 
Barber, R., Scheltens, P., Gholkar, A., Ballard, C., McKeith, I., Ince, P., Perry, R. 
and O'Brien, J. (1999b) 'White matter lesions on magnetic resonance imaging 
in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and 
normal aging', Journal of Neurology Neurosurgery and Psychiatry, 67, (1), 
pp. 66-72. 
 
Basser, P. J., Mattiello, J. and Lebihan, D. (1994) 'MR diffusion tensor spectroscopy 
and imaging', Biophysical Journal, 66, (1), pp. 259-267. 
 
Beaulieu, C. (2002) 'The basis of anisotropic water diffusion in the nervous system - 
a technical review', NMR in Biomedicine, 15, (7-8), pp. 435-455. 
 
Bekris, L. M., Yu, C. E., Bird, T. D. and Tsuang, D. W. (2010) 'Genetics of 
Alzheimer disease', Journal of Geriatric Psychiatry and Neurology, 23, (4), 
pp. 213-227. 
 
Benedict, R. H. (1997) 'Brief Visuospatial Memory Test - Revised', in  Odessa, FL: 
Psychological Assessment Resources Inc. 
 
Benedict, R. H. and Groninger, L. (1995) 'Preliminary standardization and validation 
of a new visuo-spatial memory test with six alternate forms. ', Clinical 
Neuropsychology, 9, pp. 11-16. 
 
Beyer, M. K. and Aarsland, D. (2008) 'Grey matter atrophy in early versus late 
dementia in Parkinson's disease', Parkinsonism & Related Disorders, 14, (8), 
pp. 620-625. 
 
Beyer, M. K., Aarsland, D., Greve, O. J. and Larsen, J. P. (2006) 'Visual rating of 
white matter hyperintensities in Parkinson's disease', Movement Disorders, 21, 
(2), pp. 223-229. 
 
Beyer, M. K., Larsen, J. P. and Aarsland, D. (2007) 'Gray matter atrophy in 
Parkinson disease with dementia and dementia with Lewy bodies', Neurology, 
69, (8), pp. 747-754. 
 
References 
 
120 
Bhasin, M., Rowan, E., Edwards, K. and McKeith, I. (2007) 'Cholinesterase 
inhibitors in Dementia with Lewy bodies - A comparative analysis', 
International Journal of Geriatric Psychiatry, 22, pp. 890-895. 
 
Birks, J. (2006) 'Cholinesterase inhibitors for Alzheimer's disease', Cochrane 
Database of Systematic Reviews, (1), pp. CD005593. 
 
Blennow, K., de Leon, M. J. and Zetterberg, H. (2006) 'Alzheimer's disease', Lancet, 
368, (9533), pp. 387-403. 
 
Boeve, B. F. (2005) 'Clinical, diagnostic, genetic and management issues in dementia 
with Lewy bodies', Clinical Science, 109, pp. 343-354. 
 
Boeve, B. F. (2010) 'REM Sleep Behavious Disorder', Annals of the New York 
Academy of Sciences, 1184, pp. 15-54. 
 
Boeve, B. F., Silber, M. H., Parisi, J. E., Dickson, D. W., Ferman, T. J., Benarroch, 
E. E., Schmeichel, A. M., Smith, G. E., Petersen, R. C., Ahlskog, J. E., 
Matsumoto, J. Y., Knopman, D. S., Schenck, C. H. and Mahowald, M. W. 
(2003) 'Synucleinopathy pathology and REM sleep behavior disorder plus 
dementia or parkinsonism ', Neurology, 61, pp. 40-45. 
 
Bonelli, S. B., Ransmayr, G., Steffelbauer, M., Lukas, T., Lampl, C. and Deibl, M. 
(2004) 'L-dopa responsiveness in dementia with Lewy bodies, Parkinson 
disease with and without dementia', Neurology, 63, (2), pp. 376-378. 
 
Bostrom, F., Jonsson, L., Minthon, L. and Londos, E. (2007a) 'Patients with 
dementia with Lewy bodies have more impaired quality of life than patients 
with Alzheimer disease', Alzheimer Disease and Associated Disorders, 21, (2), 
pp. 150-154. 
 
Bostrom, F., Jonsson, L., Minthon, L. and Londos, E. (2007b) 'Patients with Lewy 
body dementia use more resources than those with Alzheimer's disease', 
International Journal of Geriatric Psychiatry, 22, (8), pp. 713-719. 
 
Bouchard, T. P., Malykhin, N., Martin, W. R. W., Hanstock, C. C., Emery, D. J., 
Fisher, N. J. and Camicioli, R. M. (2008) 'Age and dementia-associated 
atrophy predominates in the hippocampal head and amygdala in Parkinson's 
disease', Neurobiology of Aging, 29, (7), pp. 1027-1039. 
 
Bozzali, M., Falini, A., Cercignani, M., Baglio, F., Farina, E., Alberoni, M., Vezzulli, 
P., Olivotto, F., Mantovani, F., Shallice, T., Scotti, G., Canal, N. and Nemni, R. 
References 
 
121 
(2005) 'Brain tissue damage in dementia with Lewy bodies: an in vivo 
diffusion tensor MRI study', Brain, 128, (Pt 7), pp. 1595-604. 
 
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. and Del Tredici, K. (2004) 
'Stages in the development of Parkinson's disease-related pathology', Cell and 
Tissue Research, 318, (1), pp. 121-134. 
 
Braak, H., Rub, U., Gai, W. P. and Del Tredici, K. (2003) 'Idiopathic Parkinson's 
disease: possible routes by which vulnerable neuronal types may be subject to 
neuroinvasion by an unknown pathogen', Journal of Neural Transmission, 110, 
(5), pp. 517-536. 
 
Brandt, J. (1991) 'The Hopkins Verbal Learning Test: development of a new memoy 
test with six equivalent forms', Clinical Neuropsychology, 5, pp. 125-142. 
 
Brenneis, C., Wenning, G. K., Egger, K. E., Schocke, M., Trieb, T., Seppi, K., 
Marksteiner, J., Ransmayr, G., Benke, T. and Poewe, W. (2004) 'Basal 
forebrain atrophy is a distinctive pattern in dementia with Lewy bodies.', 
NeuroReport, 15, (11), pp. 1711-1714. 
 
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., 
Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C. and Mintun, M. A. 
(2005) 'Molecular, structural, and functional characterization of Alzheimer's 
disease: Evidence for a relationship between default activity, amyloid, and 
memory', Journal of Neuroscience, 25, (34), pp. 7709-7717. 
 
Bucks, R. S., Ashworth, D. L., Wilcock, G. K. and Siegfried, K. (1996) 'Assessment 
of activities of daily living in dementia: development of the Bristol Activities 
of Daily Living Scale', Age and Ageing, 25, pp. 113-120. 
 
Bucks, R. S. and Haworth, J. (2002) 'Bristol Activities of Daily Living Scale: a 
critical evaluation', Expert Review of Neurotherapeutics, 2, (5), pp. 669-676. 
 
Burke, W. J., Pfeiffer, R. F. and McComb, R. D. (1998) 'Neuroleptic sensitivity to 
clozapine in dementia with Lewy bodies', Journal of Neuropsychiatry and 
Clinical Neurosciences, 10, (2), pp. 227-229. 
 
Burn, D. J., Rowan, E. N., Allan, L. M., Molloy, S., T O'Brien, J. and McKeith, I. G. 
(2006) 'Motor subtype and cognitive decline in Parkinson's disease, Parkinson's 
disease with dementia, and dementia with Lewy bodies', Journal of Neurology 
Neurosurgery and Psychiatry, 77, (5), pp. 585-589. 
 
References 
 
122 
Burn, D. J., Rowan, E. N., Minett, T., Sanders, J., Myint, P., Richardson, J., Thomas, 
A., Newby, J., Reid, J., O'Brien, J. T. and McKeith, I. G. (2003) 
'Extrapyramidal features in Parkinson's disease with and without dementia and 
dementia with Lewy bodies: A cross-sectional comparative study', Movement 
Disorders, 18, (8), pp. 884-889. 
 
Burton, E. J., Barber, R., Mukaetova-Ladinska, E. B., Robson, J., Perry, R. H., Jaros, 
E., Kalaria, R. N. and O'Brien, J. T. (2009) 'Medial temporal lobe atrophy on 
MRI differentiates Alzheimer's disease from dementia with Lewy bodies and 
vascular cognitive impairment: a prospective study with pathological 
verification of diagnosis', Brain, 132, pp. 195-203. 
 
Burton, E. J., Karas, G., Paling, S. M., Barber, R., Williams, E. D., Ballard, C. G., 
McKeith, I. G., Scheltens, P., Barkhof, F. and O'Brien, J. T. (2002) 'Patterns of 
cerebral atrophy in dementia with Lewy bodies using voxel-based 
morphometry', Neuroimage, 17, (2), pp. 618-630. 
 
Burton, E. J., McKeith, I. G., Burn, D. J., Firbank, M. J. and O'Brien, J. T. (2006) 
'Progression of white matter hyperintensities in Alzheimer disease, dementia 
with Lewy bodies, and Parkinson disease dementia: a comparison with normal 
aging', American Journal of Geriatric Psychiatry, 14, (10), pp. 842-849. 
 
Burton, E. J., McKeith, I. G., Burn, D. J. and O'Brien, J. T. (2005) 'Brain atrophy 
rates in Parkinson's disease with and without dementia using serial magnetic 
resonance imaging', Movement Disorders, 20, (12), pp. 1571-1576. 
 
Burton, E. J., McKeith, I. G., Burn, D. J., Williams, E. D. and O'Brien, J. T. (2004) 
'Cerebral atrophy in Parkinson's disease with and without dementia: a 
comparison with Alzheimer's disease, dementia with Lewy bodies and 
controls', Brain, 127, (Pt 4), pp. 791-800. 
 
Burton, E. J., Mukaetova-Ladinska, E. B., Perry, R. H., Jaros, E., Barber, R. and 
O'Brien, J. T. (2011) 'Neuropathological correlates of volumetric MRI in 
autopsy-confirmed Lewy body dementia', Neurobiology of Aging. Epublished 
ahead of print, DOI: 10.1016/j.neurobiolaging.2010.12.015 
 
Camicioli, R., Moore, M. M., Kinney, A., Corbridge, E., Glassberg, K. and Kaye, J. 
A. (2003) 'Parkinson's disease is associated with hippocampal atrophy', 
Movement Disorders, 18, (7), pp. 784-790. 
 
Coffey, C. E., Figiel, G. S., Djang, W. T., Saunders, W. B. and Weiner, R. D. (1989) 
'White matter hyperintensity on magnetic resonance imaging: clinical and 
References 
 
123 
neuroanatomic correlates in the depressed elderly', The Journal of 
Neuropsychiatry Clinical Neurosciences, 1, (2), pp. 135-144. 
 
Collerton, D., Burn, D., McKeith, I. and O'Brien, J. (2003) 'Systematic review and 
meta-analysis show that dementia with Lewy bodies is a visual-perceptual and 
attentional-executive dementia', Dementia and Geriatric Cognitive Disorders, 
16, (4), pp. 229-237. 
 
Collette, F., Hogge, M., Salmon, E. and Van der Linden, M. (2006) 'Exploration of 
the neural substrates of executive functioning by functional neuroimaging', 
Neuroscience, 139, (1), pp. 209-221. 
 
Colloby, S. J., Fenwick, J. D., Williams, E. D., Paling, S. M., Lobotesis, K., Ballard, 
C., McKeith, I. and O'Brien, J. T. (2002) 'A comparison of Tc-99m-HMPAO 
SPET changes in dementia with Lewy bodies and Alzheimer's disease using 
statistical parametric mapping', European Journal of Nuclear Medicine and 
Molecular Imaging, 29, (5), pp. 615-622. 
 
Cousins, D. A., Burton, E. J., Burn, D., Gholkar, A., McKeith, I. G. and O'Brien, J. 
T. (2003) 'Atrophy of the putamen in dementia with Lewy bodies but not 
Alzheimer's disease: an MRI study', Neurology, 61, (9), pp. 1191-1195. 
 
Crews, L., Tsigelny, I., Hashimoto, M. and Masliah, E. (2009) 'Role of Synucleins in 
Alzheimer's Disease', Neurotoxicity Research, 16, (3), pp. 306-317. 
 
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and 
Gornbein, J. (1994) 'The Neuropsychiatric Inventory: comprehensive 
assessment of psychopathology in dementia', Neurology, 44, (12), pp. 2308-
2814. 
 
Dalfo, E., Albasanz, J. L., Martin, M. and Ferrer, I. (2004) 'Abnormal metabotropic 
glutamate receptor expression and signaling in the cerebral cortex in diffuse 
Lewy body disease is associated with irregular alpha-synuclein/phospholipase 
C (PLCbeta1) interactions', Brain Pathology, 14, (4), pp. 388-398. 
 
Delis, D. C., Kaplan, E. and Kramer, J. H. (2001) 'Delis-Kaplan Executive Function 
System: Examiner's Manual.', in  San Antonio: The Psychological Corporation. 
 
Dougall, N. J., Bruggink, S. and Ebmeier, K. P. (2004) 'Systematic review of the 
diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia', American 
Journal of Geriatric Psychiatry, 12, (6), pp. 554-570. 
 
References 
 
124 
Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., 
Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., Meguro, K., 
O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., Stern, Y., Visser, 
P. J. and Scheltens, P. (2007) 'Research criteria for the diagnosis of Alzheimer's 
disease: revising the NINCDS-ADRDA criteria', Lancet Neurology, 6, (8), pp. 
734-746. 
 
Duda, J. (2004) 'Pathology and neurotransmitter abnormalities of dementia with 
Lewy bodies', Dementia and Geriatric Cognitive Disorders, 17, pp. 3-14. 
 
Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N., 
Villemagne, V. L., O'Keefe, G., Nagren, K., Chaudhury, K. R., Masters, C. L. 
and Brooks, D. J. (2008) 'Amyloid load in Parkinson's disease dementia and 
Lewy body dementia measured with [11C]PIB positron emission tomography', 
Journal of Neurology Neurosurgery and Psychiatry, 79, (12), pp. 1331-1338. 
 
Emre, M., Tsolaki, M., Bonuccelli, U., Destee, A., Tolosa, E., Kutzelnigg, A., 
Ceballos-Baumann, A., Zdravkovic, S., Bladstrom, A. and Jones, R. (2010) 
'Memantine for patients with Parkinson's disease dementia or dementia with 
Lewy bodies: a randomised, double-blind, placebo-controlled trial', Lancet 
Neurology, 9, (10), pp. 969-977. 
 
Fahn, S., Elton, R. and Committee, a. m. o. t. U. D. (1987) 'Unified Parkinson's 
Disease Rating Scale', in  Fahn, S., Marsden, C., Calne, D. and Goldstein, 
M.(eds) Recent development in Parkinson's Disease. Vol. 2 Florham Park: 
Macmillan Health Care Information, pp. 153-164. 
 
Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I. and Zimmerman, R. A. (1987) 
'MR Signal Abnormalities at 1.5T in Alzheimer's Dementia and Normal 
Aging', American Journal of Roentgenology, 149, (2), pp. 351-356. 
 
Ferman, T. J., Smith, G. E., Boeve, B. F., Ivnik, R. J., Petersen, R. C., Knopman, D., 
Graff-Radford, N., Parisi, J. and Dickson, D. W. (2004) 'DLB fluctuations - 
Specific features that reliably differentiate DLB from AD and normal aging', 
Neurology, 62, (2), pp. 181-187. 
 
Fernandez, H. H., Wu, C. K. and Ott, B. R. (2003) 'Pharmacotherapy of dementia 
with Lewy bodies', Expert Opinion on Pharmacotherapy, 4, (11), pp. 2027-
2037. 
 
Firbank, M. J., Blamire, A. M., Krishnan, M. S., Teodorczuk, A., English, P., 
Gholkar, A., Harrison, R. and O'Brien, J. T. (2007a) 'Atrophy is associated with 
References 
 
125 
posterior cingulate white matter disruption in dementia with Lewy bodies and 
Alzheimer's disease', Neuroimage, 36, (1), pp. 1-7. 
 
Firbank, M. J., Blamire, A. M., Krishnan, M. S., Teodorczuk, A., English, P., 
Gholkar, A., Harrison, R. M. and O'Brien, J. T. (2007b) 'Diffusion tensor 
imaging in dementia with Lewy bodies and Alzheimer's disease', Psychiatry 
Research-Neuroimaging, 155, (2), pp. 135-145. 
 
Firbank, M. J., Blamire, A. M., Teodorczuk, A., Teper, E., Burton, E. J., Mitra, D. 
and O'Brien, J. T. (2010) 'High resolution imaging of the medial temporal lobe 
in Alzheimer's disease and dementia with Lewy bodies', Journal of Alzheimers 
Disease, 21, (4), pp. 1129-1140. 
 
Firbank, M. J., Colloby, S. J., Burn, D. J., McKeith, I. G. and O'Brien, J. T. (2003) 
'Regional cerebral blood flow in Parkinson's disease with and without 
dementia', Neuroimage, 20, (2), pp. 1309-1319. 
 
Folstein, M., Folstein, S. and McHugh, P. (1975) '"Mini-mental state". A practical 
method for grading the cognitive state of patients for the clinician.', Journal of 
Psychiatric Research., 12, pp. 189-198. 
 
Francis, P. T. (2009) 'Biochemical and pathological correlates of cognitive and 
behavioural change in DLB/PDD', Journal of Neurology, 256 (Suppl 3), 
pp. 280-285. 
 
Francis, P. T. and Perry, E. K. (2007) 'Cholinergic and Other Neurotransmitter 
Mechanisms in Parkinson's Disease, Parkinson's Disease Dementia and 
Dementia with Lewy Bodies', Movement Disorders, 22, (Suppl 17), pp. 351-
357. 
 
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J.-P., Frith, C. D. and 
Frackowiak, R. S. J. (1995) 'Statistical parametric maps in functional imaging: 
A general linear approach', Human Brain Mapping, 2, pp. 189-210. 
 
Galvan, A. and Wichmann, T. (2008) 'Pathophysiology of parkinsonism', Clinical 
Neurophysiology, 119, (7), pp. 1459-1474. 
 
Galvin, J. E., Price, J. L., Yan, Z., Morris, J. C. and Sheline, Y. I. (2011) 'Resting 
bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease', 
Neurology, 76, (21), pp. 1797-1803. 
 
References 
 
126 
Gaudin, D. G. (ed.) (1995) NMR and its applications to living systems. Second ed 
Oxford: Oxford University Press. 
 
Gerety, M. B., Williams, J. W., Jr., Mulrow, C. D., Cornell, J. E., Kadri, A. A., 
Rosenberg, J., Chiodo, L. K. and Long, M. (1994) 'Performance of case-finding 
tools for depression in the nursing home: influence of clinical and functional 
characteristics and selection of optimal threshold scores', Journal of American 
Geriatric Society, 42, (10), pp. 1103-1109. 
 
Geser, F., Wenning, G. K., Poewe, W. and McKeith, I. (2005) 'How to Diagnose 
Dementia with Lewy Bodies: State of the Art', Movement Disorders, 20, 
(Suppl 12), pp. S11-S20. 
 
Gomez-Isla, T., Growdon, W. B., McNamara, M., Newell, K., Gomez-Tortosa, E., 
Hedley-Whyte, E. T. and Hyman, B. T. (1999) 'Clinicopathologic correlates in 
temporal cortex in dementia with Lewy bodies', Neurology, 53, (9), pp. 2003-
2009. 
 
Gomez-Tortosa, E., Newell, K., Irizarry, M. C., Albert, M., Growdon, J. H. and 
Hyman, B. T. (1999) 'Clinical and quantitative pathologic correlates of 
dementia with Lewy bodies', Neurology, 53, (6), pp. 1284-1291. 
 
Gomez-Tortosa, E., Newell, K., Irizarry, M. C., Sanders, J. L. and Hyman, B. T. 
(2000) 'alpha-Synuclein immunoreactivity in dementia with Lewy bodies: 
morphological staging and comparison with ubiquitin immunostaining', Acta 
Neuropathologica, 99, (4), pp. 352-357. 
 
Gomperts, S. N., Rentz, D. M., Moran, E., Becker, J. A., Locascio, J. J., Klunk, W. 
E., Mathis, C. A., Elmaleh, D. R., Shoup, T., Fischman, A. J., Hyman, B. T., 
Growdon, J. H. and Johnson, K. A. (2008) 'Imaging amyloid deposition in 
Lewy body diseases', Neurology, 71, (12), pp. 903-910. 
 
Goodale, M. A. and Milner, A. D. (1992) 'Separate Visual Pathways for Perception 
and Action', Trends in Neurosciences, 15, (1), pp. 20-25. 
 
Gosche, K. M., Mortimer, J. A., Smith, C. D., Markesbery, W. R. and Snowdon, D. 
A. (2002) 'Hippocampal volume as an index of Alzheimer neuropathology: 
findings from the Nun Study', Neurology, 58, (10), pp. 1476-1482. 
 
Griffith, H., den Hollander, J., Okonkwo, O., O'Brien, T., Watts, R. and Marson, D. 
(2008a) 'Brain N-acetylaspartate is reduced in Parkinson disease with 
dementia', Alzheimers Disease & Associated Disorders, 22, (1), pp. 54-60. 
References 
 
127 
 
Griffith, H. R., den Hollander, J. A., Okonkwo, O. C., O'Brien, T., Watts, R. L. and 
Marson, D. C. (2008b) 'Brain metabolism differs in Alzheimer's disease and 
Parkinson's disease dementia', Alzheimers & Dementia, 4, (6), pp. 421-427. 
 
Gupta, D. and Nair, M. D. (2008) 'Neurogenic orthostatic hypotension: chasing "the 
fall''', Postgraduate Medical Journal, 84, (987), pp. 6-14. 
 
Hanyu, H., Asano, T., Sakurai, H., Takasaki, M., Shindo, H. and Abe, K. (2001) 
'Magnetisation transfer measurements of the subcortical grey and white matter 
in Parkinson's disease with and without dementia and in progressive 
supranuclear palsy', Neuroradiology, 43, (7), pp. 542-546. 
 
Hanyu, H., Shimizu, S., Tanaka, Y., Hirao, K., Iwamoto, T. and Abe, K. (2007) 'MR 
features of the substantia innominata and therapeutic implications in 
dementias', Neurobiology of Aging, 28, (4), pp. 548-554. 
 
Hanyu, H., Shimizu, S., Tanaka, Y., Kanetaka, H., Iwamoto, T. and Abe, K. (2005) 
'Differences in magnetization transfer ratios of the hippocampus between 
dementia with Lewy bodies and Alzheimer's disease', Neuroscience Letters, 
380, (1-2), pp. 166-169. 
 
Harding, A. J., Broe, G. A. and Halliday, G. M. (2002) 'Visual hallucinations in 
Lewy body disease relate to Lewy bodies in the temporal lobe', Brain, 125, 
pp. 391-403. 
 
Harding, A. J. and Halliday, G. M. (2001) 'Cortical Lewy body pathology in the 
diagnosis of dementia', Acta Neuropathologica, 102, (4), pp. 355-363. 
 
Hardy, J. and Selkoe, D. J. (2002) 'The amyloid hypothesis of Alzheimer's disease: 
progress and problems on the road to therapeutics', Science, 297, (5580), 
pp. 353-356. 
 
Harvey, G. T., Hughes, J., McKeith, I. G., Briel, R., Ballard, C., Gholkar, A., 
Scheltens, P., Perry, R. H., Ince, P. and O'Brien, J. T. (1999) 'Magnetic 
resonance imaging differences between dementia with Lewy bodies and 
Alzheimer's disease: a pilot study', Psychological Medicine, 29, (1), pp. 181-
187. 
 
Harvey, R. J., Skelton-Robinson, M. and Rossor, M. N. (2003) 'The prevalence and 
causes of dementia in people under the age of 65 years', Journal of Neurology 
Neurosurgery and Psychiatry, 74, (9), pp. 1206-1209. 
References 
 
128 
 
Hashimoto, M., Kitagaki, H., Imamura, T., Hirono, N., Shimomura, T., Kazui, H., 
Tanimukai, S., Hanihara, T. and Mori, E. (1998) 'Medial temporal and whole-
brain atrophy in dementia with Lewy bodies: a volumetric MRI study', 
Neurology, 51, (2), pp. 357-362. 
 
Hollingworth, P., Harold, D., Sims, R., Gerrish, A., Lambert, J. C., Carrasquillo, M. 
M., Abraham, R., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., 
Jones, N., Stretton, A., Thomas, C., Richards, A., Ivanov, D., Widdowson, C., 
Chapman, J., Lovestone, S., Powell, J., Proitsi, P., Lupton, M. K., Brayne, C., 
Rubinsztein, D. C., Gill, M., Lawlor, B., Lynch, A., Brown, K. S., Passmore, P. 
A., Craig, D., McGuinness, B., Todd, S., Holmes, C., Mann, D., Smith, A. D., 
Beaumont, H., Warden, D., Wilcock, G., Love, S., Kehoe, P. G., Hooper, N. 
M., Vardy, E. R., Hardy, J., Mead, S., Fox, N. C., Rossor, M., Collinge, J., 
Maier, W., Jessen, F., Ruther, E., Schurmann, B., Heun, R., Kolsch, H., van 
den Bussche, H., Heuser, I., Kornhuber, J., Wiltfang, J., Dichgans, M., Frolich, 
L., Hampel, H., Gallacher, J., Hull, M., Rujescu, D., Giegling, I., Goate, A. M., 
Kauwe, J. S., Cruchaga, C., Nowotny, P., Morris, J. C., Mayo, K., Sleegers, K., 
Bettens, K., Engelborghs, S., De Deyn, P. P., Van Broeckhoven, C., 
Livingston, G., Bass, N. J., Gurling, H., McQuillin, A., Gwilliam, R., 
Deloukas, P., Al-Chalabi, A., Shaw, C. E., Tsolaki, M., Singleton, A. B., 
Guerreiro, R., Muhleisen, T. W., Nothen, M. M., Moebus, S., Jockel, K. H., 
Klopp, N., Wichmann, H. E., Pankratz, V. S., Sando, S. B., Aasly, J. O., 
Barcikowska, M., Wszolek, Z. K., Dickson, D. W., Graff-Radford, N. R., 
Petersen, R. C., et al. (2011) 'Common variants at ABCA7, 
MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with 
Alzheimer's disease', Nature Genetics, 43, (5), pp. 429-435. 
 
Horimoto, Y., Matsumoto, M., Akatsu, H., Ikari, H., Kojima, K., Yamamoto, T., 
Otsuka, Y., Ojika, K., Ueda, R. and Kosaka, K. (2003) 'Autonomic 
dysfunctions in dementia with Lewy bodies', Journal of Neurology, 250, 
pp. 530-533. 
 
Huang, C., Tang, C., Feigin, A., Lesser, M., Ma, Y., Pourfar, M., Dhawan, V. and 
Eidelberg, D. (2007) 'Changes in network activity with the progression of 
Parkinson's disease', Brain, 130, (Pt 7), pp. 1834-1846. 
 
Huber, S. J., Shuttleworth, E. C., Christy, J. A., Chakeres, D. W., Curtin, A. and 
Paulson, G. W. (1989) 'Magnetic resonance imaging in dementia of Parkinson's 
disease', Journal of Neurology Neurosurgery and Psychiatry, 52, pp. 1221-
1227. 
 
Hughes, A. J., Daniel, S. E., Kilford, L. and Lees, A. J. (1992) 'Accuracy of Clinical 
Diagnosis - Diagnosis of Idiopathic Parkinsons Disease - A Clinicopathological 
References 
 
129 
Study of 100 Cases', Journal of Neurology Neurosurgery and Psychiatry, 55, 
(3), pp. 181-184. 
 
Ibarretxe-Bilbao, N., Ramirez-Ruiz, B., Tolosa, E., Marti, M. J., Valldeoriola, F., 
Bargallo, N. and Junque, C. (2008) 'Hippocampal head atrophy predominance 
in Parkinson's disease with hallucinations and with dementia', Journal of 
Neurology, 255, (9), pp. 1324-1331. 
 
Idiaquez, J. and Roman, G. C. (2011) 'Autonomic dysfunction in neurodegenerative 
dementias', Journal of the Neurological Sciences, 305, (1-2), pp. 22-27. 
 
Imamura, T., Ishii, K., Sasaki, M., Kitagaki, H., Yamaji, S., Hirono, N., Shimomura, 
T., Hashimoto, M., Tanimukai, S., Kazui, H. and Mori, E. (1997) 'Regional 
cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's 
disease: a comparative study using positron emission tomography', 
Neuroscience Letters, 235, (1-2), pp. 49-52. 
 
Ishii, K., Imamura, T., Sasaki, M., Yamaji, S., Sakamoto, S., Kitagaki, H., 
Hashimoto, M., Hirono, N., Shimomura, T. and Mori, E. (1998) 'Regional 
cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's 
disease', Neurology, 51, (1), pp. 125-130. 
 
Ishii, K., Yamaji, S., Kitagaki, H., Imamura, T., Hirono, N. and Mori, E. (1999) 
'Regional cerebral blood flow difference between dementia with Lewy bodies 
and AD', Neurology, 53, (2), pp. 413-416. 
 
Jack, C. R., Jr., Dickson, D. W., Parisi, J. E., Xu, Y. C., Cha, R. H., O'Brien, P. C., 
Edland, S. D., Smith, G. E., Boeve, B. F., Tangalos, E. G., Kokmen, E. and 
Petersen, R. C. (2002) 'Antemortem MRI findings correlate with hippocampal 
neuropathology in typical aging and dementia', Neurology, 58, (5), pp. 750-
757. 
 
Jack, C. R., Jr., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, 
D. S., Shiung, M. M., Gunter, J. L., Boeve, B. F., Kemp, B. J., Weiner, M. and 
Petersen, R. C. (2009) 'Serial PIB and MRI in normal, mild cognitive 
impairment and Alzheimer's disease: implications for sequence of pathological 
events in Alzheimer's disease', Brain, 132, (Pt 5), pp. 1355-1365. 
 
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. 
W., Petersen, R. C. and Trojanowski, J. Q. (2010) 'Hypothetical model of 
dynamic biomarkers of the Alzheimer's pathological cascade', Lancet 
Neurology, 9, (1), pp. 119-128. 
 
References 
 
130 
Jack, C. R., Petersen, R. C., Obrien, P. C. and Tangalos, E. G. (1992) 'MR-based 
Hippocampal Volumetry in the diagnosis of Alzheimer's Disease', Neurology, 
42, (1), pp. 183-188. 
 
Jagust, W., Reed, B., Mungas, D., Ellis, W. and Decarli, C. (2007) 'What does 
fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?', 
Neurology, 69, (9), pp. 871-877. 
 
Janvin, C. C., Larsen, J. P., Salmon, D. P., Galasko, D., Hugdahl, K. and Aarsland, 
D. (2006) 'Cognitive profiles of individual patients with Parkinson's disease 
and dementia: Comparison with dementia with Lewy bodies and Alzheimer's 
disease', Movement Disorders, 21, (3), pp. 337-342. 
 
Jellinger, K. A. (2003) 'Neuropathological spectrum of synucleinopathies', Movement 
Disorders, 18 (Suppl 6), pp. S2-S12. 
 
Jezzard, P., Matthews, P. M. and Smith, S. M. (eds.) (2001) Functional MRI. Oxford: 
Oxford University Press. 
 
Jones, L., Harold, D. and Williams, J. (2010) 'Genetic evidence for the involvement 
of lipid metabolism in Alzheimer's disease', Biochimica Biophysica Acta, 1801, 
(8), pp. 754-761. 
 
Junque, C., Ramirez-Ruiz, B., Tolosa, E., Summerfield, C., Marti, M. J., Pastor, P., 
Gomez-Anson, B. and Mercader, J. M. (2005) 'Amygdalar and hippocampal 
MRI volumetric reductions in Parkinson's disease with dementia', Movement 
Disorders, 20, (5), pp. 540-544. 
 
Kantarci, K., Avula, R., Senjem, M. L., Samikoglu, A. R., Zhang, B., Weigand, S. 
D., Przybelski, S. A., Edmonson, H. A., Vemuri, P., Knopman, D. S., Ferman, 
T. J., Boeve, B. F., Petersen, R. C. and Jack, C. R. (2010) 'Dementia with Lewy 
bodies and Alzheimer disease Neurodegenerative patterns characterized by 
DTI', Neurology, 74, (22), pp. 1814-1821. 
 
Kantarci, K., Petersen, R. C., Boeve, B. F., Knopman, D. S., Tang-Wei, D. F., 
O'Brien, P. C., Weigand, S. D., Edland, S. D., Smith, G. E., Ivnik, R. J., 
Ferman, T. J., Tangalos, E. G. and Jack, C. R. (2004) '
1
H MR spectroscopy in 
common dementias', Neurology, 63, pp. 1393-1398. 
 
Karagulle Kendi, A. T., Lehericy, S., Luciana, M., Ugurbil, K. and Tuite, P. (2008) 
'Altered diffusion in the frontal lobe in Parkinson disease', American Journal of 
Neuroradiology, 29, (3), pp. 501-505. 
References 
 
131 
 
Kenny, E. R., Burton, E. J. and O'Brien, J. T. (2008) 'A Volumetric Magnetic 
Resonance Imaging Study of Entorhinal Cortex Volume in Dementia with 
Lewy Bodies', Dementia and Geriatric Cognitive Disorders, 26, (3), pp. 218-
225. 
 
King, A. E., Mintz, J. and Royall, D. R. (2011) 'Meta-analysis of (123) I-MIBG 
cardiac scintigraphy for the diagnosis of Lewy body-related disorders', 
Movement Disorders, 26, (7), pp. 1218-1224. 
 
Knapp, M. and Prince, M. (2007) 'Dementia UK.', Alzheimer's Society, [Online]. 
Available at: http://alzheimers.org.uk/site/scripts/download.php?fileID=2 
(Accessed: September 2008). 
 
Kovari, E., Gold, G., Herrmann, F. R., Canuto, A., Hof, P. R., Bouras, C. and 
Giannakopoulos, P. (2003) 'Lewy body densities in the entorhinal and anterior 
cingulate cortex predict cognitive deficits in Parkinson's disease', Acta 
Neuropathologica, 106, (1), pp. 83-88. 
 
Kovari, E., Horvath, J. and Bouras, C. (2009) 'Neuropathology of Lewy body 
disorders', Brain Research Bulletin, 80, pp. 203-210. 
 
Kramer, M. L. and Schulz-Schaeffer, W. J. (2007) 'Presynaptic alpha-synuclein 
aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy 
bodies', Journal of Neuroscience, 27, (6), pp. 1405-1410. 
 
Laakso, M. P., Partanen, K., Riekkinen, P., Lehtovirta, M., Helkala, E. L., 
Hallikainen, M., Hanninen, T., Vainio, P. and Soininen, H. (1996) 
'Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and 
without dementia, and in vascular dementia: An MRI study', Neurology, 46, 
(3), pp. 678-681. 
 
Landman, B. A., Farrell, J. A., Jones, C. K., Smith, S. A., Prince, J. L. and Mori, S. 
(2007) 'Effects of diffusion weighting schemes on the reproducibility of DTI-
derived fractional anisotropy, mean diffusivity, and principal eigenvector 
measurements at 1.5T', NeuroImage, 36, (4), pp. 1123-1138. 
 
Le Bihan, D. (2007) 'The 'wet mind': water and functional neuroimaging', Physics in 
Medicine and Biology, 52, pp. R57-R90. 
 
Lee, J. E., Park, B., Song, S. K., Sohn, Y. H., Park, H. J. and Lee, P. H. (2010a) 'A 
Comparison of Gray and White Matter Density in Patients with Parkinson's 
References 
 
132 
Disease Dementia and Dementia with Lewy Bodies Using Voxel-Based 
Morphometry', Movement Disorders, 25, (1), pp. 28-34. 
 
Lee, J. E., Park, H. J., Park, B., Song, S. K., Sohn, Y. H., Lee, J. D. and Lee, P. H. 
(2010b) 'A comparative analysis of cognitive profiles and white-matter 
alterations using voxel-based diffusion tensor imaging between patients with 
Parkinson's disease dementia and dementia with Lewy bodies', Journal of 
Neurology Neurosurgery and Psychiatry, 81, (3), pp. 320-326. 
 
Lippa, C., Smith, T. and Perry, E. (1999) 'Dementia with Lewy bodies: choline 
acetyltransferase parallels nucleus basalis pathology', Journal of Neural 
Transmission, 106, pp. 525-535. 
 
Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., 
Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., Fahn, S., Farmer, J. M., 
Galasko, D., Galvin, J. E., Goetz, C. G., Growdon, J. H., Gwinn-Hardy, K. A., 
Hardy, J., Heutink, P., Iwatsubo, T., Kosaka, K., Lee, V. M. Y., Leverenz, J. 
B., Masliah, E., McKeith, I. G., Nussbaum, R. L., Olanow, C. W., Ravina, B. 
M., Singleton, A. B., Tanner, C. M., Trojanowski, J. Q., Wszolek, Z. K. for the 
DLB/PDD Working Group. (2007) 'DLB and PDD boundary issues - 
Diagnosis, treatment, molecular pathology, and biomarkers', Neurology, 68, 
(11), pp. 812-819. 
 
Lippa, C. F., Johnson, R. and Smith, T. W. (1998) 'The medial temporal lobe in 
dementia with Lewy bodies: A comparative study with Alzheimer's disease', 
Annals of Neurology, 43, (1), pp. 102-106. 
 
Lippa, S. M., Lippa, C. F. and Hiroshi, M. (2005) '-Synuclein aggegation in 
pathological aging and Alzheimer's disease: The impact of -amyloid plaque 
level', American Journal of Alzheimer's Disease and Other Dementias, 20, (5), 
pp. 315-318. 
 
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E. and McKeith, I. G. 
(2003) 'Movement Disorders Society Scientific Issues Commitee report: SIC 
Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders', 
Movement Disorders, 18, pp. 467-486. 
 
Lobotesis, K., Fenwick, J. D., Phipps, A., Ryman, A., Swann, A., Ballard, C., 
McKeith, I. G. and O'Brien, J. T. (2001) 'Occipital hypoperfusion on SPECT in 
dementia with Lewy bodies but not AD', Neurology, 56, (5), pp. 643-649. 
 
References 
 
133 
Matsui, H., Nishinaka, K., Oda, M., Niikawa, H., Kubori, T. and Udaka, F. (2007) 
'Dementia in Parkinson's disease: diffusion tensor imaging', Acta Neurologica 
Scandinavica, 116, pp. 117-181. 
 
McKeith, I., Ballard, C., Perry, R., Ince, P., O’Brien, J., Neill, D., Lowery, K., Jaros, 
E., Barber, R., Thompson, P., Swann, A., Fairbairn, A. and Perry, E. (2000a) 
'Prospective validation of the consensus criteria for the diagnosis of dementia 
with Lewy bodies.', Neurology, 54, pp. 1050-1058. 
 
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, 
A., Ferrara, R. and Spiegel, R. (2000b) 'Efficacy of rivastigmine in dementia 
with Lewy bodies: a randomised, double-blind, placebo-controlled 
international study', Lancet 356, pp. 2031-2036. 
 
McKeith, I., Fairbairn, A., Perry, R., Thompson, P. and Perry, E. (1992) 'Neuroleptic 
Sensitivity in Patients with Senile Dementia of Lewy Body Type', British 
Medical Journal, 305, (6855), pp. 673-678. 
 
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. 
A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., Lennox, G., Quinn, N. 
P., Edwardson, J. A., Ince, P. G., Bergeron, C., Burns, A., Miller, B. L., 
Lovestone, S., Collerton, D., Jansen, E. N., Ballard, C., de Vos, R. A., Wilcock, 
G. K., Jellinger, K. A. and Perry, R. H. (1996) 'Consensus guidelines for the 
clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report 
of the consortium on DLB international workshop. ', Neurology, 47, (5), pp. 
1113-1124. 
 
McKeith, I., Mintzer, J., Aarsland, D., Burn, D., Chiu, H., Cohen-Mansfield, J., 
Dickson, D., Dubois, B., Duda, J., Feldman, H., Gauthier, S., Halliday, G., 
Lawlor, B., Lippa, C., Lopez, O. L., Manchado, J. C., O'Brien, J., Playfer, J., 
Reid, W on behalf of the International Psychogeriatrics Association Expert 
Meeting on DLB. (2004) 'Dementia with Lewy Bodies', Lancet Neurology, 3, 
pp. 19-28. 
 
McKeith, I., O'Brien, J., Tatsch, K., Booij, J., Padovani, A., Giubbini, R., Bonuccelli, 
U., Volterrani, D., Holmes, C., Kemp, P., Tabet, N., Meyer, I. and Reininger, 
C. (2007) 'Sensitivity and specificity of dopamine transporter imaging with 
123
I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre 
study', Lancet Neurology, 6, pp. 305-313. 
 
McKeith, I. G., Burn, D. J., Ballard, C. G., Collerton, D., Jaros, E., Morris, C. M., 
McLaren, A., Perry, E. K., Perry, R., Piggott, M. A. and O'Brien, J. T. (2003) 
'Dementia with Lewy bodies', Seminars in Clinical Neuropsychiatry, 8, (1), 
pp. 46-57. 
References 
 
134 
 
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., 
Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., Aarsland, D., Arai, H., 
Ballard, C. G., Boeve, B., Burn, D. J., Costa, D., Del Ser, T., Dubois, B., 
Galasko, D., Gauthier, S., Goetz, C. G., Gomez-Tortosa, E., Halliday, G., 
Hansen, L. A., Hardy, J., Iwatsubo, T., Kalaria, R. N., Kaufer, D., Kenny, R. 
A., Korczyn, A., Kosaka, K., Lee, V. M., Lees, A., Litvan, I., Londos, E., 
Lopez, O. L., Minoshima, S., Mizuno, Y., Molina, J. A., Mukaetova-Ladinska, 
E. B., Pasquier, F., Perry, R. H., Schulz, J. B., Trojanowski, J. Q. and Yamada, 
M. (2005) 'Diagnosis and management of dementia with Lewy bodies: third 
report of the DLB Consortium', Neurology, 65, (12), pp. 1863-1872. 
 
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. 
(1984) 'Clinical diagnosis of Alzheimer's disease: report of the NINCDS-
ADRDA Work Group under the auspices of Department of Health and Human 
Services Task Force on Alzheimer's Disease', Neurology, 34, (7), pp. 939-944. 
 
Mega, M. S., Masterman, D. L., Benson, D. F., Vinters, H. V., Tomiyasu, U., Craig, 
A. H., Foti, D. J., Kaufer, D., Scharre, D. W., Fairbanks, L. and Cummings, J. 
L. (1996) 'Dementia with Lewy bodies: Reliability and validity of clinical and 
pathologic criteria', Neurology, 47, (6), pp. 1403-1409. 
 
Metzler-Baddeley, C. (2007) 'A review of cognitive impairments in dementia with 
Lewy bodies relative to Alzheimer's disease and Parkinson's disease with 
dementia', Cortex, 43, (5), pp. 583-600. 
 
Middelkoop, H. A., van der Flier, W. M., Burton, E. J., Lloyd, A. J., Paling, S., 
Barber, R., Ballard, C., McKeith, I. G. and O'Brien, J. T. (2001) 'Dementia 
with Lewy bodies and AD are not associated with occipital lobe atrophy on 
MRI', Neurology, 57, (11), pp. 2117-2120. 
 
Minoshima, S., Foster, N. L., Petrie, E. C., Albin, R. L., Frey, K. A. and Kuhl, D. E. 
(2002) 'Neuroimaging in dementia with Lewy bodies: metabolism, 
neurochemistry, and morphology', Journal Geriatric Psychiatry and 
Neurology, 15, (4), pp. 200-209. 
 
Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L. and Kuhl, D. E. 
(1997) 'Metabolic reduction in the posterior cingulate cortex in very early 
Alzheimer's disease', Annals of Neurology, 42, (1), pp. 85-94. 
 
Molina, J. A., Garcia-Segura, J. M., Benito-Leon, J., Gomez-Escalonilla, C., del Ser, 
T., Martinez, V. and Viano, J. (2002) 'Proton Magnetic Spectroscopy in 
Dementia with Lewy Bodies', European Neurology, 48, pp. 158-163. 
 
References 
 
135 
Molloy, S., McKeith, I. G., O'Brien, J. T. and Burn, D. J. (2005) 'The role of 
levodopa in the management of dementia with Lewy bodies', Journal of 
Neurology Neurosurgery and Psychiatry, 76, (9), pp. 1200-1203. 
 
Mosimann, U. P., Mather, G., Wesnes, K. A., O'Brien, J. T., Burn, D. J. and 
McKeith, I. G. (2004) 'Visual perception in Parkinson disease dementia and 
dementia with Lewy bodies', Neurology, 63, pp. 2091-2096. 
 
Nagano-Saito, A., Kato, T., Arahata, Y., Washimi, Y., Nakamura, A., Abe, Y., 
Yamada, T., Iwai, K., Hatano, K., Kawasumi, Y., Kachi, T., Dagher, A. and 
Ito, K. (2004) 'Cognitive- and motor-related regions in Parkinson's disease: 
FDOPA and FDG PET studies', NeuroImage, 22, (2), pp. 553-561. 
 
Nelson, H. E. and Willison, J. R. (1991) 'National Adult Reading Test (NART) Test 
Manual (Part 2)',  Windsor, UK: NFER-Nelson. 
 
Norris, J. T., Gallagher, D., Wilson, A. and Winograd, C. H. (1987) 'Assessment of 
depression in geriatric medical outpatients: the validity of two screening 
measures', Journal of the American Geriatric Society, 35, (11), pp. 989-995. 
 
O'Brien, J., McKeith, I., Ames, D. and Chiu, E. (eds.) (2006) Dementia with Lewy 
bodies. UK: Taylor & Francis Group. 
 
O'Brien, J. T., Colloby, S., Fenwick, J., Williams, D., Firbank, M., Burn, D., 
Aarsland, D. and McKeith, I. G. (2004) 'Dopamine Transporter Loss 
Visualized with FP-CIT SPECT in the Differential Diagnosis of Dementia with 
Lewy Bodies', Archives of Neurology, 61, pp. 919-925. 
 
O'Brien, J. T., Erkinjuntti, T., Reisberg, B., Roman, G., Sawada, T., Pantoni, L., 
Bowler, J. V., Ballard, C., DeCarli, C., Gorelick, P. B., Rockwood, K., Burns, 
A., Gauthier, S. and DeKosky, S. T. (2003) 'Vascular cognitive impairment', 
Lancet Neurology, 2, (2), pp. 89-98. 
 
O'Brien, J. T., Firbank, M. J., Mosimann, U. P., Burn, D. J. and McKeith, I. G. 
(2005) 'Change in perfusion, hallucinations and fluctuations in consciousness 
in dementia with Lewy bodies', Psychiatry Research-Neuroimaging, 139, (2), 
pp. 79-88. 
 
O'Brien, J. T., Paling, S., Barber, R., Williams, E. D., Ballard, C., McKeith, I. G., 
Gholkar, A., Crum, W. R., Rossor, M. N. and Fox, N. C. (2001) 'Progressive 
brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular 
dementia', Neurology, 56, (10), pp. 1386-1388. 
References 
 
136 
 
Ota, M., Sato, N., Ogawa, M., Murata, M., Kuno, S., Kida, J. and Asada, T. (2009) 
'Degeneration of dementia with Lewy bodies measured by diffusion tensor 
imaging', NMR in Biomedicine, 22, (3), pp. 280-284. 
 
Parkkinen, L., Pirttila, T. and Alafuzoff, I. (2008) 'Applicability of current 
staging/categorization of alpha-synuclein pathology and their clinical 
relevance', Acta Neuropathologica, 115, (4), pp. 399-407. 
 
Perry, E. K., Irving, D., Kerwin, J. M., McKeith, I. G., Thompson, P., Collerton, D., 
Fairbairn, A. F., Ince, P. G., Morris, C. M., Cheng, A. V. and Perry, R. H. 
(1993) 'Cholinergic transmitter and neurotrophic activities in Lewy body 
dementia - similarity to Parkinson and distinction from Alzheimer disease.', 
Alzheimer Disease & Associated Disorders, 7, (2), pp. 69-79. 
 
Piggot, M. A., Marshall, E. F., Thomas, N., Lloyd, S., Court, J. A., Jaros, E., Burn, 
D., Johnson, M., Perry, R. H., McKeith, I. G., Ballard, C. and Perry, E. K. 
(1999) 'Striatal dopaminergic markers in dementia with Lewy bodies, 
Alzheimer's and Parkinson's diseases: rostrocaudal distribution', Brain, 122, 
pp. 1449-1468. 
 
Piggott, M. A., Ballard, C. G., Dickinson, H. O., McKeith, I. G., Perry, R. H. and 
Perry, E. K. (2007) 'Thalamic D2 receptors in dementia with Lewy bodies, 
Parkinson's disease, and Parkinson's disease dementia', International Journal of 
Neuropsychopharmacology, 10, (2), pp. 231-244. 
 
Poewe, W. (2005) 'Treatment of dementia with Lewy bodies and Parkinson's disease 
dementia', Movement Disorders, 20, pp. S77-S82. 
 
Popescu, A., Lippa, C. F., Lee, V. M. and Trojanowski, J. Q. (2004) 'Lewy bodies in 
the amygdala: increase of alpha-synuclein aggregates in neurodegenerative 
diseases with tau-based inclusions', Archives of Neurology, 61, (12), pp. 1915-
1919. 
 
Raber, J., Huang, Y. and Ashford, J. W. (2004) 'ApoE genotype accounts for the vast 
majority of AD risk and AD pathology', Neurobiology of Aging, 25, (5), 
pp. 641-650. 
 
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, 
L. and Oremus, M. (2008) 'Effectiveness of cholinesterase inhibitors and 
memantine for treating dementia: evidence review for a clinical practice 
guideline', Annals of Internal Medicine, 148, (5), pp. 379-397. 
References 
 
137 
 
Ramaker, C., Marinus, J., Stiggelbout, A. M. and Van Hilten, B. J. (2002) 
'Systematic evaluation of rating scales for impairment and disability in 
Parkinson's disease', Movement Disorders, 17, (5), pp. 867-876. 
 
Ramirez-Ruiz, B., Marti, M. J., Tolosa, E., Bartres-Faz, D., Summerfield, C., 
Salgado-Pineda, P., Gomez-Anson, B. and Junque, C. (2005) 'Longitudinal 
evaluation of cerebral morphological changes in Parkinson's disease with and 
without dementia', Journal of Neurology, 252, (11), pp. 1345-1352. 
 
Rueckert, D., Sonoda, L. I., Hayes, C., Hill, D. L. G., Leach, M. O. and Hawkes, D. 
J. (1999) 'Non-rigid registration using free-form deformations: Application to 
breast MR images. ', IEEE Transactions on Medical Imaging, 18, (8), pp. 712-
721. 
 
Sabattoli, F., Boccardi, M., Galluzzi, S., Treves, A., Thompson, P. M. and Frisoni, G. 
B. (2008) 'Hippocampal shape differences in dementia with Lewy bodies', 
Neuroimage, 41, (3), pp. 699-705. 
 
Sacchetti, E., Turrina, C. and Valsecchi, P. (2010) 'Cerebrovascular accidents in 
elderly people treated with antipsychotic drugs: a systematic review', Drug 
Safety, 33, (4), pp. 273-288. 
 
Sahai, A., Khan, M. S., Arya, M., John, J., Singh, R. and Patel, H. R. H. (2006) 'The 
overactive bladder: review of current pharmacotherapy in adults. Part 1: 
pathophysiology and anticholinergic therapy', Expert Opinion on 
Pharmacotherapy, 7, (5), pp. 509-527. 
 
Sauer, J., ffytche, D. H., Ballard, C., Brown, R. G. and Howard, R. (2006) 
'Differences between Alzheimer's disease and dementia with Lewy bodies: an 
fMRI study of task-related brain activity', Brain, 129, (Pt 7), pp. 1780-1788. 
 
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., Brayne, C. 
and Med Res Council Cognitive, F. (2009) 'Age, Neuropathology, and 
Dementia', New England Journal of Medicine, 360, (22), pp. 2302-2309. 
 
Scheltens, P., Fox, N., Barkhof, F. and De Carli, C. (2002) 'Structural magnetic 
resonance imaging in the practical assessment of dementia: beyond exclusion', 
Lancet Neurology, 1, (1), pp. 13-21. 
 
Schiff, N. D. (2008) 'Central thalamic contributions to arousal regulation and 
neurological disorders of consciousness', in  Molecular and Biophysical 
References 
 
138 
Mechanisms of Arousal, Alertness, and Attention. Vol. 1129 Oxford: Blackwell 
Publishing, pp. 105-118. 
 
Scola, E., Bozzali, M., Agosta, F., Magnani, G., Franceschi, M., Sormani, M. P., 
Cercignani, M., Pagani, E., Falautano, M., Filippi, M. and Falini, A. (2010) 'A 
diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical 
follow-up', Journal of Neurology Neurosurgery and Psychiatry, 81, (7), 
pp. 798-805. 
 
Sethi, K. (2008) 'Levodopa unresponsive symptoms in Parkinson disease', Movement 
Disorders, 23, pp. S521-S533. 
 
Sheikh, J. and Yesavage, J. (1986) 'Geriatric Depression Scale (GDS): Recent 
evidence and development of a shorter version p.165-173', in  Brink, T.(ed), 
Clinical Gerontolgy. A guide to assessment and intervention. New York: The 
Haworth Press. 
 
Shen Y, Larkman DJ, Counsell S, Pu IM, Edwards D and JV, H. (2004) 'Correction 
of high-order eddy current induced geometric distortion in diffusion-weighted 
echo-planar images.', Magnetic Resonance Medicine, 52, pp. 1184-1189. 
 
Shimizu, S., Hanyu, H., Hirao, K., Sato, T., Iwamoto, T. and Koizumi, K. (2008) 
'Value of analyzing deep gray matter and occipital lobe perfusion to 
differentiate dementia with Lewy bodies from Alzheimer's disease', Annals of 
Nuclear Medicine, 22, (10), pp. 911-916. 
 
Sinha, N., Firbank, M. and O'Brien, J. T. (2011) 'Biomarkers in dementia with Lewy 
bodies: a review', International Journal of Geriatric Psychiatry. Epublished 
ahead of print, doi: 10.1002/gps.2749 
 
Smith, S. M., Jenkinson, M., Johansen-Berg, H., Rueckert, D., Nichols, T. E., 
Mackay, C. E., Watkins, K. E., Ciccarelli, O., Cader, M. Z., Matthews, P. M. 
and Behrens, T. E. J. (2006) 'Tract-based spatial statistics: Voxelwise analysis 
of multi-subject diffusion data.', NeuroImage, 31, pp. 1487-1505. 
 
Smith, S. M., Jenkinson, M., Woolrich, M. W., Beckmann, C. F., Behrens, T. E. J., 
Johansen-Berg, H., Bannister, P. R., De Luca, M., Drobnjak, I., Flitney, D. E., 
Niazy, R., Saunders, J., Vickers, J., Zhang, Y., De Stefano, N., Brady, J. M. 
and Matthews, P. M. (2004) 'Advances in functional and structural MR image 
analysis and implementation as FSL. ', NeuroImage, 23 (S1), pp. 208-219. 
 
References 
 
139 
Smith, S. M. and Nichols, T. E. (2009) 'Threshold-free cluster enhancement: 
Addressing problems of smoothing, threshold dependence and localisation in 
cluster inference', NeuroImage, 44, (1), pp. 83-98. 
 
Soares, D. P. and Law, M. (2009) 'Magnetic resonance spectroscopy of the brain: 
review of metabolites and clinical applications', Clinical Radiology, 64, pp. 12-
21. 
 
Stevens, T., Livingston, G., Kitchen, G., Manela, M., Walker, Z. and Katona, C. 
(2002) 'Islington study of dementia subtypes in the community', British Journal 
of Psychiatry, 180, pp. 270-276. 
 
Summerfield, C., Gomez-Anson, B., Tolosa, E., Mercader, J. M., Marti, J., Pastor, P. 
and Junque, C. (2002) 'Dementia in Parkinson Disease. A Proton Magnetic 
Resonance Spectroscopy Study', Archives of Neurology, 59, pp. 1415-1420. 
 
Summerfield, C., Junque, C., Tolosa, E., Salgado-Pineda, P., Gomez-Anson, B., 
Marti, M., Ramirez-Ruiz, B. and Mercader, J. (2005) 'Structural brain changes 
in Parkinson disease with dementia', Archives of Neurology, 62, (2), pp. 281-
285. 
 
Takahashi, R., Ishii, K., Miyamoto, N., Yoshikawa, T., Shimada, K., Ohkawa, S., 
Kakigi, T. and Yokoyama, K. (2010a) 'Measurement of gray and white matter 
atrophy in dementia with Lewy bodies using diffeomorphic anatomic 
registration through exponentiated lie algebra: A comparison with conventional 
voxel-based morphometry', American Journal of Neuroradiology, 31, (10), 
pp. 1873-1878. 
 
Takahashi, R., Ishii, K., Shimada, K., Ohkawa, S. and Nishimura, Y. (2010b) 
'Hypoperfusion of the motor cortex associated with parkinsonism in dementia 
with Lewy bodies', Journal of the Neurological Sciences, 288, (1-2), pp. 88-91. 
 
Tam, C. W. C., Burton, E. J., McKeith, I. G., Burn, D. J. and O'Brien, J. T. (2005) 
'Temporal lobe atrophy on MRI in Parkinson disease with dementia: a 
comparison with Alzheimer disease and dementia with Lewy bodies', 
Neurology, 64, (5), pp. 861-865. 
 
Tanaka, M., Kim, Y. M., Lee, G., Junn, E., Iwatsubo, T. and Mouradian, M. M. 
(2004) 'Aggresomes formed by alpha-synuclein and synphilin-1 are 
cytoprotective', Journal of Biological Chemistry, 279, (6), pp. 4625-4631. 
 
References 
 
140 
Tekin, S. and Cummings, J. L. (2002) 'Frontal-subcortical neuronal circuits and 
clinical neuropsychiatry - An update', Journal of Psychosomatic Research, 53, 
(2), pp. 647-654. 
 
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, 
L. A. and Katzman, R. (1991) 'Physical basis of cognitive alterations in 
Alzheimer's disease: synapse loss is the major correlate of cognitive 
impairment', Annals of Neurology, 30, (4), pp. 572-580. 
 
Treglia, G. and Cason, E. (2010) 'Diagnostic Performance of Myocardial Innervation 
Imaging Using MIBG Scintigraphy in Differential Diagnosis between 
Dementia with Lewy Bodies and Other Dementias: A Systematic Review and a 
Meta-Analysis', Journal of Neuroimaging. Epublished ahead of print, doi: 
10.1111/j.1552-6569.2010.00532.x  
 
Tsuboi, Y., Uchikado, H. and Dickson, D. W. (2007) 'Neuropathology of Parkinson's 
disease dementia and dementia with Lewy bodies with reference to striatal 
pathology', Parkinsonism & Related Disorders, 13 Suppl 3, pp. S221-S224. 
 
Turner, R. S. (2002) 'Idiopathic rapid eye movement sleep behaviour disorder is a 
harbinger of dementia with Lewy bodies', Journal of Geriatric Psychiatry 
Neurology, 15, pp. 195-199. 
 
Walker, M. P., Ayre, G. A., Cummings, J. L., Wesnes, K., McKeith, I. G., O'Brien, J. 
T. and Ballard, C. G. (2000a) 'Quantifying fluctuation in dementia with Lewy 
bodies, Alzheimer's disease, and vascular dementia', Neurology, 54, (8), pp. 
1616-1625. 
 
Walker, M. P., Ballard, C. G., Ayre, G. A., Wesnes, K., Cummings, J. L., McKeith, 
I. G. and O'Brien, J. T. (2000b) 'The Clinician Assessment of Fluctuation and 
the One Day Fluctuation Assessment Scale', British Journal of Psychiatry, 177, 
pp. 252-256. 
 
Walker, R. W. and Walker, Z. (2009) 'Dopamine transporter single photon emission 
computerized tomography in the diagnosis of dementia with Lewy bodies', 
Movement Disorders, 24 Suppl 2, pp. S754-S759. 
 
Weintraub, D. and Hurtig, H. I. (2007) 'Presentation and management of psychosis in 
Parkinson's disease and dementia with Lewy bodies', American Journal of 
Psychiatry, 164, (10), pp. 1491-1498. 
 
References 
 
141 
Wesnes, K. A., McKeith, I. G., Ferrara, R., Emre, M., Del Ser, T., Spano, P. F., 
Cicin-Sain, A., Anand, R. and Spiegel, R. (2002) 'Effects of rivastigmine on 
cognitive function in dementia with Lewy bodies: a randomised placebo-
controlled international study using the cognitive drug research computerised 
assessment system', Dementia and Geriatric Cognitive Disorders, 13, (3), 
pp. 183-192. 
 
Whitwell, J. L., Jack, C. R., Jr., Parisi, J. E., Knopman, D. S., Boeve, B. F., Petersen, 
R. C., Ferman, T. J., Dickson, D. W. and Josephs, K. A. (2007a) 'Rates of 
cerebral atrophy differ in different degenerative pathologies', Brain, 130, (Pt 4), 
pp. 1148-1158. 
 
Whitwell, J. L., Shiung, M. M., Przybelski, S. A., Weigand, S. D., Knopman, D. S., 
Boeve, B. F., Petersen, R. C. and Jack, C. R. (2008) 'MRI patterns of atrophy 
associated with progression to AD in amnestic mild cognitive impairment', 
Neurology, 70, (7), pp. 512-520. 
 
Whitwell, J. L., Weigand, S. D., Shiung, M. M., Boeve, B. F., Ferman, T. J., Smith, 
G. E., Knopman, D. S., Petersen, R. C., Benarroch, E. E., Josephs, K. A. and 
Jack, C. R., Jr. (2007b) 'Focal atrophy in dementia with Lewy bodies on MRI: 
a distinct pattern from Alzheimer's disease', Brain, 130, (Pt 3), pp. 708-719. 
 
Wiltshire, K., Foster, S., Kaye, J. A., Small, B. J. and Camicioli, R. (2005) 'Corpus 
callosum in neurodegenerative diseases: Findings in Parkinson's disease', 
Dementia and Geriatric Cognitive Disorders, 20, (6), pp. 345-351. 
 
Woo, B. K. P., Harwood, D. G., Melrose, R. J., Mandelkern, M. A., Campa, O. M., 
Walston, A. and Sultzer, D. L. (2010) 'Executive deficits and regional brain 
metabolism in Alzheimer's disease', International Journal of Geriatric 
Psychiatry, 25, (11), pp. 1150-1158. 
 
Xie, S., Xiao, J. X., Wang, Y. H., Wu, H. K., Gong, G. L. and Jiang, X. X. (2005) 
'Evaluation of bilateral cingulum with tractography in patients with 
Alzheimer's disease', NeuroReport, 16, (12), pp. 1275-1278. 
 
Xuan, X., Ding, M. and Gong, X. (2008) 'Proton Magnetic Resonance Spectroscopy 
Detects a Relative Decrease of N-Acetylaspartate in the Hippocampus of 
Patients with Dementia with Lewy Bodies', Journal of Neuroimaging, 18, 
pp. 137-141. 
 
Zaccai, J., Brayne, C., McKeith, I., Matthews, F., Ince, P. G.; on behalf of the MRC 
Cognitive Function, Ageing Neuropathology Study (2008) 'Patterns and stages 
of alpha-synucleinopathy - Relevance in a population-based cohort', 
Neurology, 70, (13), pp. 1042-1048. 
 
